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SYNAPTIC LOSS IN THE PRIMARY TAUOPATHIES OF PROGRESSIVE 
SUPRANUCLEAR PALSY AND CORTICOBASAL DEGENERATION. 
Dr Negin Holland 
In this thesis I address the debilitating symptom of cognitive dysfunction in the primary 
tauopathies of Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration 
(CBD). Both PSP and CBD are associated with an accumulation of 4-repeat tau in cortical 
and subcortical areas. As well as movement disorders, they impair cognitive function, even 
where there is minimal atrophy. Neurophysiological studies have also identified 
electrophysiological changes associated with cognitive dysfunction, in areas without 
atrophy. I propose that synaptic loss prior to cell loss contributes to these effects of disease.  
Chapter two summarises my cohort and principal methods. I quantify synaptic density in 
vivo with dynamic [11C]UCB-J PET, and molecular pathology with [18F]AV1451 PET. 
Brain structural changes are quantified by MRI. Disease severity and cognition are assessed 
with the PSP rating scale, and neuropsychological tests. Patients with CBD are negative on 
amyloid-imaging ([11C]PiB PET) to exclude those with Alzheimer’s pathology. In chapter 
three, [11C]UCB-J PET reveals widespread loss of synapses in PSP and CBD including 
areas with minimal atrophy. The loss of synapses correlated with cognition and disease 
severity.   
In chapter four, I test whether presynaptic changes (from [11C]UCB-J PET) are correlated 
with postsynaptic abnormalities (i.e. changes to postsynaptic dendritic microstructural 
integrity quantified by MRI using the Neurite Orientation and Dispersion Index, NODDI).  
In accordance with in vitro and animal models, I confirm that loss of dendritic complexity 
is tightly coupled with presynaptic density, over and above the effects of atrophy. 
In chapter five, I test the relationship between the molecular pathology in primary 
tauopathies (tau burden) and synaptic loss, using [18F]AV-1451 and [11C]UCB-J PET. The 
use of the “tau” ligand [18F]AV-1451 has become controversial in PSP. With due 
consideration to the caveats, I report that brain regions with a higher synaptic density have 





progression of tauopathy. I further show that accrual of pathology in any given area is 
associated with loss of synapses, consistent with synaptic injury from tauopathy. 
I conclude my thesis in chapter 6, by discussing and highlighting the importance of synaptic 
density in primary tauopathies. The findings are relevant to other neurodegenerative 
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1 GENERAL INTRODUCTION 
Neurodegenerative diseases are a major global cause of morbidity and mortality. A 
common symptom experienced by many patients with neurodegenerative disease is 
cognitive dysfunction (or dementia) manifesting as impairment in previously attained 
functioning – it can present with difficulties with memory, language, attention, and 
executive function. These symptoms are debilitating for patients, their carers and families, 
and result in great financial and personal cost (Winblad et al., 2016).  Yet attempts to 
effectively treat or cure cognitive dysfunction in neurodegeneration, although promising 
(Boxer et al., 2019; Panza et al., 2019), has proven challenging. This has been in part due 
to the challenges in understanding the multifaceted underlying pathology:  from genetic 
and environmental risk factors, accumulation and spread of misfolded proteins leading to 
dysfunction of neuronal communications and oscillations, and neurotransmitter deficits, 
with ensuing neuronal loss and loss of functional brain network connectivity – each of these 
processes contribute to cognition and affect survival both directly and synergistically. Of 
note however, cognitive symptoms can occur early in the disease process and neuronal loss 
is not essential to symptom manifestation. Indeed, in Alzheimer’s disease, the loss of the 
core units of communication within the central nervous system – the synapse, correlates 
better with cognitive dysfunction than neuronal loss (Masliah et al., 1992; Scheff et al., 
2006; Terry et al., 1991).  
Synaptic loss is a common, early pathological process in neurodegeneration (Hamos et al., 
1989), and occurs in response to misfolded proteins (Jacobsen et al., 2006), resulting in 
neuronal dysfunction before neuronal loss (Kaniyappan et al., 2017; Menkes-Caspi et al., 
2015). Targeting this pathway in clinical trials may therefore provide an opportunity to 
modulate cognition and other physical symptoms early in neurodegeneration.  
Summary 
 




In this chapter, I introduce the main disease focus of my thesis – primary tauopathies - as a 
disease model for studying synaptic dysfunction. I review the pathological and clinical 
phenotypes of primary tauopathies and the common symptom of cognitive dysfunction, 
focusing in particular on Progressive Supranuclear Palsy and Corticobasal Degeneration. I 
then review the neural mechanisms underlying cognitive dysfunction, and emphasise the 
critical and central role of synapses as evidenced by animal models, post mortem and in 
vivo assessments. I summarise this chapter by setting out the hypotheses for each 
subsequent experimental chapter.  Firstly, I propose that there is significant synaptic loss 
in vivo, in the primary tauopathies of Progressive Supranuclear Palsy and Corticobasal 
Degeneration correlating with cognition. Secondly, I hypothesise that the distribution of 
the underlying pathology in primary tauopathies correlates with synaptic loss, but that this 
relationship may be moderated by disease severity. Overall, I propose a key role of 
synapses in primary tauopathies and the associated cognitive dysfunction that is applicable 
to other neurodegenerative disorders, and a potential therapeutic target in future 
intervention studies.  
1.1 PRIMARY TAUOPATHIES 
1.1.1 PATHOLOGICAL PHENOTYPES ASSOCIATED WITH PRIMARY TAUOPATHIES 
Primary tauopathies encompass a family of pathologies that are associated with 
frontotemporal lobar degeneration (FTLD) and the intracellular accumulation of the 
misfolded and hyperphosphorylated tau protein. The distinct pathological phenotypes are 
differentiated by the anatomical location of the abnormal tau protein, the specific cell types 
affected (astrocytes, oligodendrocytes, neurons), and the distinct tau isomers in the protein 
deposit (Kovacs, 2015). The pathological phenotypes include pure 4-repeat tauopathies: 
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), globular glial 
tauopathy (GGT), argyrophilic grain disease (AGD), and rarely associated with 
frontotemporal lobar degeneration associated with mutations in the microtubule associated 
protein tau (FTLD-MAPT; which can also present as a pure 3-repeat tauopathy and a mixed 
3,4-repeat tauopathy); pure 3-repeat tauopathies: Pick’s disease; and mixed 3 and 4-repeat 




tauopathies: primary age-related tauopathy (PART) and neurofibrillary tangles dementia 
(NFT) (Figure 1-1).  
  
Figure 1-1. Molecular pathological classification of primary tauopathies. 
Tauopathies are characterised by the predominant aggregation of tau isoforms with 3 repeats (3R), or 4 repeats (4R) of the microtubule-
binding domain, or mixed 3R/4R isoforms. Secondary tauopathies are associated with other diseases or aetiologies (dashed lines; these 
include e.g. Alzheimer’s disease (AD), chronic traumatic encephalopathy (CTE) or anti-IgLON5-related tauopathy). Primary 
tauopathies are pure in nature and are rarely associated with other proteinopathies but concomitant co-pathologies may exist. 
Pathological slices in this figure represent molecular pathological characteristics, evidenced by anti- phospho-tau antibodies of the 
following tauopathies: Progressive supranuclear palsy (PSP): tufted astrocyte (A), globose neurofibrillary tangle in the caudate nucleus 
(B), oligodendroglial coiled bodies in the internal capsule (C); corticobasal degeneration (CBD): astrocytic plaque in the frontal cortex 
(D), neuronal corticobasal bodies in the substantia nigra (E), threads and coiled bodies in the parietal white matter (F); argyrophilic 
grain disease (AGD): classical Gallyas-positive argyrophilic grains (G), tau-positive grains and neuronal cytoplasmic 
immunoreactivities (pre- tangles) in the hippocampus (H), coiled bodies in the hippocampal white matter (I); glial globular tauopathy 
(GGT): globular astroglial inclusions (J), spherical neuronal inclusions in the frontal cortex (K), globular oligodendroglial inclusions 
in the hippocampal white matter (L). Aging-related tau astrogliopathy (ARTAG): subpial (M), subependymal (N), white matter (O), 
perivascular (P) and grey matter (Q) astrogliopathy. Reproduced from Rösler et al. 2019, with permission from Elsevier. 




1.1.2 CLINICAL PHENOTYPES ASSOCIATED WITH PRIMARY TAUOPATHIES  
The clinical phenotypes associated with primary tauopathies are heterogenous, and 
manifest as movement disorders, cognitive disorders or commonly a mixture of both. 
The clinical syndromes associated with pathologies of frontotemporal lobar degeneration 
(FTLD, Figure 1-2), include behavioural variant frontotemporal lobe dementia (with or 
without motor neuron disease), the primary progressive aphasias (including the non-fluent, 
semantic and logopenic variants), progressive supranuclear palsy and corticobasal 
syndrome (Coyle-Gilchrist et al., 2016; Gorno-Tempini et al., 2011; Murley et al., 2020a), 
all presenting with cognitive dysfunction as well as, in some cases, a movement disorder.  
Cognitive dysfunction, in the form of personality change, executive dysfunction, 
impulsivity, apathy, and language deficits, are common in FTLD-related syndromes and 
debilitating for both patients and their carers (Burrell et al., 2014; Coyle-Gilchrist et al., 
2016; Murley et al., 2020a; Piguet et al., 2011; Rascovsky et al., 2007). Yet the 
management of these disabling symptoms remains a challenge for clinicians. This is partly 
due to the multi-faceted underlying neural mechanisms, causing the clinical symptoms. 
These interlinked pathological entities include genetic/epigenetic (Ferrari et al., 2019; 
Höglinger et al., 2011; Wen et al., 2021; Yokoyama et al., 2017), and environmental risk 
factors (Litvan et al., 2016; Litvan et al., 2021), the aggregation and spread of misfolded 
proteins (Goedert et al., 2017a), alterations to neuronal physiology (Adams et al., 2021; 
Hughes et al., 2013; Sami et al., 2018)  and chemical balance (Murley & Rowe, 2018), and 
the ensuing neuronal loss and functional brain connectivity (Cope et al., 2018; Gardner et 
al., 2013). Neuronal loss is however, a late phenomenon in neurodegeneration and 
electrochemical disturbances as well as communication breakdown, occur early with a 
better correlation with clinical symptoms. In this thesis, I focus on the concept of 
communication loss as a key neural basis for cognitive dysfunction in the primary 
tauopathies of progressive supranuclear palsy and corticobasal syndrome. 
Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), are primary 
tauopathies that were first described by Richardson, Steele and Olszweski (Steele et al., 
1964), and Rebeiz and colleagues (Rebeiz et al., 1968), respectively. Our understanding of 
the pathophysiology of these two conditions has substantially increased since their original 
description in the 1960s. Through advancements in cryo-electron microscopy, we now 




know the structure of the underlying pathogenic 4-repeat tau species (Scheres et al., 2020; 
W. Zhang et al., 2020); genome wide association studies have identified several risk loci, 
including the Microtubule Associated Protein Tau (MAPT)-H1 haplotype as a shared 
pathogenic risk factor for both PSP and CBS (Di Maria et al., 2000); and neuroimaging has 
helped in understanding the macrostructural, molecular and longitudinal changes through 
the disease course. Below I review the clinical features seen in PSP and CBS, with a 
particular emphasis on the cognitive profile and the potential underlying neural mechanism 
underlying cognitive dysfunction in these conditions.  
Figure 1-2. Clinicopathological spectrum of frontotemporal lobar degeneration syndromes including primary 
tauopathies.  
The clinical syndromes caused by frontotemporal lobar degeneration (FTLD), coloured by the prevalence of each 
FTLD subtype:  bvFTD: behavioural variant frontotemporal dementia; nvfPPA: non-fluent variant primary progressive 
aphasia; svPPA: semantic variant primary progressive aphasia; PSP: progressive supranuclear palsy-Richardson’s 
syndrome; CBS: corticobasal syndrome; lvPPA: logopenic variant primary progressive aphasia. Neuropathological 
subtypes of FTLD: PSP: progressive supranuclear palsy. CBD: corticobasal degeneration. AGD: argyrophilic grain 
disease. GGT: globular glial tauopathy. FTLD-FET: Fused in sarcoma (FUS), Ewing’s sarcoma (EWS), and TAF15 
proteins; FTLD-U: ubiquitin positive inclusions; BIBD: basophilic inclusion body disease. NIFID: neuronal intermediate 
filament inclusion disease. Possible genetic mutations underlying FLTD: MAPT: microtubule-associated protein tau; 
PGRN: progranulin; TARDBP: TAR DNA-binding Protein; FUS: fused in sarcoma; CHMP2B: charged multivesicular 
body protein 2b. Figure idea taken, and adapted from Professor William Seely, UCSF. 




1.1.3 PROGRESSIVE SUPRANUCLEAR PALSY - CLINICAL SYMPTOMS AND SIGNS 
 
Progressive supranuclear palsy (PSP) is a rare neurocognitive disorder with a prevalence 
of 10 per 100,000 (Coyle-Gilchrist et al., 2016). It was first described by Richardson, Steele 
and Olszweski (Steele et al., 1964) and initially clinically characterised by a vertical 
supranuclear gaze palsy, early postural instability and falls. This classic phenotype of PSP 
is referred to as Richardson’s syndrome (PSP-RS), but it does not capture one of the main 
debilitating symptoms of PSP, namely cognitive dysfunction. Indeed, of the first nine 
patients described by Richardson, Steele and Olszweski, seven had significant cognitive 
dysfunction or dementia.  The more recent diagnostic criteria, published in 2017, recognises 
PSP as a spectrum with features of movement abnormalities, visual and language 
difficulties, and cognitive dysfunction (Höglinger et al., 2017) (Supplementary Figure A1). 
In PSP, difficulties with movement are often due to a combination of global akinesia and 
rigidity, particularly around the neck and axial muscles, giving patients the typical 
hyperextended posture. Visual disturbance in PSP is a common symptom, presenting as 
slow and irregular vertical saccadic eye movements in early disease (Shaikh et al., 2017), 
and restricted eye movements overcome with the vestibulo-occular reflex, as the disease 
progresses (Anderson, 2015). Visual disturbance also occurs secondary to reduced blink 
rate (Bologna et al., 2009), lack of coordination (apraxia) of eye-lid opening or closing, and 
eye-lid spasms (blepharospasm) (Yoon et al., 2005). Postural instability is yet another 
common symptom, presenting within two to three years of symptom onset (Höglinger et 
al., 2017). Together with visual disturbance and movement abnormalities, postural 
instability leads to frequent falls in PSP but impulsivity and impaired decision making also 
heavily contribute (reviewed in Brown et al. (2020)).  
Both speech and language are affected in PSP. Patients characteristically present with a 
slow, and dysarthrophonic speech, combined with hypokinetic, spastic and ataxic elements 
(Kluin et al., 2001; Rusz et al., 2015; Tykalova et al., 2017). The commonest language 
impairment is reduced fluency, but deficits in comprehension, and naming are also seen 
(Burrell et al., 2014; Peterson et al., 2021). In addition to speech impairment, other bulbar 
presentations in PSP include swallowing difficulties (dysphagia), a predictor of survival in 
PSP, which requires early attention and careful management (Glasmacher et al., 2017).  




A degree of behavioural and cognitive impairment occurs in almost all patients with PSP; 
and behavioural change is a strong predictor of survival (Glasmacher et al., 2017; Murley 
et al., 2021), but management remains a challenge (Rittman et al., 2016; Rowe et al., 2021). 
The spectrum of symptoms overlap with those seen in patients with frontotemporal lobe 
dementia (FTD) (Bak et al., 2010). Impairments span those affecting frontal executive 
function (impaired decision making and problem solving, impaired attention, and rigid 
thinking), action inhibition (impulsivity), motivation (apathy), and speed of thinking 
(bradyphrenia), to social cognitive deficits (including impaired emotion recognition, loss 
of social behaviours with abnormal eating habits, and lack of insight) (Bak et al., 2010; 
Burrell et al., 2014; Lansdall et al., 2017; Robbins et al., 1994).  
1.1.4 CORTICOBASAL SYNDROME - CLINICAL SYMPTOMS AND SIGNS 
Cortricobasal syndrome (CBS) is a clinical diagnosis, first described by Rebeiz et al in 
1968 (Rebeiz et al., 1968) (Figure A2). CBS is the commonest clinical presentation of the 
pathological diagnosis of the primary 4-repeat tauopathy of Corticobasal Degeneration 
(CBD), with a similar prevalence to PSP of 10 per 100,000 (Coyle-Gilchrist et al., 2016).  
The terms CBD and CBS have sometimes been used interchangeably, but this is no longer 
the case. Not all cases of CBD present with CBS; and not all people with CBS have CBD. 
The clinical features arising from CBD may overlap with frontotemporal lobe dementia, 
non-fluent variant primary progressive aphasia, or PSP (Rösler et al., 2019). Similar 
heterogeneity is seen in the underlying pathological diagnosis presenting with a CBS 
phenotype, including CBD, Alzheimer’s disease (Alexander et al., 2014; Burrell et al., 
2013; S. E. Lee et al., 2011), PSP (Josephs et al., 2006; Ling et al., 2010), and TAR DNA-
binding Protein (TDP-43) (S. E. Lee et al., 2011) .  
The clinical phenotype of CBS manifests with motor signs, language difficulties and 
cognitive dysfunction (Armstrong et al., 2013).  Symptoms include asymmetric cortical 
and basal (subcortical) features (Supplementary Figure A2). Cortical symptoms include 
apraxia (affecting the eye lids, face, speech and limbs) (Zadikoff & Lang, 2005), alien limb 
phenomenon (Lewis-Smith et al., 2020), cortical sensory loss, and visuospatial dysfunction 
(simultagnosia and visual inattention) (Burrell et al., 2014; Rittman et al., 2013). 
Subcortical features include dystonia, rigidity, and akinesia. Dystonia in CBS can affect 
the limbs, neck or the eyelids and in some cases is responsive to dopaminergic medication 




(Stamelou et al., 2012). Patients can also present with myoclonus (coarse tremor) featuring 
as either a subcortical (Grosse et al., 2003) or cortical phenomenon (Carella et al., 1997).  
Speech production in CBS can be affected by apraxia of speech (orobuccal apraxia) but 
primary language deficits affecting comprehension, fluency and repetition are also seen 
(Burrell et al., 2014; Peterson et al., 2021; Rittman et al., 2013). Behavioural features in 
CBS overlap with those seen in PSP and frontotemporal lobe dementia, manifesting as 
apathy, impulsivity, and stereotyped movements (Burrell et al., 2014; Lansdall et al., 2017; 
Litvan et al., 1998).  
On terminology of CBS/CBD, the current consensus is that CBS refers to the clinical 
syndrome whilst CBD refers to the characteristic 4-repeat tau pathology. About a third of 
those with CBS have Alzheimer’s pathology (Alexander et al., 2014). In experimental 
chapters 3-5, I exclude this cohort of patients using amyloid imaging and use the term CBD 
to describe the group in whom amyloid imaging is negative.    
1.1.5 NEURAL MECHANISMS OF COGNITIVE DYSFUNCTION IN PSP AND CBS 
Many different pathological processes contribute to the cognitive deficits seen in PSP/CBS. 
At their core however, lies synaptic toxicity caused by the underlying pathology, and in 
turn leading to loss of structural and functional connectivity. I briefly review these 
pathological mechanisms below before expanding on pertinent aspects in chapters 3-5.  
1.1.5.1 Tau Pathology 
 
In a healthy brain, tau protein is abundant within neuronal axons (although it is also found 
in the somatodendritic compartment), where it serves as a key regulator of microtubular 
stability, neuronal dynamic and intracellular transport (V. M. Lee et al., 2001; Trojanowski 
et al., 1989; Y. Yoshiyama et al., 2013). Tau protein is encoded by the microtubule-
associated protein tau (MAPT) on chromosome 17 and can form 6 different isomers 
through alternative splicing. The latter process determines how many repeat regions reside 
within the microtubule-binding domain of the protein, generating three isoforms each with 
three (3R) or four repeats (4R) (V. M. Lee et al., 2001). 
Under normal conditions, tau can undergo a series of post-translational modifications 
including phosphorylation, acetylation and methylation (reviewed in Rösler et al. (2019)). 
Due to genetic and/or environmental risk factors, the normal unfolded tau protein can 




become hyperphosphorylated, misfolded, and subsequently form soluble oligomers and 
then insoluble intracellular fibril aggregates in neurons and glial cells. The downstream 
effect of hyperphosphorylated tau is many fold: (1) within the axon it has reduced binding 
affinity for microtubules and other proteins therefore leading to an abnormal cytoskeleton, 
and ineffective intracellular molecular transport (Niewidok et al., 2016); (2) within the 
dendritic spine, it interferes with synaptic function (Frandemiche et al., 2014; Regan & 
Cho, 2019), and loses the ability to interact with other binding targets for example the 
plasma membrane or DNA (Ekinci & Shea, 2000; Hanger et al., 2009); and (3) within both 
neurons and glial cells it gains toxic function and the ability to propagate across the brain 
(Clavaguera et al., 2009; Goedert et al., 2017a; Mandelkow & Mandelkow, 2012). In 
addition to hyperphosphorylation, abnormal methylation can also contribute to tau 
pathology (Park et al., 2018; Weber et al., 2018).  
Hyperphosphorylated tau is the principal pathology in primary tauopathies, unlike the 
secondary tauopathy of Alzheimer’s disease where tau proteinopathy is secondary to beta-
amyloid pathology (Selkoe & Hardy, 2016). Primary tauopathies can be mixed in their tau 
isoforms 3R/4R, predominant 3R, and predominant 4R.  
The staging of the disease process in PSP depends on the anatomical areas affected, as well 
as the specific cell type harbouring hyperphosphorylated tau. Tau neurofibrillary tangles 
and threads, as well as tufted astrocytes, are seen initially within subcortical nuclei of 
patients with PSP before spreading cortically. Additionally, coiled bodies within 
oligodendroglial cells with diffuse cytoplasmic immunoreactivity within neurons, are also 
observed. With disease progression to fronto-parietal, temporal and occipital cortices, 
cortical astroglial tau accumulation ensues, followed by the involvement of cortical 
neuronal and oligodendroglial cells (Kovacs et al., 2020). In CBD, tau aggregates are seen 
in neurons and glial cells giving the appearance of coiled bodies and astrocytic plaques, 
with tau threads found within the white and grey matter. PSP and CBD tau filaments are 
subtly different in their biochemical features and distribution. Neuronal tau pathology is 
more pronounced in the forebrain in CBD, whilst PSP mainly affects hindbrain structures. 
Similarly, the degree of white matter involvement is greater in CBD than PSP, whilst 
subcortical neurofibrillary tangles are more pronounced in PSP (Rösler et al., 2019).  




The density of cortical neurofibrillary tangles is strongly correlated with cognitive function, 
in PSP, CBS and Alzheimer’s disease (Murray et al., 2014; Nelson et al., 2012), particularly 
affecting the executive cognitive domain (Koga et al., 2017). The mechanisms by which 
tau affects cognition are however multifaceted, and include both direct and indirect 
mechanisms with synaptic dysfunction as a key pathological consequence (Jadhav et al., 
2015; Spires-Jones & Hyman, 2014). Direct pathways of tau-mediated synaptotoxicity 
include interference with dendritic morphology, synaptic protein expression, and synaptic 
vesicle numbers. Indirectly, tau adversely affects the functioning of the neuronal support 
network, including microglia cells and astrocytes, which in turn affect synaptic function 
(Kovacs et al., 2020; Vogels et al., 2019).   
1.1.5.2 Genetic risk factors in PSP and CBS 
 
Genetic risk factors, although not directly linked with cognitive outcomes in primary 
tauopathies, are linked to key pathogenic mechanisms that correlate with cognition and 
survival. For example, a recent Genome Wide Association Study (GWAS) in PSP has 
identified a single nucleotide polymorphism at loci rs2242367 associated with increased 
expression of pathogenic LRRK2 mutations, and decreased survival (Jabbari et al., 2021).  
Pathogenic mutations in LRRK2 lead to phosphorylation of a subset of Rab proteins 
(involved in synaptic vesicle trafficking) (Alessi & Sammler, 2018), therefore disrupting 
synaptic neurotransmitter release and proteostasis. Additionally, pathogenic LRRK2 
interferes with actin and mitochondrial dynamics and with tau aggregate clearance, via the 
proteosome system. Consequently, although there is no direct link between LRRK2 risk 
alleles and cognition, the pathogenic mechanisms arising from mutations in this gene, 
synaptic transmission and tau accumulation and spread (Guerreiro et al., 2016; Islam et al., 
2016; Lin et al., 2010), do cause cognitive dysfunction both in animal models, and human 
studies. An earlier GWAS identified genetic polymorphisms in the tripartite motif-
containing protein 11 (TRIM11) associated with variations in PSP phenotype (PSP-
Richardson’s syndrome versus non-Richardson’s syndrome including those patients with 
predominant cognitive features – PSP-frontal, PSP-CBS, and PSP-language (Höglinger et 
al., 2017; Jabbari et al., 2018) . TRIM11 is a component of the ubiquitin proteosome system 
and therefore central to the clearance of misfolded proteins (L. Chen et al., 2017); mutations 
may therefore interfere with the clearance of pathogenic tau species in primary tauopathies, 
consequently affecting cognitive symptoms. 






Glial cells are the immune cells of the central nervous system and are divided into microglia 
(macrophage cells, acting as the immune cells of the brain), and macroglia 
(oligodendrocytes, astrocytes, and ependymal cells). There is growing evidence for their 
role in PSP/CBD pathogenesis. Under normal physiological conditions, neuroinflammation 
within the central nervous system acts as a protective mechanism to maintain homeostatis; 
it is a controlled mechanism triggered by environmental factors, infection, toxic aggregates, 
and neuronal damage. Furthermore, a key role for glia cells, particularly astrocytes, in 
neural transmission has long been identified, such that many propose synaptic transmission 
to be dependent not only on the pre- and postsynaptic compartment but also the astrocytes. 
In this role, they are able to release neurotransmitters in response to neural activity, and 
therefore modulate synaptic function (Reid et al., 2020). PSP/CBD tau aggregates within 
astroglial cells, and in the extracellular space, disturb normal neuronal homeostasis, and 
co-localise with markers of inflammation at post mortem (Kovacs, 2020) and in vivo 
(Gerhard et al., 2006; Gerhard et al., 2004; Malpetti et al., 2020b). The mechanism by which 
inflammation causes functional impairment is again multifactorial with synaptic 
dysfunction as a key mechanistic player (reviewed in Vogels et al. (2019)).  
1.1.5.4 Synaptic loss in primary tauopathies 
 
Abnormal functioning of synapses and reductions of up to 50-60% in synaptic numbers 
have been observed in animal models of tauopathy (e.g. rTg4510) (Kaniyappan et al., 2017; 
Menkes-Caspi et al., 2015), in human post mortem brains (Bigio et al., 2001; Lipton et al., 
2001), and proposed from measures of indirect effects of synaptic density and function via 
fluorodeoxyglucose (18F) positron emission tomography, FDG-PET (Beyer et al., 2018), in 
both PSP and CBD. Loss of synaptic function and number is linked to the direct and indirect 
consequence of toxic tau oligomers and aggregates, as well as neuroinflammation (Jadhav 
et al., 2015; Spires-Jones & Hyman, 2014; Vogels et al., 2019). The downstream effect is 
that of interference with vesicular trafficking, disturbances in neurotransmitter release and 
the balanced electrochemical activities of a neuron, even before neuronal death occurs. This 
consequential effect is seen in both the presynaptic, and postsynaptic compartments. In 
animal models of tauopathy, and in post mortem studies, tau aggregates, as well as being 
concentrated within the cytoplasm are also present in dendritic processes (as well as in the 
extracellular compartment), subsequently interfering with synaptic transmission both 




presynaptically and postsynaptically (Feany & Dickson, 1995; Herms & Dorostkar, 2016; 
Hoffmann et al., 2014; Hoover et al., 2010). The consequence of this, is disturbances in 
functional connectivity, and structural integrity. The effect of synaptic dysfunction and loss 
on cognitive function, has been investigated in animal models of tauopathy that mimic 
primary tauopathies (Menkes-Caspi et al., 2015), in post mortem brains of patients with the 
secondary tauopathy of Alzheimer’s disease (Terry et al., 1991), and more recently directly 
using a novel PET radioligand [11C]UCB-J (Finnema et al., 2016). Using the latter PET 
radiotracer has enabled the in vivo assessment of synaptic loss in mild cognitive impairment 
and Alzheimer’s disease (M. K. Chen et al., 2018; Mecca et al., 2020), and Parkinson’s 
disease and Lewy Body Dementia (Andersen et al., 2021; Matuskey et al., 2020; Nicastro 
et al., 2020), with significant correlations with the severity of cognitive symptoms. 
However, the direct in vivo evaluation of synaptic density and its relationship with 
cognition, in primary tauopathies, is yet to be determined.    
1.1.5.5 Neurotransmitter deficits, and disturbed cortical physiology  
 
A consequence of tau and inflammation mediated synaptic dysfunction, is disturbance in 
neurotransmitter release and therefore abnormal cortical physiology, in turn affecting 
cognition. Many key neurotransmitters for normal cognition are reduced in PSP, and CBS, 
albeit to a variable extent in each disease. These include noradrenaline, dopamine, γ-
aminobutyric acid (GABA), glutamate, serotonin and acetylcholine (Holland et al., 2021; 
Murley & Rowe, 2018). Cortical physiology, as measured with magnetoencephalography 
is disturbed in PSP (Adams et al., 2021; Hughes et al., 2013; Sami et al., 2018). Impairment 
in baseline GABA levels in PSP has been identified as a key contributor to abnormal 
cortical physiology (Adams et al., 2021), and correlates with frontal executive dysfunction 
both directly, and indirectly (through interaction with glutamate) (Bastos et al., 2012; 
Murley et al., 2020b).  
1.1.5.6 Structural and functional connectivity  
 
The downstream effect of tau accumulation, inflammation, synaptic loss and abnormal 
cortical circuitry is neuronal loss and changes in structural and functional connectivity. 
Structural connectivity can be assessed using MRI. On volumetric MRI sequences, grey 
matter atrophy of the basal ganglia, midbrain, thalamus, and the cerebellum are common 
findings in PSP (J. L. Whitwell et al., 2017a). MRI assessment of midbrain atrophy is 




particularly used in clinical practice, with atrophy here giving rise to the so called 
“hummingbird”, “Mickey Mouse” and “morning glory” signs representing dorsal midbrain 
atrophy, rectangular midbrain peduncles, and the concavity of the midbrain tegmentum, 
respectively (Massey et al., 2012; C. Mueller et al., 2018). In PSP, frontal atrophy can affect 
the motor, premotor, orbitofrontal and medial frontal cortices. The degree to which this 
occurs depends on the dominant clinical phenotype – for example in patients with a more 
cortical presentation of PSP, as per the 2017 MDS criteria, including PSP-frontal, PSP-
speech/language, or PSP-CBS overlap, frontal atrophy is more evident but it is present to 
some extent in most phenotypes during the course of the disease (Jabbari et al., 2019).  
Frontal atrophy is also present in CBS, more prominent in the posterior frontal lobes 
(supplementary motor cortex, dorsal premotor, prefrontal cortex and anterior central 
gyrus). Atrophy in the anterior parietal lobes, central structures such as the cerebellum, 
caudate and thalamus are also seen, but may be initially asymmetric underlying the 
asymmetric clinical signs in CBS (Constantinides et al., 2019). The underlying pathology 
of CBS determines the distribution of atrophy, with those due to CBD and PSP pathology 
mimicking PSP patterns of atrophy. Frontal cortical atrophy in PSP is directly linked to 
cognitive function (Cordato et al., 2005; Cordato et al., 2002), however atrophy is rather a 
late phenomenon in the pathogenesis of PSP/CBS, and in neurodegeneration at large, as 
depicted schematically in Figure 1-3 (Sperling et al., 2011), and frontal executive 
dysfunction is present even when atrophy is minimal or absent.  
A complementary way of assessing structural integrity is through Diffusion Tensor 
Imaging (DTI). In PSP, changes to white matter tracts seen on DTI, including the superior 
cerebellar peduncle, commissural and association fibres (superior longitudinal fasciculus, 
superior fronto-occipital fasciculus, cortico-cortical association fibres), and corticostriatal 
descending fibres are widely reported (Agosta et al., 2012; Crespi et al., 2020; Padovani et 
al., 2006; Jennifer L. Whitwell et al., 2011; Jennifer L Whitwell et al., 2021). In CBS, 
abnormal diffusion in anterior and posterior central gyri, middle frontal gyrus bilaterally, 
and superior and inferior frontal gyrus contralateral to the most clinically affected side have 
been reported (Boelmans et al., 2009; Bozzali et al., 2008; Jennifer L Whitwell et al., 2014). 
Reduced diffusion in the body of the corpus callosum, middle cingulum bundle, and the 
prefrontal cortices, and fronto-occipital fasciculus are common in both CBS and PSP 
(Jennifer L Whitwell et al., 2014). Abnormal diffusion is correlated with decline in 




cognitive function, and clinical symptoms over time. For example, in PSP changes in the 
superior cerebellar peduncle integrity are correlated with rate of decline in the PSP rating 
scale (ocular sub-score), whereas decline in global cognition is correlated with changes in 
the post-central region and the mid-posterior cingulum. In CBS, rates of decline in the PSP 
rating scale (limb sub-score) are correlated with abnormal diffusion in the post-central 
white matter regions (Y. Zhang et al., 2016).  
Functional connectivity in PSP and CBS is abnormal and can be measured using task-free 
functional MRI. Evidence thus far suggests increased within network connectivity, for 
example within the default mode network, cerebellum (Bharti et al., 2017), or within 
cortical areas (Cope et al., 2018). Connectivity between networks is however reduced, for 
example between the lateral visual and auditory resting state networks, and cortical-
subcortical areas (Ballarini et al., 2020; Bharti et al., 2017; Cope et al., 2018; Gardner et 
al., 2013). This pattern of change in connectivity suggests a functional reorganisation in 
which local networks are strengthened, and long-distance connections are weakened, in 
response to disease. Changes in functional connectivity within the cerebellar resting state 










































In this chapter, I have provided an overview of the clinical syndromes associated with the 
primary tauopathies of PSP and CBD, and highlighted the importance of synaptic pathology 
as a contributor to functional changes (this topic will be covered in greater detail in Chapter 
3). I therefore propose a critical role of synaptic density in cognition, and investigate this 
proposal in primary tauopathies, in this thesis. Throughout this thesis, I consider PSP and 
CBD as disease models of neurodegeneration given their high clinicopathological 
correlation with 4-repeat tauopathy at post mortem (where Alzheimer’s pathology in the 
case of CBS has been eliminated, and referred to as CBD). In my experimental chapters I 
consider PSP and CBD together given the clinicopathological overlap but will highlight 
differences where relevant.  
Figure 1-3. Theoretical model of dynamic changes to tauopathy related biomarkers in 
relation to clinical symptom manifestation.  
This model emphasises the preclinical phase of tauopathies (but is applicable to other 
neurodegenerative disorders). Here synaptic dysfunction, shown in orange (indicated by 
metabolic changes measured by fluorodeoxyglucose positron emission tomography, FDG-
PET, UCB-J PET or functional MRI) occurs before macro-structural change (volumetric 
MRI). Synaptic dysfunction may be detectable before detectable tau accumulation. 
Biomarkers change from normal to maximally abnormal (y-axis) as a function of disease 
stage (x-axis) – figure reproduced from Sperling et al 2011 with permission from Wiley.  




1.3 AIMS AND STRUCTURE OF THIS THESIS 
This thesis aims to test the hypothesis that synaptic pathology plays a key role in primary 
tauopathies of PSP and CBD. In the experimental chapters, I use the novel positron 
emission tomography (PET) radioligand [11C]UCB-J as a measure of in vivo synaptic 
density, and review the evidence for the use of this ligand in the introduction to chapter 3. 
In chapter 2, I summarise the clinical cohort, the research protocol, and the analysis 
techniques forming the basis of this thesis.   
In chapter 3, I test the hypothesis that synapses are lost in vivo in PSP and CBD compared 
to healthy controls. To do this, I use [11C]UCB-J PET as a measure of synaptic density, 3T 
MRI for structural brain volume analysis and, a neuropsychological battery for the 
assessment of cognition and disease severity. I predict a synaptic loss of 20-30% in vivo, 
considering there is up to 60% loss at post mortem. I further predict that this loss is beyond 
the degree of brain atrophy, and that it correlates with functional outcomes. Subsequently 
in chapter 4, I test whether in vivo changes in presynaptic density correlates with changes 
within the postsynaptic compartments. I test the degree of presynaptic synaptic loss with 
[11C]UCB-J PET and changes within the postsynaptic compartment with Orientation 
Dispersion MRI (a measure of neurite complexity and a correlate for postsynaptic density).  
I predict that presynaptic loss as measured with [11C]UCB-J PET, is positively correlated 
with changes in postsynaptic dendritic complexity.   
To understand the contribution of tau pathology in PSP and CBD, in chapter 5, I test the 
hypothesis that synaptic density correlates with molecular pathology (using [18F]AV-1451 
PET). I predict that the relationship between the two processes will be complex and 
moderated by disease severity. I conclude this thesis by discussing the evidence for a 
critical role of synapses in neurodegeneration, and how this allows an opportunity for the 
development of future therapeutic targets.   




2 GENERAL METHODS 
Summary 
In this chapter I outline the general methods which underpin each experimental chapter in 
my thesis, in particular the selection and recruitment of participants, the neuropsychological 
assessment and neuroimaging aspects of the protocol, and the analysis techniques used 
(with more detail included in respective chapters). This study of synaptic pathology in 
primary tauopathies is observational in nature and is conducted within the overarching 
Synaptic Evaluation in Neurodegeneration Research (SENDeR), and Tau Evaluation in 
Neurodegeneration Research (TENDeR) protocols which form two major research themes 
of the Cambridge Centre for Parkinson-Plus.   






Patients with Progressive Supranuclear Palsy – Richardson’s Syndrome (PSP-RS) 
(Höglinger et al., 2017), and possible or probable Corticobasal Syndrome (CBS) 
(Armstrong et al., 2013), were recruited into the study, as well as suitably matched healthy 
control participants defined by a Mini-Mental State Examination (MMSE) score greater 
than 26, and absence of regular memory complaints or signs/symptoms of dementia or 
unstable/ significant medical illness.  
Patient participants were identified from clinics for cognitive and movement disorders 
within Cambridge University Hospitals and from neurology, and related services within 
other Trusts within the region including those in Cambridgeshire, Lincolnshire, 
Bedfordshire, Norfolk, Suffolk, Hertfordshire and Essex, and outside the region including 
London and Nottingham. Patient and control participants were also recruited from the 
National Institute for Health Research ‘Join Dementia Research’ (JDR) programme. JDR 
is an on-line self-registration service that enables volunteers with memory problems or 
dementia, carers of those with memory problems or dementia, and healthy volunteers to 
register their interest in taking part in research.   
Potential participants so identified who expressed a willingness to take part in research 
were sent a copy of the study information sheet, together with the standard PET and MRI 
safety questionnaires. After a period to consider these materials (minimum 48h) they were 
contacted to inquire whether they were willing to take part, and to provide further 
information or allow further time for consideration as appropriate, as well as ensuring that 
they are likely to be suitable to take part in the study. 
2.1.2 INCLUSION CRITERIA 
Participants of both sexes, and above the age of 50 were included in the study and had 
sufficient proficiency in English to allow standardised cognitive testing.  All patient 
participants had a reliable informant, who was able to complete questionnaires for 
informant-rated scales and provide background history. For patient participants, only those 
with mild to moderate dementia were included with MMSE ≥ 12, since subjects scoring 
lower than this were highly unlikely to be able to comply with study procedures.  




2.1.3 EXCLUSION CRITERIA  
Potential participants with concurrent major psychiatric illness (e.g. major depression), 
severe physical illness or co-morbidity that would limit ability to fully participate in the 
study were excluded, as well as those with contraindications to MRI safety (pacemaker, 
certain protheses, or claustrophobia). Potential participants were also excluded if they had 
atypical or focal parenchymal appearances on previous MRI which were not in keeping 
with their diagnosis, or which would interfere with neuroimaging processing (for example, 
excess white matter changes, or large areas of previous stroke). Potential participants taking 
concurrent medications that might have affected study assessments were also excluded - 
for example, the anti-epileptic medication levetiracetam (Lynch et al., 2004), which binds 
to the molecular target of the synaptic PET radioligand used in this study. 
Eligible participants suitable to take part, provided written informed consent in accordance 
with the Deceleration of Helsinki, with patients being supported by their relative, spouse, 
close friends, or advocate when necessary.  
2.2 ETHICAL & RADIATION APPROVALS  
All PET radioligands were subject to prior approval from the Administration of Radioactive 
Substances Advisory Committee (ARSAC). The study protocol was approved by the 
Research Ethical Committee (18/EE/0059). All participants completed an approved MRI 
safety questionnaire to establish safety for scanning.  PET scanning was undertaken within 
the safety procedures operating within the Wolfson Brain Imaging Centre (WBIC).  
2.3 OVERVIEW OF STUDY PROTOCOL 
Upon the provision of written consent, participants underwent a clinical and 
neuropsychological assessment as well as neuroimaging; the study procedure is set out in 
Figure 2-1. Most participants consented to having blood samples taken to measure a 
number of neurodegenerative biomarkers. A percentage of patient participants will be 
followed-up longitudinally, however this phase of the study as well as biomarker analysis 
lie outside the scope of my PhD.  




2.3.1 NEUROPSYCHOLOGICAL AND CLINICAL ASSESSMENT 
All participants underwent an initial clinical assessment, including the collection of basic 
clinical and demographic variables (e.g. symptoms pertaining to the neurodegenerative 
diagnosis, previous medical history, smoking/alcohol and family history). Participants 
completed a neuropsychological assessment using a test battery tailored according to the 
condition under study, which included measures of: pre-morbid ability, current activities 
of daily living, motor function and coordination, anxiety, depression and behavioural 
changes, visuospatial perception, working memory and attention, episodic memory, 
semantic memory, logic and reasoning, and verbal fluency. For the purposes of my thesis, 
the neuropsychological assessments used were the Addenbrooke’s Cognitive Examination-
Revised (ACE-R) (Mioshi et al., 2006), Mini-Mental State Examination (MMSE) 
(Arevalo-Rodriguez et al., 2015), Montreal Cognitive Assessment (MoCA) (Nasreddine et 
al., 2005), Ineco (frontal lobe assessment tool) (Torralva et al., 2009), and the Schwab and 
England Activities of Daily Living (SEADL) (Schwab & England, 1969). Patients’ 
relatives also provided their report of the patient’s functional abilities through completion 
of the Cambridge Behavioural Inventory (CBI) questionnaire (Wear et al., 2008) (Table 
2-1). Disease severity was assessed using the clinician-rated PSP rating scale (Golbe & 
Ohman-Strickland, 2007), and Cortico Basal ganglia Functional Scale (CBFS) (Lang et al., 
2020), where both scales are highly correlated and appropriate for use in both cohorts (Lang 
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Figure 2-1. Flowchart illustrating the participants’ journey through the study. 






Table 2-1. Clinical and neuropsychological assessment battery, and questionnaires  
 
2.3.2 NEUROIMAGING  
Participants underwent MRI scanning at baseline, as well as two PET scans ([11C]UCB-J, 
and [18F]-AV1451). Those participants with Corticobasal Syndrome (CBS), had an 
additional PET scan with [11C]PiB to determine their amyloid status – those with a negative 
amyloid status (henceforth referred to as CBD) were carried forward for subsequent 
analysis in this thesis. All scanning sessions were carried out at the Wolfson Brain Imaging 
Centre (WBIC).  
2.3.2.1 Magnetic Resonance Imaging  
 
MRI scanning was performed on two separate occasions. One was acquired during PET 
data acquisition including a T1-weighted sequence specifically used for the purpose of co-
registration with PET images. Here, T1-weighted images were acquired on a 3 Tesla GE 
Assessment Format  Purpose 
 
Clinical  
Progressive Supranuclear Palsy Rating Scale (PSPRS) Researcher administered 
structured assessment  
Disease severity scale  
Cortico Basal ganglia Functional Scale  (CBFS) Researcher administered 
structured assessment 
Disease severity scale 




Addenbrooke’s Cognitive Examination-Revised (ACE-R) Researcher administered 
structured assessment 
Multi-domain cognitive 
screening tool  
Mini-Mental State Examination (MMSE) Researcher administered 
structured assessment 
Multi-domain cognitive 
screening tool  
Montreal Cognitive Assessment (MoCA) Researcher administered 
structured assessment 
Multi-domain cognitive 
screening tool  
INECO Frontal Screening Tool Researcher administered 
structured assessment 
Frontal lobe assessment 
tool 





Cambridge Behavioural Inventory (CBI) Carer-reported 
questionnaire  
Assessment of several 
behavioural 
abnormalities in 
everyday life including 
impulsivity and apathy 




SIGNA PET/MR with the following parameters: repetition time (TR) = 3.6 msec, echo time 
(TE) = 9.2 msec, 192 sagittal slices, in plane resolution 0.55 x 0.55 mm, interpolated to 1.0 
x 1.0 mm; slice thickness = 1.0 mm). T1 images acquired here allowed tissue classification 
into grey and white matter and CSF and were rigidly registered to PET images; using a 
version of the Hammersmith atlas (http://brain-development.org) with modified posterior 
fossa regions, combined regions of interest (ROIs; including aggregated regions for frontal, 
parietal, occipital, and temporal lobes, cingulate, and cerebellum) were spatially 
normalized to the T1-weighted MRI of each participant using Advanced Normalization 
Tools (ANTs) software (Avants et al., 2008). Further details of how PET images were 
subsequently processed are outlined in section 2.3.2.2.  
A second MRI scan was acquired on a 3 Tesla Siemens MAGNETOM Prisma scanner, 
either on the same day as the PET scan or on a different day depending on patient 
tolerability. Sequences are outlined in Table 2-2 and were specifically used for the analysis 
in chapter 4 (where postsynaptic dendritic complexity was estimated using the Neurite 
Orientation Dispersion sequence). Other sequences were also acquired as part of this scan 
including diffusion tensor imaging (DTI), arterial spin labelling (ASL), resting-state 
functional MRI, T2-weighted sequences, as well as fluid attenuated inversion recovery 
(FLAIR), but were not used for the analyses in this thesis.  
 
Modality  Key parameters 
  
T1 - MPRAGE Sagittal slices, TE=2.93 msec, TR=2s, flip angle 8°, 
slice thickness = 1.1 mm, resolution 1.1 mm3 isotropic, 208 slices.     
Neurite Orientation Dispersion 
Imaging - NODDI 
TE = 75.6 msec, TR = 2.4s, slice thickness = 1.75mm, 104 slices,  
bvals = 300, 1000, 2000. 
 
Table 2-2. Baseline High Resolution MRI protocol.  
Siemens MAGNETOM Prisma scanner. TR = repetition time; TE= echo time. 
 
 
2.3.2.2 Positron Emission Tomography imaging  
All participants underwent synaptic imaging with [11C]UCB-J PET (radiation exposure = 
1.7 mSv), tau imaging with [18F]AV-1451 PET (radiation exposure = 6.3mSv), with the 
CBS cohort also completing amyloid imaging with [11C]PiB PET (radiation exposure = 2.9 
mSv). All radioligands were prepared at the WBIC, with high radiochemical purity (>95%), 
and specific activity of >150 MBq, at the end of synthesis. 







Dynamic PET data acquisition was performed on a GE SIGNA PET/MR for 90 minutes 
starting immediately after [11C]UCB-J injection with attenuation correction including the 
use of a multi-subject atlas. Each PET emission image series was aligned using SPM12 
(www.fil.ion.ucl.ac.uk/spm/software/spm12/) then rigidly registered to the T1-weighted 
MRI acquired during PET data acquisition. Regional time-activity curves were extracted 
following the application of geometric transfer matrix (GTM) partial volume correction 
(PVC, (Rousset et al., 1998)) to each of the dynamic PET images. Regions of interest 
(ROIs) were multiplied by a binary grey matter mask (>50% on the SPM12 grey matter 
probability map smoothed to PET spatial resolution), with the exception of the pallidum, 
substantia nigra, pons and medulla because masking eliminated the ROI for some or all of 
the subjects. Multiple background grey matter, white matter and cerebrospinal fluid (CSF) 
regions were also defined to provide whole brain coverage for GTM PVC. The mean grey 
matter/(grey matter + white matter) fraction in the masked ROIs was 0.97 ± 0.03, 0.96 ± 
0.03 and 0.96 ± 0.03 for the control, CBD and PSP groups, respectively, illustrating the 
predominance of grey matter in the masked ROIs. To assess the impact of PVC, time-
activity curves were also extracted from the same ROIs without the application of GTM 
PVC. 
To quantify synaptic density, [11C]UCB-J non-displaceable binding potential (BPND) was 
determined, both regionally and at the voxel level, using a basis function implementation 
of the simplified reference tissue model (Wu & Carson, 2002), with the reference tissue 
defined in the centrum semiovale (Koole et al., 2019; Rossano et al., 2019). The volume-




As for [11C]UCB-J PET dynamic PET data acquisition here was also performed on a GE 
SIGNA PET/MR for 90 minutes starting immediately after [18F]AV-1451 injection with 
attenuation correction including the use of a multi-subject atlas – preprocessing followed 
the steps outlined in Passamonti et al. (2017). Each PET emission image series was aligned 
using SPM12 to correct for patient motion during data acquisition 




(www.fil.ion.ucl.ac.uk/spm/software/spm8). The mean aligned PET images were rigidly 
registered to the T1-weighted images acquired during PET data acquisition. This allowed 
extraction of values from both the Hammers atlas regions of interest (ROIs) and those in a 
reference tissue defined in the inferior cerebellar grey matter (GM) using a 90% GM 
threshold on the GM probability map produced by SPM8 smoothed to PET resolution. 
Regional time-activity curves were extracted following the application of geometric 
transfer matrix (GTM) partial volume correction (PVC, (Rousset et al., 1998)) to each of 
the dynamic PET images. Regions of interest (ROIs) were multiplied by a binary grey 
matter mask (>50% on the SPM12 grey matter probability map smoothed to PET spatial 
resolution), with the exception of the pallidum, substantia nigra, pons and medulla because 
masking eliminated the ROI for some or all of the subjects. Multiple background grey 
matter, white matter and cerebrospinal fluid (CSF) regions were also defined to provide 
whole brain coverage for GTM PVC. [18F]AV-1451 non-displaceable binding potential 
(BPND) was determined for each ROI using a basis function implementation of the 
simplified reference tissue model (Gunn et al., 1997). To assess the impact of PVC, time-




Amyloid PET imaging was carried out on a GE SIGNA PET/MR 50-70 minutes post 
injection of Pittsburgh Compound B ([11C]PiB), in the CBS cohort only. Cortical 
standardised uptake value ratio (SUVR), was determined using the Centiloid Project 
methodology, with the whole cerebellum as the reference tissue (Klunk et al., 2015). Only 
those CBS participants with a negative amyloid status as characterised by a cortical 
[11C]PiB SUVR less than 1.21 (obtained by converting the Centiloid cut-off of 19 to SUVR 
using the Centiloid-to-SUVR transformation) (Jack et al., 2017a), were included in the 
subsequent analyses, with the aim of excluding patients with CBS due to Alzheimer’s 
disease. This amyloid-negative group is interpreted as having CBD, although I 
acknowledge that other pathologies are possible.  
The total numbers of participants completing each arm of the study are outlined in Table 
2-3 which reflects total recruitment numbers at the time of writing this thesis; the number 




of participants forming the basis of the analysis in each chapter varies depending on the 
availability of data for each individual: for example, in chapter 4 not all participants with a 
NODDI sequence on the PRISMA scanner, had completed their [11C]UCB-J scan. 
Likewise in chapter 5, not all patients with an [18F]AV-1451 PET had completed their 
[11C]UCB-J scan at the time of thesis write-up. The sample size for each analysis is 







Control 27 27 22 20 

















Table 2-3. Total number of participants completing each arm of the study.  
PSP=Progressive Supranuclear Palsy - Richardson's Syndrome; CBS = Corticobasal Syndrome. 
2.4 ANALYSIS 
2.4.1 POWER CALCULATION 
Given the novelty of this study, power could not be calculated on available pilot data. I 
therefore based the power calculations on our recent experience and data of [18F]AV-1451 
PET imaging in “NeuroInflaMation Research Of Dementia (NIMROD)” study in PSP and 
frontotemporal lobe dementia (Bevan-Jones et al., 2020; Bevan-Jones et al., 2018a; Bevan-
Jones et al., 2018b; Passamonti et al., 2017), and extensive studies of other PET ligands in 
dementia groups. A sample size of 24 per group provides >85% power to detect medium 
to large effects sizes, d=0.8, for <0.05, and >85% power to detect correlations of moderate 
strength |ρ|>0.5. Recruiting 30 participants per group accommodates 10% technical and 
synthesis failure and 10% participant attrition from withdrawal or co-morbidity. Power 
calculations used the GPower software.  
2.4.2 STATISTICAL ANALYSIS 
Analysis primarily adopts regions of interest approach using parametric statistics from 
general linear models of group differences (patient versus control), and correlations within 
the patient group against clinical severity. Where multimodal imaging is involved, linear 
mixed effect models have been utilised. Where data distributions indicated the need for 




non-parametric tests, non-parametric analogues, and permutations tests have been used. All 
statistical analysis were performed in the statistical package R (version 3.6.2). Specific 
details are provided in each respective experimental chapter.    





3 SYNAPTIC LOSS IN PRIMARY TAUOPATHIES 
REVEALED BY [11C]UCB-J POSITRON 
EMISSION TOMOGRAPHY 
  A manuscript related to this chapter has been published as:  
Holland N, Jones PS, Savulich G, et al. Synaptic loss in the primary tauopathies, revealed 
by [11C]UCB-J Positron Emission Tomography. Mov Disord. 2020;35(10):1834-1842. 
doi:10.1002/mds.28188.  
The original data, on which the analyses in this chapter are based, were collected by 
myself, Dr George Savulich and Mrs Julie Wiggins.  Patients were scanned and assessed 
as part of the Synaptic Evaluation in NeuroDegeneration Research (SENDeR) study 
which was conceived by Professor James Rowe and Professor John O’Brien. The PET 
data were pre-processed by Dr Tim Fryer and Dr Young Hong. I designed the analysis 
strategy, performed the analyses, constructed the figures, and wrote the text. 
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Synaptic loss is a prominent and early feature of many neurodegenerative diseases. In this 
chapter I test the hypothesis that synaptic density is reduced in the primary tauopathies of 
progressive supranuclear palsy (PSP-Richardson’s syndrome) and amyloid–negative 
corticobasal syndrome (CBS). Thirty eight participants (9 CBD, 14 PSP, and 15 age-/sex-
/education-matched controls) underwent positron emission tomography (PET) with the 
radioligand [11C]UCB-J, which binds to synaptic vesicle glycoprotein 2A (SV2A), a 
marker of synaptic density. Participants also had 3T magnetic resonance imaging and 
clinical and neuropsychological assessment. All nine CBD patients had negative amyloid 
biomarkers determined by [11C]PiB PET.  Patients with PSP-Richardson’s syndrome and 
CBD were impaired in executive, memory and visuospatial tasks. [11C]UCB-J binding was 
reduced across frontal, temporal, parietal, and occipital lobes, cingulate, hippocampus, 
insula, amygdala and subcortical structures in both PSP and CBD patients compared to 
controls (p<0.01), with median reductions of up to 50%, consistent with post mortem data. 
Reductions of 20-30% were widespread even in the areas of the brain with minimal atrophy. 
There was a negative correlation between global [11C]UCB-J binding and the PSP and CBD 
rating scales (R= -0.61 p<0.002, R= -0.72 p<0.001, respectively), and a positive correlation 
with the revised Addenbrookes Cognitive Examination (R=0.52, p=0.01). I confirm severe 
synaptic loss in PSP and CBD in proportion to disease severity, providing critical insight 




3 | Synaptic loss in primary tauopathies revealed by [11C]UCB-J Positron Emission 
Tomography. 






Both PSP and CBD are associated with cortical and subcortical atrophy on magnetic 
resonance imaging (MRI) (Jabbari et al., 2019) and changes in neurophysiology and 
connectivity measured by magnetoencephalography (Sami et al., 2018) and functional MRI 
(reviewed in Filippi et al. (2019)), respectively. However, functional changes are also seen 
in the areas of the brain that are minimally atrophic, as reviewed in chapter 1.1.6. In this 
chapter I test the hypothesis that the neurophysiological and functional impairments in PSP 
and CBD are at least in part a consequence of synaptic loss. For example, at post mortem 
there is approximately 50% loss of cortical synapses in PSP and CBD (Bigio et al., 2001; 
Lipton et al., 2001), and in vivo there is limited evidence of a ~20% loss of postsynaptic 
GABAA receptors as shown with [
11C]flumazenil positron emission tomography (PET) (J. 
D. Andersson et al., 2019; Foster et al., 2000). Indeed abnormal physiology in pathways 
involved in presynaptic function have been identified from transcriptomic studies in 
patients with mutations in the microtubule-associated protein tau (MAPT) gene (Jiang et 
al., 2018). Transgenic models of tauopathies (e.g. rTg4510) confirm a synaptotoxic effect 
of oligomeric tau, before cell death (Kaniyappan et al., 2017; Menkes-Caspi et al., 2015). 
Moreover, in other neurodegenerative dementias, such as Alzheimer’s disease, synaptic 
loss correlates better with cognitive dysfunction than atrophy (Terry et al., 1991). To date 
however, there have been no direct in vivo assessment of synaptic density in PSP and CBD. 
Before outlining the methodology, I will review the normal physiological role of the 
synapse, the evidence suggesting a central role in cognition and the techniques used for 
measuring synapses in vivo.  
3.1.1 THE SYNAPSE 
3.1.1.1 The physiological role, and the structure of the synapse 
 
Synapses are fundamental components of neurons and allow an organised flux of 
information in the brain (Alberts et al., 1997). The emergence, diversification, and 
specialisation of synapses played a critical role in the evolution of higher brain functions 
and cognition in vertebrates (reviewed in Ryan and Grant (2009)). There are 100 trillion 
interconnecting synapses (Azevedo et al., 2009), each comprising of the pre- and 
postsynaptic membranes (separated by ~20 nm) and the synaptic cleft (Figure 3-1) (Stewart 
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et al., 2014). The efficiency of synaptic transmission and therefore intact cognition is 
dependent on the orchestrated activity and intact components of the pre- and postsynaptic 
membranes. Key to the process of neurotransmission is the release of neurotransmitter 
molecules from synaptic vesicles (residing in the presynaptic membrane) in response to an 
action potential induced rise in intracellular calcium. The presynaptic compartment 
contains the key molecules for formation, storage and release of neurotransmitter-
containing vesicles (Südhof, 2013). Once released into the synaptic cleft, neurotransmitters 
bind to the postsynaptic membrane (also known as dendritic spines) and transmit signals 
through activating either the excitatory (glutamatergic transmission) or inhibitory pathways 
(GABAergic transmission) (Chang-Lu Tao et al., 2018; Hering & Sheng, 2001) . Fast, 
point-to-point synaptic transmission is enabled by the temporal and spatial restriction of 
neurotransmitter release and reception, and by the precise alignment of pre- and 
postsynaptic structures at the synaptic junction. The presynaptic membrane almost always 
belongs to a neuron, however although the postsynaptic membrane is mostly neuronal, it 
can also be part of non-neuronal oligodendrocyte precursor cells suggesting a key role for 
neuroinflammatory cells in regulating synaptic transmission (Südhof, 2004).  
Synapses can be excitatory or inhibitory in nature, with slightly different structural 
morphology of the postsynaptic compartment. Excitatory synapses have an asymmetrical 
synaptic junction with a prominent postsynaptic density, and synaptic vesicles of spheroid 
character, whereas inhibitory synapses are typically GABA-ergic, have a synaptic junction 
that is symmetrical in form, do not contain a prominent postsynaptic density, and possess 
ellipsoidal synaptic vesicles (Stewart et al., 2014).  
In humans, most synapses are formed during pre- and postnatal development, with 
approximately 50% pruned in the first 2 decades of life, with prefrontal cortical synaptic 
pruning continuing well into the 3rd decade (Stewart et al., 2014).  Beyond this, synaptic 
numbers remain stable with a balance between some pruning and new synaptic formation, 
with a mild decline beyond the age of 80 (Peter R., 1979). 
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Figure 3-1. Schematic diagram of the components of a central synapse.  
Schematic drawing of a synaptic junction with a cluster of synaptic vesicles (SV) on the presynaptic 
side and neurotransmitter receptors on the postsynaptic side. Pre- and postsynaptic transport vesicles 
for receptors, active zone components, and trans-synaptic cell-adhesion molecules (CAMs) are 
indicated, as well as presynaptic endosomes and postsynaptic organelles (Golgi apparatus, 
endosomes, and endoplasmic reticulum [ER]). In the brain, the synaptic cleft is usually wider than 
the surrounding interstitial space. All synapses contain similar presynaptic components independent 
of type, although the specific isoforms of various proteins (synaptotagmins, neurotransmitter 
transporters, Ca2+ channels, etc.) vary. In contrast, postsynaptic components of excitatory and 
inhibitory synapses exhibit no homology, neither at the level of receptors nor in the postsynaptic 
scaffolding proteins. Additionally, presynaptic specialisations are formed exclusively by neurons, but 
postsynaptic specialisations can likely be formed by any cell in the body. Figure reproduced from 
Sudhof 2018 with permission from Elsevier.  
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3.1.1.2 Synaptic vesicle and their membrane proteins  
 
Key to synaptic transmission are synaptic vesicles which are packed within the presynaptic 
terminal of a synapse. There are several hundred to thousands of vesicles, each covered 
with numerous synaptic vesicle proteins on their membrane, containing neurotransmitters. 
In response to an action potential and calcium-dependent depolarisation of a presynaptic 
membrane, synaptic vesicles are primed, ready to fuse with the presynaptic terminal for 
neurotransmitter release. Synaptic vesicle distribution therefore appears to be related to 
functional activity with redistribution of vesicles in the synaptic bouton toward the synaptic 
active zone only occurring in response to an action potential. This mechanism underlies the 
phenomenon of long-term pentation and is the basis for learning and memory formation. 
The process of long-term potentiation involves a change in the efficacy of synaptic 
transmission, through changes in the morphology of synapses – this manifests as structural 
plasticity secondary to strengthening and growth of existing synapses and/or development 
of new synapses (Stewart et al., 2014).  
Efficient synaptic transmission depends on three sets of synaptic vesicles that have been 
identified based on location within the presynaptic compartment: those that are primed and 
ready to be fused with the presynaptic membrane (0.5-5% of all vesicles); the recycling 
pool (5-20% of all vesicles) which form part of the exocytosis-endocytosis cycle under high 
frequency physiological conditions, and used repeatedly during sustained activity; the 
reserve or resting pool (80-90% of all vesicles) which are only used under intense 
stimulation or when the recycling pool is depleted (Südhof, 2004). The mobilisation, 
priming, and docking of vesicles at the active zone, and subsequent exo- and endocytosis 
of synaptic vesicles are dependent on key proteins within the synaptic vesicle membrane 
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3.1.2 THE ROLE OF SYNAPSES IN COGNITION AND BEHAVIOUR 
The concept of synaptic involvement in learning and memory was first postulated by Hebb 
stating that changes underlying learning and memory occur in three stages, the first 
including synaptic plasticity (Hebb, 1949):  
“When an axon of cell A is near enough to excite a cell B and repeatedly or persistently 
takes part in firing it, some growth process or metabolic change takes place in one or both 
cells such that A’s efficiency, as one of the cells firing B, is increased.” 
Since the above postulation, many different methods have been devised to study synapses 
in the context of memory formation. These include post mortem studies of synaptic vesicle 
proteins, most commonly synaptophysin, the expression of which is considered a proxy for 
synaptic density (Hamos et al., 1989; Masliah et al., 1990). Alternative methods include in 
Figure 3-2. Synaptic Vesicle Proteins are key for neurotransmission.  
Schematic diagram of the structure of presynaptic vesicle proteins; the specific proteins shown here are key in 
the synaptic vesicle cycle and trafficking. SCAMPS: secretory membrane carrier proteins; VAMPs: vesicle-
associated membrane protein. CSP: cysteine string proteins. SVs: synaptic vesicle proteins. Figure reproduced 
from Südhof 1999, with permission from Nature publishing.  
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vitro synaptic assessments in transgenic or knock-out mouse models. For example, knock-
out mouse models lacking the presynaptic protein synaptotagmin-4 (key for 
neurotransmitter release), exhibit difficulties with hippocampal-dependent memory, 
contextual fear conditioning and the social transmission of food preference (Ferguson et 
al., 2000); synapsin-II knock-out mice show behavioural difficulties such as prepulse 
inhibition, decreased social behaviour and locomotor hyperactivity (Dyck et al., 2009) – an 
observation that was later replicated by downregulating the same protein within the medial-
frontal cortex (Dyck et al., 2011). One caveat to these experimental models for the study 
of synaptic function in learning and memory however, is the widespread effect knock-out 
models have on reducing specific synaptic proteins across whole brain, therefore hindering 
association with particular behavioural deficits. Additionally, given such knock-out mouse 
models do not survive to maturity, studying behaviour across the age-span becomes 
difficult. An alternative approach is therefore to study synaptic protein downregulation in 
specific parts of the brain by selective blockade – for example by using tetanus toxin. Using 
this approach, localised reductions in hippocampal synaptobrevin-2 has been associated 
with deficits in spatial learning and memory recall (Südhof, 2004). Acknowledging the key 
role of synapses in learning and memory, synaptic dysfunction has become a key focus of 
research in neurodegenerative diseases with prominent cognitive dysfunction and 
dementia, where for example in Alzheimer’s disease reductions have been reported as a 
better correlate with functional outcomes than neuronal loss (Scheff et al., 2006; Terry et 
al., 1991).   
3.1.3 MEASURING SYNAPSES IN VIVO  
The first method of quantifying synapses in patients with dementia utilised electron 
microscopy, however this technique is limited by its focus on a very small section of tissue, 
vulnerability to tissue processing and the need for rapid tissue fixation. Antigen-specific 
immunochemical detection methods have subsequently been developed. Given that 
synaptophysin is the most abundant synaptic vesicle protein, synaptophysin 
immunohistochemistry has been widely used as a marker of synaptic density, where its 
density as well as that of other synaptic proteins are reduced in PSP and CBD (Bigio et al., 
2001; Lipton et al., 2001), as well as in Alzheimer’s disease (Sze et al., 1997). Using the 
latter technique to assess synaptic density in humans is dependent on brain tissue from 
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autopsy or surgical resection, therefore greatly limiting the use of this approach for early 
diagnosis and therapeutic monitoring.   
In vivo assessment of synaptic density is possible using positron emission tomography 
(PET). Previously, the most widely used PET radioligand for the study of synaptic function 
was fluorodeoxyglucose (F18) positron emission tomography (FDG-PET). FDG-PET is a 
marker of glucose metabolism, and its uptake is therefore highly affected by synaptic 
density and activity. Using this method glucose hypometabolism is reported in the central 
region, the frontal and parietal association fibres, the putamen contralateral to the clinically 
affected side and the thalamus in CBS, and bilateral anterior cingulate and the midbrain in 
PSP (Amtage et al., 2014; Hellwig et al., 2012; Hellwig et al., 2015; Zhao et al., 2012).  
Glucose hypometabolism is however not only affected by neuronal synapses but also by 
the surrounding neuroinflammatory cells – synaptic loss can therefore be misrepresented 
given increased in FDG-PET due to neuroinflammation in PSP and CBS. An alternative in 
vivo assessment of synaptic density is through the use of synapse-specific PET 
radioligands, targeting the GABAA receptors ([
11C]flumazenil), dopamine receptors 
([18F]dopa and [11C]raclopride),  opioid receptors ([11C]diprenorphine), and muscarinic 
acetylcholine receptors ([11C]NMPB) (Niccolini & Politis, 2016) . Using dopamine and 
GABAA specific PET ligands in PSP and CBS, reductions in PET signal in hypometabolic 
cortical regions, and the basal ganglia, respectively have been observed. However, the 
interpretation of the signal from such receptor-specific scans is limited to the areas of the 
brain where these receptors are primarily located.  
More recently advances in synaptic imaging has allowed direct visualisation of synapses 
by targeting the synaptic vesicle 2A (SV2A) protein. SV2A is ubiquitous to all synaptic 
vesicles within the human brain except for the trigeminal and facial nuclei (Mendoza-
Torreblanca et al., 2013). This synaptic vesicle protein is an integral 12-transmembrane 
domain glycoprotein forming 3 isoforms within the synaptic vesicle glycoprotein family, 
including SV2A, B, and C, where the latter two isoforms have a more restricted distribution 
(Bajjalieh et al., 1994; Bajjalieh et al., 1993b). SV2A is present in both excitatory and 
inhibitory synapses, where it acts as a transporter and a gel matrix for the immobilisation 
and subsequent liberation of neurotransmitters; given its acidic N terminus, it is also 
postulated to be involved in calcium-dependent exocytosis (Südhof, 2004).  SV2A plays a 
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key role in the pathogenesis of epilepsy, where knock-out mice manifest with severe 
seizures, making this protein a focus for anti-epileptic drug targets. One such drug is 
levetiracetam (Keppra) which directly binds SV2A (Lynch et al., 2004), giving the 
opportunity to use its chemical structure in the recent development of the synaptic vesicle 
2A specific PET radioligand [11C]UCB-J ((R)-1-((3-(methyl-11C)pyridin-4-yl)methyl)-4-
(3,4,5-trifluorophenyl)pyr-rolidin-2-one) (Finnema et al., 2016).  
To date, [11C]UCB-J has been widely used in Alzheimer’s research where widespread 
reductions in SV2A binding have been reported in the medial temporal and neocortical 
brain regions in early disease, beyond the extent of grey matter volume loss. Furthermore, 
reductions in hippocampal SV2A binding were correlated with episodic memory loss and 
the clinical dementia rating scale (M. K. Chen et al., 2018; Mecca et al., 2020).  
I therefore use [11C]UCB-J PET to test the hypothesis that PSP and CBS reduce synaptic 
density, in proportion to disease severity. In this experimental chapter I include patients 
with the classic phenotype of PSP, PSP-Richardson’s syndrome, which has a high 
clinicopathological correlation (Gazzina et al., 2019). I include patients with Corticobasal 
Syndrome (CBS) with probable underlying CBD. In order to do this, it is necessary to 
exclude the substantial minority of CBS caused by Alzheimer’s disease pathology 
(Alexander et al., 2014). I therefore used amyloid imaging to distinguish those with CBS 
due to CBD, versus Alzheimer’s disease; I refer to this group as the CBD cohort. I further 
assess correlations between regional [11C]UCB-J binding potential, a metric of synaptic 
density, and disease severity, in terms of cognitive decline and global impairment on the 
PSP and CBD rating scales.  
  






3.2.1 PARTICIPANTS AND STUDY DESIGN  
Fourteen patients with PSP-Richardson’s syndrome and fifteen patients with CBS were 
recruited from a tertiary specialist clinic for PSP/CBS at the Cambridge University Centre 
for Parkinson-Plus. Fifteen healthy volunteers were recruited from the UK National 
Institute for Health Research Join Dementia Research (JDR) register. Patients had either 
probable PSP–Richardson Syndrome (Höglinger et al., 2017), or both probable CBS and 
probable CBD (Armstrong et al., 2013). Healthy controls and patient volunteers were 
initially screened by telephone; exclusion criteria were as per Chapter 2 (2.1.3). Eligible 
participants were invited for a research visit where they underwent clinical and cognitive 
assessment including measures of disease severity (Table 1); these included a neurological 
examination by a clinician including the PSP and CBD rating scales, the Schwab and 
England Activities of Daily Living (SEADL) and Clinical Dementia Rating Scale (CDR). 
Cognitive testing included the revised Addenbrooke’s Cognitive Examination (ACE-R), 
the Mini-mental State Examination (MMSE), and the INECO frontal assessment test. 
Patients’ carers completed the revised Cambridge Behavioural Inventory (CBI). 
All participants underwent simultaneous 3T MRI and [11C]UCB-J PET. Patients with CBS 
also underwent amyloid PET imaging using Pittsburgh Compound B ([11C]PiB) and 
cortical standardised uptake value ratio (SUVR; 50-70 minutes post injection; whole 
cerebellum reference tissue) was determined using the Centiloid Project methodology 
(Klunk et al., 2015). Only those with a negative amyloid status as characterised by a cortical 
[11C]PiB SUVR less than 1.21 (obtained by converting the Centiloid cut-off of 19 to SUVR 
using the Centiloid-to-SUVR transformation) (Jack et al., 2017b), are included in the 
subsequent analysis, with the aim of excluding patients with CBS due to Alzheimer’s 
disease. I interpret this amyloid-negative group as having CBD, although acknowledge that 
other pathologies are possible.  
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3.2.2 NEUROIMAGING PRE-PROCESSING  
 [11C]UCB-J was synthesised at the Radiopharmacy Unit, Wolfson Brain Imaging Centre, 
Cambridge University, using the methodology previously described (Milicevic Sephton et 
al., 2020) . Dynamic PET data acquisition was performed on a GE SIGNA PET/MR (GE 
Healthcare, Waukesha, USA) for 90 minutes starting immediately after [11C]UCB-J 
injection (median injected activity: 351  107 MBq, injected mass  10 g), with 
attenuation correction including the use of a multi-subject atlas method (Burgos et al., 
2014)  and also improvements to the MRI brain coil component (Manavaki et al., 2019). 
Each emission image series was aligned using SPM12 
(www.fil.ion.ucl.ac.uk/spm/software/spm12/) then rigidly registered to a T1-weighted 
MRI acquired during PET data acquisition (TR = 3.6 msec, TE = 9.2 msec, 192 sagittal 
slices, in plane resolution 0.55 x 0.55 mm (subsequently interpolated to 1.0 x 1.0 mm); slice 
thickness 1.0 mm). Using a version of the Hammersmith atlas (http://brain-
development.org) with modified posterior fossa regions, combined regions of interest 
(including aggregated regions for frontal, parietal, occipital, and temporal lobes; cingulate; 
and cerebellum) were spatially normalized to the T1-weighted MRI of each participant 
using Advanced Normalisation Tools (ANTs) software(Avants et al., 2008). Regional time-
activity curves were extracted following the application of geometric transfer matrix 
(GTM) partial volume correction (PVC, (Rousset et al., 1998)) to each of the dynamic PET 
images. Regions of interest (ROIs) were multiplied by a binary grey matter mask (>50% 
on the SPM12 grey matter probability map smoothed to PET spatial resolution), with the 
exception of the pallidum, substantia nigra, pons and medulla because masking eliminated 
the ROI for some or all of the subjects. Multiple background grey matter, white matter and 
cerebrospinal fluid (CSF) regions were also defined to provide whole brain coverage for 
GTM PVC. The mean grey matter/(grey matter + white matter) fraction in the masked ROIs 
was 0.97 ± 0.03, 0.96 ± 0.03 and 0.96 ± 0.03 for the control, CBD and PSP groups, 
respectively, illustrating the predominance of grey matter in the masked ROIs. To assess 
the impact of PVC, time-activity curves were also extracted from the same ROIs without 
the application of GTM PVC. 
To quantify SV2A density, [11C]UCB-J non-displaceable binding potential (BPND) was 
determined, both regionally and at the voxel level, using a basis function implementation 
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of the simplified reference tissue model (Wu & Carson, 2002), with the reference tissue 
defined in the centrum semiovale (Koole et al., 2019; Rossano et al., 2019). The volume-
weighted average of the GTM PVC BPND values in the masked ROIs was used as a global 
BPND metric. Group average BPND images (illustrated in Figure 3-3) were obtained by 
spatially normalising each individual T1-weighted MRI (and thereby the co-registered 
BPND map) to MNI space, and then to the group template using ANTs.  
3.2.3 STATISTICAL ANALYSIS 
Statistical analyses used R (version 3.6.2), with analysis of covariance (ANCOVA) to 
compare regional [11C]UCB-J BPND between the three groups (Control, CBD, PSP), with 
age as a covariate of no interest. Regions of interest were: frontal, temporal, parietal, 
occipital lobes; cingulate cortex, hippocampus, insula, amygdala, caudate nucleus, nucleus 
accumbens, putamen, pallidum, thalamus, cerebellum, substantia nigra, midbrain, pons, 
and medulla.   
The relationships between [11C]UCB-J BPND, disease severity (PSP and CBD Rating 
Scales) and cognition (revised Addenbrooke’s Cognitive Examination) were tested through 
linear models of the patient data, with age as a covariate of no interest.  
The primary analyses used BPND determined following GTM PVC, but all analyses were 
repeated using BPND without PVC yielding similar results.   
3.3 RESULTS 
3.3.1 CLINICAL SUMMARY AND DEMOGRAPHICS  
Of the fifteen patients with CBS, six had a cortical [11C]PiB SUVR more than 1.21 and 
were therefore excluded from further analysis in this chapter. The remaining groups (9 
CBD, 14 PSP, 15 controls) were matched in age, sex and education (Table 3-1). We 
observed typical cognitive profiles, as summarised in Table 1: patients were impaired on 
memory, verbal fluency, language, and visuospatial domains of the ACE-R, and MMSE. 
There were high endorsements on the Cambridge Behavioural Inventory, and the Clinical 
Dementia Rating scale, with impairment of activities of daily living on the Schwab and 
England scale. Patients were not on any medications that are known to affect [11C]UCB-J 
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binding.  Four of our patients (1 PSP, 3 CBD) were on dopaminergic medication, and 9 on 
amantadine (3 PSP, 6 CBD).  
 
Table 3-1. Demographics and neuropsychological profile for each participant cohort 
The results are given as mean (standard deviation). CBD here refers to corticobasal syndrome with a negative 
amyloid biomarker from [11C]PiB PET, and PSP refers to patients with PSP-Richardson’s syndrome. The F-
statistic and p-values are derived from ANOVA. ACE-R: revised Addenbrooke’s Cognitive Examination, 
MMSE: Mini-mental State Examination, PSPRS: Progressive Supranuclear Palsy Rating Scale, CBDRS: 
CBD functional rating scale, INECO: frontal assessment tool, CDR: Clinical Dementia Rating Scale, CBI: 
revised Cambridge Behavioural Inventory, SEADL: Schwab and England Activities of Daily Living Scale. a 




3.3.2 WIDESPREAD REDUCTION IN CORTICAL AND SUBCORTICAL SYNAPTIC DENSITY 
Compared to controls, in patients there was a significant global reduction in [11C]UCB-J 
BPND (Figure 3-3) across all major cortical and subcortical areas (p<0.05 FDR corrected 
for all regions of interest shown in Figure 3-3); regional BPND values for the three groups 
are reported in Table 3-2. BPND in PSP and CBD was 20-50% lower than controls (p<0.01), 
 Control CBD PSP F (p) 
 M:F  
7:8 7:2 7:7 nsa 
 Age at [11C]UCB-J PET in years  
68 (7.45) 70.56 (8.23) 72.79 (7.74) ns 
 Disease duration in years  
NA 3.94 (2.2) 4.28 (2.57) nsb  
 Education in years  
13.69 (2.66) 12.78 (3.27) 12.77 (5.43) ns 
 ACE-R total (max. 100) 96.47 (2.88) 81.56 (10.83) 80.57 (15.02) 9.61 (<.0004) 
       Attention_Orientation (max .18) 17.87 (0.35) 16.89 (1.05) 16.43 (2.06) 4.11 (0.02) 
       Memory (max .26) 24.53 (1.85) 20.67 (5.66) 21.43 (4.27) 3.50 (0.04) 
       Fluency (max .14) 12.80 (1.15) 8.22 (2.86) 6.43 (3.44) 22.81 (<.001) 
       Language (max .26) 25.53 (0.92) 22.44 (5.34) 23.43 (5.21) ns 
       Visuospatial (max .16)  
15.73 (0.59) 13.33 (2.55) 12.86 (3.98) 4.46 (0.02) 
 MMSE (max. 30) 
 
 
29.27 (1.33) 26.44 (3.13) 27.00 (2.88) 4.78 (0.01) 
 PSPRS (max. 100) 
 
0.13 (0.52) 26.78 (9.61) 29.21 (10.27) nsb 
 CBDRS (max. 124) 
 
0.20 (0.77) 29.12 (13.52) 36.80 (20.41) nsb 
 INECO (max. 30)  
26.00 (1.85) 14.6 0(8.47) 17.70 (4.74) 17.22 (<.001) 
 CDR sum of boxes (max. 32)  
0.07 (0.26) 6.78 (4.71) 7.54 (6.55) 11.28 (<.001) 
 CBI (max. 180)  
2.47 (4.81) 27.44 (13.5) 42.43 (38.13) 9.97 (<.001) 
 SEADL (max. 1) 0.99 (0.03) 0.56 (0.28) 0.60 (0.22) 10.54 (<.001) 
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with the most severe median reduction seen in the medulla, substantia nigra, pallidum, 
midbrain, pons and caudate nucleus in patients with PSP, and in the medulla, hippocampus, 
amygdala, caudate nucleus, insula and thalamus in patients with CBD. Post-hoc analysis 
revealed that the significant differences in BPND between patients and controls in the 
pallidum and substantia nigra were mainly driven by the PSP cohort. Using data without 
GTM PVC, the pattern of statistically significant differences in BPND for the reported 
regions in Table 2 remains, p<0.001. 
3.3.3 SYNAPTIC LOSS OCCURS BEYOND THE EXTENT OF ATROPHY  
The reduction in synaptic density was seen even in the areas of the brain that did not show 
significant grey matter atrophy. Figure 3-4A shows group differences in grey matter 
volume normalized against the mean of the control group. The significant areas of grey 
matter volume loss were in the caudate nucleus (p=0.01), and thalamus (p=0.04) in the 
CBD cohort, and in the frontal (p<0.01), temporal (p=0.04), parietal (p<0.01), occipital 
lobes (p<0.01), caudate nucleus (p<0.001), and the thalamus (p<0.01) in the PSP cohort. 
The reduction in [11C]UCB-J BPND however, is more extensive and consistently 
significantly different across all major cortical and subcortical areas as shown in the 
normalised plot in  Figure 3-4B  (binding potentials were normalised against the mean 
binding potential of the control cohort for each region of interest). 
  



















Figure 3-3. Widespread reductions in cortical and subcortical synaptic density in PSP and CBD. 
(A) Mean [11C]UCB-J BPND maps for control participants (top row), CBD (middle row), and PSP (bottom 
row); high and low BPND values are shown by red and blue areas, respectively. (B) Reduction in global 
[11C]UCB-J BPND across patients compared to controls (P<0.05). (C) Individual regional GTM PVC 
[11C]UCB-J BPND values for control, CBD and PSP participants, across major regions of interests. Binding 
potential values for patients differed significantly from controls in all the regions depicted (P<0.05, FDR 
corrected).  
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Region Control CBD PSP F (p) 
Frontal Lobe 
2.96 (0.17) 2.60 (0.29) 2.48 (0.28) 15.05 (<0.0001) 
Temporal Lobe 
2.68 (0.16) 2.30 (0.23) 2.17 (0.27) 19.34 (<0.0001) 
Parietal Lobe  
3.11 (0.19) 2.75 (0.32) 2.63 (0.36) 10.10 (<0.0003) 
Occipital Lobe  
2.98 (0.23) 2.66 (0.29) 2.48 (0.41) 8.80 (0.0008) 
Cingulate 
3.02 (0.21) 2.56 (0.26) 2.46 (0.28) 20.41 (<0.0001) 
Insula  
2.76 (0.15) 2.24 (0.26) 2.17 (0.27) 28.55 (<0.0001) 
Amygdala 
2.71 (0.20) 2.18 (0.34) 2.20 (0.33) 14.67 (<0.0001) 
Nucleus Accumbens  
4.18 (0.31) 3.85 (0.46) 3.54 (0.33) 11.28 (0.0002) 
Hippocampus 
2.00 (0.20) 1.57 (0.29) 1.57 (0.30) 12.37 (<0.0001) 
Caudate Nucleus 
3.12 (0.22) 2.59 (0.41) 2.48 (0.36) 15.59 (<0.0001) 
Pallidum 
1.90 (0.22) 1.65 (0.24) 1.27 (0.31) 20.69 (<0.0001)a 
Putamen 
3.99 (0.24) 3.43 (0.32) 3.28 (0.37) 19.94 (<0.0001) 
Thalamus 
2.86 (0.25) 2.29 (0.45) 2.25 (0.44) 11.23 (<0.0002) 
Cerebellum 
2.13 (0.22) 1.75 (0.30) 1.69 (0.28) 11.50 (0.0001) 
Midbrain 
2.61 (0.29) 2.16 (0.38) 1.83 (0.42) 16.61 (<0.0001) 
Substantia Nigra 
2.13 (0.28) 1.72 (0.34) 1.32 (0.59) 12.79 (<0.0001)a 
Pons 
0.93 (0.13) 0.75 (0.18) 0.71 (0.18) 7.69 (0.002) 
Medulla 
0.62 (0.16) 0.37 (0.17) 0.28 (0.24) 12.04 (<0.001) 
 
Table 3-2. Mean (standard deviation) GTM PVC [11C]UCB-J BPND values per group. 
Values are shown for cortical and subcortical regions of interest (surviving false discovery rate correction 
over 18 regions). CBD here refers to corticobasal syndrome with a negative amyloid biomarker from [11C]PiB 
PET, and PSP refers to patients with PSP-Richardson’s syndrome. F-statistic and p-values derived from an 
ANCOVA across the three groups, with age as a covariate of no interest. athe significant difference here is 
driven by the PSP group only.  
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Figure 3-4. Normalised grey matter volume and [11C]UCB-J BPND in regions of interest.  
(A) Cortical and subcortical grey matter volumes, normalised against the corresponding volumes in controls, 
were significantly reduced in the caudate nucleus and thalamus in CBD; and in frontal, temporal, parietal and 
occipital lobes, as well as in the caudate nucleus, and thalamus in PSP, P<0.05.  (B) Mean-centred [11C]UCB-
J BPND across cortical and subcortical regions of interest normalised against the corresponding BPND values 
in controls, demonstrating a median reduction of 20-50%.  
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3.3.4 SYNAPTIC LOSS CORRELATES WITH DISEASE SEVERITY AND GLOBAL 
COGNITION 
Correlations between [11C]UCB-J BPND and both global cognition and disease severity are 
given in Figure 3-5. A significant positive correlation was seen between global [11C]UCB-
J BPND and the revised Addenbrooke’s Cognitive Examination total score (R=0.52, p=0.01) 
(Figure 3-5A). There was a significant negative correlation between global [11C]UCB-J 
BPND and the PSP (R= -0.61, p<0.01), and CBD (R= -0.72, p<0.001) rating scales (Figure 
3-5B&C). 
  
Figure 3-5. Synaptic loss correlates with disease severity and global cognition.  
Correlations between global [11C]UCB-J BPND and total ACE-R score (A),  total PSP rating scale (B),  and total CBD rating 
scale (C) for the two patient groups.   
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The principal result of this experimental chapter is a widespread reduction in synaptic 
density in PSP-Richardson’s syndrome and amyloid-negative Corticobasal Syndrome 
(CBS) (which I define as Corticobasal Degeneration (CBD)). This accords with post 
mortem estimates of synaptic loss in PSP and CBD, using synaptophysin 
immunohistochemistry (Bigio et al., 2001; Lipton et al., 2001), imaging of neurite density 
in PSP (Mitchell et al., 2019)  and morphological studies of cortical dendrites in the closely 
related condition of frontotemporal lobe dementia (I Ferrer et al., 1991). Indirect evidence 
of synaptic loss, from consequential reduction in metabolism, comes from [18F]FDG PET 
changes in frontal, temporal and parietal lobes (Blin et al., 1992; Eidelberg et al., 1991; 
Foster et al., 1988; Juh et al., 2004). However, PET imaging with the ligand [11C]UCB-J 
provides direct evidence in vivo of severe and extensive loss of cortical and subcortical 
synapses, including areas of the brain that are minimally atrophic (Josephs et al., 2008).  
Progressive supranuclear palsy and corticobasal degeneration are progressive, with an 
average disease duration of five to eight years from symptom onset (Coyle-Gilchrist et al., 
2016). In our clinically diagnosed CBD and PSP groups, the mean symptom duration at the 
time of PET was three and a half years, and our patients were likely to be approximately 
mid-way through their symptomatic disease course (not including a potentially long pre-
symptomatic period). The median reduction of 20% (and maximal 50%) in [11C]UCB-J 
binding observed in vivo compared to controls, is therefore in keeping with the predictions 
from post mortem data.  
The synaptic loss observed in our study is widespread, extending beyond the regions that 
are arguably most associated with the diseases. In PSP, from post mortem studies, these 
include basal ganglia, thalamus, substantia nigra, premotor cortex, as well as the dentate 
nucleus. In CBD, areas associated with the disease include cortex, thalamus, basal ganglia 
and brainstem, without significant cerebellar involvement (Dickson et al., 2011; Kovacs et 
al., 2020). However, in our study the loss of synapses in PSP is global across the cortex, 
and not confined to the premotor and motor areas, and extends beyond the substantia nigra 
in the brainstem with pontine and medullary involvement. The loss of synapses in the 
cerebellum in PSP echoes pathological studies of tau distribution in this disease. 
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Interestingly, the cerebellum was also markedly abnormal in CBD; although cerebellar 
atrophy and tau accumulation are not typical associations of CBD. Cerebellar synaptic loss 
in CBD may therefore represent cerebellar diaschisis in response to widespread cortical 
pathology and loss of cortico-cerebellar projections; an alternative explanation is that a 
small minority of individuals in an amyloid-negative CBS cohort may have PSP as the 
underlying cause for their corticobasal syndrome, although this is unlikely to be sufficient 
to drive the group-wise effect.   
Preclinical models of tauopathy suggest early synaptotoxicity with reduced plasticity and 
density (Menkes-Caspi et al., 2015), in response to soluble oligomeric tau aggregates 
(Kaniyappan et al., 2017) and inflammation (Rajendran & Paolicelli, 2018; Vogels et al., 
2019). Recently in patients with Alzheimer’s disease, using [11C]UCB-J, [18F]flortaucipir 
(PET radioligand targeting tau), and magenotoencephalography (used to assess cortical 
function in vivo), Coomans et al have demonstrated synaptic reductions with increasing tau 
load, both associated with reduced synaptic function on electrophysiology (Coomans et al., 
2021).  The toxicity associated with tau pathology leading to synapse loss is complex and 
involves direct and indirect pathways (reviewed in Spires-Jones and Hyman (2014)). 
Naturally occurring tau plays a role in synaptic function through modulating microtubule 
and axonal stability; disruptions to this machinery leads to prevention of the trafficking of 
essential components to synapses such as synaptic receptors and mitochondria (Hoover et 
al., 2010; Kopeikina et al., 2011). Indeed, over-expression of tau interferes with 
mitochondria transport (Stoothoff et al., 2009), and contributes to hyperexcitability of 
neurons and impaired calcium influx in transgenic mouse models (rTg4510) (Rocher et al., 
2010).  
The global nature of synaptic reduction suggests a more widespread pathology in the 
primary tauopathies of PSP and CBD beyond the areas that are histologically reported as 
harbouring a high tau burden such as the basal ganglia, thalamus, and brain stem (Dickson 
et al., 2011; Kovacs et al., 2020).  This may in part be explained by the global damage 
caused by oligomers of tau which are not easily visible on tau PET imaging or histology. 
In support of this are biochemical studies that report tau accumulation in both grey and 
white matter by western blot in PSP but not necessarily by immunohistochemistry 
(Zhukareva et al., 2006). The pathological role of tau fibril is under debate, however toxic 
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tau oligomers in PSP (Gerson et al., 2014) are thought to play a crucial role in the 
pathogenesis of tauopathies through their gain of toxic function; this includes causing loss 
of membrane integrity (Flach et al., 2012), mitochondrial and synaptic dysfunction 
(Lasagna-Reeves et al., 2011b), and impairment of axonal transport, long-term 
potentiation, memory and cognition (Lasagna-Reeves et al., 2011b; Morfini et al., 2009; 
Ward et al., 2012).  
In this experiment I observed a significant correlation between synaptic loss and disease 
severity in PSP and CBD. Synaptic loss correlates with cognitive impairment in another 
clinical tauopathy, Alzheimer’s disease (Scheff et al., 2006; Terry et al., 1991), and 
preclinical models of this (Kandimalla et al., 2018; Lasagna-Reeves et al., 2011b; Walsh et 
al., 2002). The in vivo PET results in this chapter support the potential use of synaptic PET 
as a marker of disease and progression, but longitudinal data are required. Synaptic PET 
may support early stage clinical trials in PSP and CBS/CBD; it is encouraging in this latter 
respect that, in another neurodegenerative disease, [11C]UCB-J PET is sensitive to 
progressive changes in synaptic density, for example in response to treatment with the 
synaptic modulator Saracatinib (Toyonaga et al., 2019). 
This experimental chapter has a few limitations. The sample size is small, however it is 
adequately powered in view of the large effect sizes predicted. Nevertheless, subtler 
relationships with mild disease, progression or individual clinical features, or phenotypic 
variants of PSP and CBS, require larger studies. I acknowledge the potential for off-target 
binding, but preclinical data indicate very high correlations between UCB-J and 
synaptophysin, a marker of presynaptic vesicular density (Finnema et al., 2016; Finnema 
et al., 2018). The diagnoses used were clinical, without neuropathology, although the 
clinicopathological correlations of PSP-Richardson syndrome are very high, and in the 
absence of Alzheimer’s disease, the clinicopathological correlation of CBS with a 4R-
tauopathy (CBD or PSP) is also high. Binding potentials for SV2A radioligands such as 
[11C]UCB-J can be confounded by the use of concurrent medication that may bind to SV2A. 
I did not enrol any individuals taking levetiracetam or any member of this family of drugs 
that are SV2A-specific ligands (Löscher et al., 2016). Previously reported studies using 
[11C]UCB-J in disease have usually not commented on medications used by participants, 
however one study using this ligand in major depressive disorders reports exclusion of 
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participants on psychotropic medications in the 2 months preceding PET scanning (S. E. 
Holmes et al., 2019); whilst many of my PSP and CBD patients are on medications falling 
under the psychotropic umbrella, to my knowledge, none of these bind to SV2A.    
Arterial blood sampling was not carried out in this study; I used reference tissue modelling 
to reduce the demand on the patient cohort. Reference tissue modelling of [11C]UCB-J with 
the centrum semiovale as the reference tissue has been verified against arterial input 
function compartmental modelling in healthy controls (Koole et al., 2019; Rossano et al., 
2019) and in Alzheimer’s disease (M. K. Chen et al., 2018; Mecca et al., 2020). To assess 
the validity of the centrum semiovale in our cohort, we determined the mean total 
distribution volume (VT) for each of our subject groups using standard arterial input 
function data from the literature (Finnema et al., 2018; Mansur et al., 2020); this approach 
assumed that the standard input function was equally valid for all groups. This analysis 
indicated a small positive bias in centrum semiovale VT for CBD (5%) and less so PSP 
(2%) relative to that in controls, which would lead to a commensurate reduction in BPND 
under the assumption that the non-displaceable distribution volume (VND) in the target 
ROIs remains invariant. These biases cannot, however, explain the much greater BPND 
reductions seen for CBD and PSP, which is especially true for PSP. Indeed, scaling BPND 
in the CBD and PSP cohorts to account for the above biases in centrum semiovale VT, 
produced a similar pattern of significant global reduction in BPND for patients compared to 
controls, except that the significant differences in the midbrain, pons, substantia nigra, 
pallidum, and occipital lobe were primarily driven by the PSP cohort in the post-hoc 
analysis. 
The therapeutic challenge in tauopathies is partly due to the complex nature of the 
underlying pathology. Early stage trials will require early accurate diagnosis, although 
diagnosis is typically made 3 years after symptom onset (Coyle-Gilchrist et al., 2016; 
Mamarabadi et al., 2018). It is unlikely that synaptic PET could provide pre-symptomatic 
diagnosis in rare conditions, but it is a promising tool to characterise pathogenetic 
mechanisms, monitor progression and assess response to experimental medicines (Cai et 
al., 2019).   
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4 IN VIVO COUPLING OF DENDRITIC 
COMPLEXITY WITH PRESYNAPTIC DENSITY 
IN PRIMARY TAUOPATHIES 
  
A manuscript related to this chapter has been published as:  
Mak, E*, Holland, N*, Jones, S, et al. In vivo coupling of dendritic complexity with 
presynaptic density in primary tauopathies. Neurobiol Aging. 2021.  DOI: 
10.1016/j.neurobiolaging.2021.01.016.     *Joint first author 
 
The original data, on which the analyses in this chapter are based, were collected by 
myself, Dr George Savulich and Mrs Julie Wiggins.  Patients were scanned and 
assessed as part of the Synaptic Evaluation in NeuroDegeneration Research 
(SENDeR) study which was conceived by Professor James Rowe and Professor John 
O’Brien. The PET data were pre-processed by Dr Tim Fryer and Dr Young Hong, 
and the MRI Neurite Orientation and Dispersion Imaging by Dr Elijah Mak. Together 
with Dr Mak, I designed the analysis strategy, performed the analyses, constructed 
the figures, and wrote the text.  





Understanding the cellular underpinnings of neurodegeneration remains a challenge. Loss 
of presynaptic density and postsynaptic dendritic complexity are characteristic and can be 
quantified in vivo, with [¹¹C]UCB-J PET and Orientation Dispersion Imaging (ODI, an 
MRI-based method), respectively. In this chapter I assess how the pre- and postsynaptic 
compartments are correlated in vivo in the 4-repeat tauopathies of Progressive Supranuclear 
Palsy and amyloid-negative Corticobasal Syndrome (CBS) as disease models of 
neurodegeneration. Patients with PSP (n= 24), and CBD (n= 15; amyloid negative as 
determined by [¹¹C]PiB PET) were recruited from a tertiary PSP/CBS clinic; 27 age- and 
gender-matched controls were recruited from the Join Dementia Research Platform. All 
participants underwent a 3T MRI with Neurite Orientation Dispersion Imaging (NODDI), 
[¹¹C]UCB-J PET, as well as neuropsychological testing. Patients with PSP and CBD had 
widespread reductions in cortical ODI, and [¹¹C]UCB-J non-displaceable binding potential 
(BPND) even when corrected for level of cortical atrophy, compared to healthy controls. 
Furthermore, presynaptic density as indexed by [¹¹C]UCB-J BPND, is tightly positively 
correlated with postsynaptic dendritic complexity, as indexed by ODI, across a wide range 
of cortical regions including the frontal and temporal cortices, as well as subcortical areas 
including the basal ganglia and brainstem (FDR corrected p < 0.05).  This correlation was 
seen in the patient cohort only. Both measures, and the correlations between them, provide 
new insights into the pathophysiology of neurodegenerative diseases, and allow for a safe 
and widely available MRI platform to be used in future studies of synaptic health in 
neurodegeneration.  





Abnormal dendritic morphology, and synaptic pathology are increasingly recognised as 
hallmarks of neurodegeneration, prior to cell death and atrophy, and correlate closely with 
cognitive dysfunction (Clare et al., 2010; DeKosky & Scheff, 1990; Dorostkar et al., 2015; 
Terry et al., 1991). However, quantification of synaptic pathology in vivo has until recently 
posed a challenge. In the previous chapter, using the novel PET radioligand [11C]UCB-J, I 
confirmed widespread loss of presynaptic density. Whether this pathogenic mechanism is 
associated with changes within the postsynaptic compartment, in primary tauopathies, has 
not been assessed in vivo.  
4.1.1 POSTSYNAPTIC COMPARTMENT AND ITS PHYSIOLOGICAL ROLE  
The postsynaptic compartment comprises of the dendritic spines of the postsynaptic 
neuron. Dendritic spines are numerous in numbers; for example, the frontal cortex layer-3 
pyramidal neurons typically possess approximately 6,000 dendritic spines (Rocher et al., 
2008). Dendritic spines are categorised based on their morphology into thin, stubby, 
mushroom, and cup-shaped (Harris et al., 1992). There is a however a dynamic change in 
spine morphology with presynaptic stimulation and in response to the surrounding 
environment. The morphology, structure and function of dendritic spines is modulated by 
a group of postsynaptic density (PDS) proteins which can be divided into four subgroups: 
scaffold proteins, receptor transmembrane proteins, cytoskeletal proteins and signalling 
proteins (Hering & Sheng, 2001; Verpelli et al., 2013). These proteins act in consort to 
ensure efficient signal transmission from the presynaptic membrane to the postsynaptic 
compartment, through the phenomenon of long-term potentiation - a functional correlate of 
dendritic spine plasticity which is dependent on the change in size and number of dendritic 
spines (Fu & Zuo, 2011).  
The most abundant, and one of the widely studied, postsynaptic scaffolding proteins is 
PSD-95. It is localised very close to the postsynaptic membrane and thus can easily interact 
with receptors, ion channels and adhesion molecules, as well as with cytoplasmic proteins 
(Verpelli et al., 2013). It plays a key role in organising the signalling complexes at the 
postsynaptic membrane and is therefore critical to the function of the dendrite and long-
term plasticity. Indeed, dysfunction of scaffolding proteins are key events in the 
pathophysiology of autism, schizophrenia and Alzheimer’s disease. For example, 




alterations in the expression of PSD-95 has been found in patients with Alzheimer’s disease  
(Leuba et al., 2008) and in mouse models of Fragile-X syndrome with prominent cognitive 
and behavioural features (Zalfa et al., 2007). Similarly, deletion of the ProSAP2/Shank3 
gene leading to absence of other scaffolding proteins, leads to Phelan-McDermid Syndrome 
presenting with significant dysfunction in multiple cognitive domains (Phelan & 
McDermid, 2012).  
There are two key cytoskeletal components within the postsynaptic density, critical for 
dendritic structure and function: filamentous actin (F-actin), and microtubules (Fischer & 
Fowler, 2015). It is therefore not surprising that in neurodegenerative diseases with 
aggregation of the hyperphosphorylated microtubule-associated protein tau, microtubule 
dynamics is changed, causing changes in dendritic structure and function (Zempel & 
Mandelkow, 2014; Zempel et al., 2010). Moreover, mutations in the LRRK2 gene, that 
have recently been associated with predicting survival in PSP (Chen-Plotkin, 2021; 
Guerreiro et al., 2016), amongst many other pathological sequelae, are thought to be 
involved in microtubule fragmentation, and therefore dendritic dysfunction (Lin et al., 
2010).  
Loss of dendritic spine, and abnormal dendritic function in tauopathies, can therefore occur 
as a result of loss of afferent input secondary to presynaptic loss (as reviewed in Chapter 
3), loss of the neuron- and axon-autonomous function, and also as a result of direct toxicity 
from hyperphosphorylated tau and tau oligomers in the extracellular space, and 
inflammation (Hoffmann et al., 2014; Kweon et al., 2017). Given that presynaptic density, 
and dendritic spine morphology are directly linked to synaptic function (Jähne et al., 2021; 
Yuste & Bonhoeffer, 2001), I propose that with the loss of synapses, presynaptic vesicle 
density as measured with [11C]UCB-J, would correlate with changes in postsynaptic 
dendritic complexity, in PSP and CBD.  
4.1.2 MEASURING DENDRITIC SPINES AND COMPLEXITY  
The gold standard technique for studying dendritic spines in vitro is electron microscopy 
allowing the analysis of dendritic spine ultrastructure. Other techniques include 
immunohistochemistry using antibodies against various postsynaptic density proteins. The 
use of such techniques on, and interpretation of results from, donated human brain tissue is 
however limited given the rapid hypoxic-induced changes in dendritic spines soon after 




death (Stewart et al., 2014). Furthermore in vitro methods do not allow correlations with 
disease severity in life, and the potential for therapeutic monitoring. 
Microstructural integrity can be assessed in vivo using Diffusion Tensor Imaging (DTI). 
However, while diffusion tensor imaging (DTI) has proved to be a valuable non-invasive 
technique to probe microstructural white matter integrity, it has limited utility to 
characterise such changes in the cortex due to the isotropic water diffusion of the grey 
matter. To address the limitations of DTI, Neurite Orientation Dispersion Imaging 
(NODDI) has been developed. NODDI is a multi-compartment biophysical diffusion 
imaging model that is capable of disentangling the diffusion signal arising from distinct 
tissue compartments, such as extracellular, intracellular water and cerebrospinal fluid (H. 
Zhang et al., 2012). This multi-compartmentalisation of the diffusion signal enables metrics 
such as Neurite Density Index and Orientation Dispersion Index (ODI) to characterise the 
number of neurites as well as the variability of neurite orientations, respectively. Both the 
clinical feasibility and relevance of NODDI alterations have been successfully 
demonstrated in normal ageing and dementia (Cox et al., 2016; Parker et al., 2018; H. 
Zhang et al., 2012). However, the biological substrates of NODDI are still unclear due to 
limited evidence of cross-validation among NODDI metrics and alternative proxies of grey 
matter microstructure. Recent studies have shown that NODDI Orientation Dispersion 
Index (ODI) is correlated with histologically-derived indices of neurite dispersion (Grussu 
et al., 2017; Schilling et al., 2018), highlighting its potential viability as a proxy of 
underlying biological changes in grey matter microstructure. Of particular relevance to this 
chapter, reductions in cortical ODI has been found in a tau-transgenic mouse model, 
entirely consistent with the severe extent of dendritic degeneration (Colgan et al., 2016). 
There has not yet been an attempt to characterise the coupling of cortical ODI with 
measurements of synaptic pathology (with [11C]UCB-J PET imaging). Compared to PET 
imaging, the ODI from NODDI would have the advantage of wide scalability in multicentre 
studies, repeatable assays without ionising radiation, and lower cost within a clinically 
feasible acquisition time (~ 15 minutes).  
In this proof-of-concept study, I focus on progressive supranuclear palsy – Richardson’s 
Syndrome (PSP) and Corticobasal Degeneration (CBD) as disease models. In PSP and 
CBD grey matter atrophy although present, is not extensive unlike in Alzheimer’s disease 
where we would expect generalised atrophy; this allows us to examine cortical 




microstructure without the influence of atrophy. I test the hypothesis that functionally 
relevant loss of presynaptic density caused by PSP and CBD is correlated to the changes in 
postsynaptic dendritic complexity, independent of changes in grey matter atrophy.    
4.2 METHODS AND STUDY DESIGN 
The current experiment and the experiment reported in Chapter 3 were both part of the 
same protocol. Thus, the participants, inclusion and exclusion criteria, and study procedure 
overlap with those reported in Chapters 2 & 3. Compared to the cohort in Chapter 3, the 
current experiment featured twelve more control participants, five more patients with CBD, 
and eight more patients with PSP. Thus, the full sample available for the analysis of changes 
in Orientation Dispersion Imaging consisted of 27 controls, 14 patients with CBD, and 22 
with PSP. Demographic details for this extended cohort are provided in Table 4-1. 
4.2.1 NEUROIMAGING PRE-PROCESSING  
4.2.1.1  T1-weighted MRI  
 
T1-MPRAGE was acquired on high resolution Siemens Magnetom 3T PRISMA scanner 
(TE = 2.93 ms, TR = 2s, slice thickness = 1.1 mm , resolution = 1.1 mm3 isotropic, 208 
slices) (Table 2-2). The data were processed using Computational Anatomy Toolbox in 
SPM12. The T1-MPRAGE images were then segmented into grey matter, white matter, 
and CSF images by using a unified tissue segmentation technique after image intensity non-
uniformity correction was performed. Regional cortical thickness was derived in CAT12 
based on the projection-based thickness method (Dahnke et al., 2013) which uses topology 
correction (Yotter et al., 2011a) and spherical mapping (Yotter et al., 2011b). Previous 
studies have shown that CAT12 produces reliable estimates of cortical thickness, yielding 
larger effect sizes in case-control comparisons (Seiger et al., 2018). All segmentations were 
visually inspected by three colleagues. Three PSP-RS subjects were excluded due to sub-
optimal contrast between grey and white matter tissue, resulting in unsatisfactory 
segmentations. 
4.2.1.2 Diffusion-weighted MRI  
 
Diffusion scans were acquired on Siemens Magnetom Prisma scanner (TE = 75.6ms, TR = 
2.4s, slice thickness = 1.75mm, 98 directions, 104 slices, bvals = 300, 1000, 2000). 




Diffusion datasets were pre-processed with FSL-FDT (FMRIB’s Diffusion Toolbox). 
Firstly, the diffusion weighted-imaging data were stripped of nonbrain tissue using the 
Brain Extraction Tool. The resulting brain masks were visually inspected for anatomic 
fidelity. Eddy currents and head movements were corrected with “eddy” in FSL (Version 
6.0.1). TOPUP was applied to correct for estimating and correcting susceptibility induced 
distortions. The b0 volume from the reversed phase-encode blip was used in TOPUP for 
the estimation and correction of susceptibility induced distortion. Quantitative 
identification of slices with signal loss was performed in “eddy” and these volumes were 
replaced by non-parametric predictions using the Gaussian process (J. L. R. Andersson et 
al., 2016). The b-matrix was subsequently reoriented by applying the rotational part of the 
affine transformation used during eddy correction (Leemans & Jones, 2009). Next, ODI 
maps were derived from the eddy-corrected datasets using the Microstructural Diffusion 
Toolbox (MDT) (Harms et al., 2017). There has been recent debate over the validity of 
NODDI’s assumption of a fixed intrinsic diffusivity across the brain, especially in the grey 
matter. Therefore, to optimise analyses of ODI, the intrinsic diffusivity was set to 1.1 x 10-
3 mm2/s as previously proposed (Fukutomi et al., 2018).  
4.2.1.3 [11C]UCB-J Positron Emission Tomography (PET) 
 
A subset of patients underwent dynamic PET imaging as well as NODDI (Controls = 19, 
PSP-RS = 20, CBD = 12 including those already included in Chapter 3) on a GE SIGNA 
PET/MR – the [11C]UCB-J data acquisition is as described in 3.2.2.  
4.2.1.4 Extraction of regional measurements from T1, ODI and [11C]UCB-J BPND 
 
ODI and [11C]UCB-J maps were co-registered to the skull-stripped T1 brain image using 
rigid registrations in Advance Normalisation Tools (ANTS; http://stnava.github.io/ANTs/). 
The accuracy of all co-registrations was visually inspected. The co-registered ODI and 
[11C]UCB-J volumes were projected to the surface for cortical analyses. To that end, a 
weighted-mean method was applied that uses a Gaussian kernel for mapping along the 
normal, based on the recommended settings in CAT12. Finally, region of interest (ROI) 
extraction was performed within the surface space using the Desikan Killiany atlas 
(Desikan et al., 2006). We used a modified Hammers atlas (Hammers et al., 2003) to extract 
measurements from the subcortical regions and midbrain. The atlas was subsequently 
transposed into the native spaces of ODI and [11C]UCB-J respectively using the inverse of 




transformations from the co-registrations between ODI or [11C]UCB-J and T1 MPRAGE. 
Mean regional ODI, [11C]UCB-J and grey matter volumes were extracted using fslstats in 
FSL. Finally, each subject has the following imaging measurements: regional cortical 
thickness, cortical ODI, cortical [11C]UCB-J BPND, as well as subcortical and midbrain grey 
matter volumes, ODI and [11C]UCB-J BPND. 
4.2.2 STATISTICAL ANALYSIS 
 
The software R was used to compare demographic variables between the diagnostic groups 
using ANOVA, Kruskal Wallis and chi-square tests where appropriate. To investigate 
regional group differences of grey matter, ODI and [11C]UCB-J BPND,  a non-parametric 
permutation-based inference was used, implementing Permutation Analysis of Linear 
Models (PALM; https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/PALM) in MATLAB, adjusted for 
age (5000 permutations) (Winkler et al., 2014). A key advantage of permutation-based 
approach is the robustness of statistics to heteroscedasticity and its minimal assumptions 
on data distributions. Next, non-parametric permutation tests for Biological Parametric 
Mapping (BPM) (Casanova et al., 2007) were used to assess whole-brain inter-regional 
associations between ODI and [11C]UCB-J BPND across the patient sample, as well as 
within CBD and PSP groups separately. Correlational analyses were adjusted for age and 
local grey matter thickness / volume. Statistical results were adjusted using the False 
Discovery Rate (FDR) correction across the cortical, subcortical regions and the midbrain 
(81 regions). Mean values, standard deviations, p values and Cohen’s D were overlaid on 
2D brain templates using the ggseg package in R (Mowinckel & Vidal-Piñeiro, 2020).   






Clinical and demographic information are summarised in Table 4-1. Patients and controls 
were matched in age and gender although in this larger group of patients compared to those 
in chapter 3, education years was significantly lower in PSP relative to controls (Post-hoc 
Dunn’s Test after Kruskal-Wallis test; p < 0.001). Patients with PSP and CBD had lower 
total ACE-R scores compared to controls as in the smaller cohort in Chapter 3 (p < 0.001). 
 
Table 4-1. Demographics and neuropsychological profile for each participant cohort.  
Abbreviations: CBD = Corticobasal Degeneration defined as amyloid negative corticobasal syndrome; PSP-
RS = Progressive Supranuclear Palsy - Richardson’s syndrome; PSPRS = Progressive Supranuclear Palsy 
Rating Scale; ACER = Addenbrooke’s Cognitive Examination-Revised. Parameters are expressed as mean ± 
standard deviation. P values are shown for analysis of variance across groups or chi-squareda test as 
appropriate. 
4.3.2 GROUP COMPARISONS OF GREY MATTER ATROPHY, ODI AND [11C]UCB-J 
BPND 
For all groups, mean ± standard deviation (SD) distributions of regional cortical thickness, 
subcortical grey matter volumes, ODI and [11C]UCB-J BPND are overlaid on brain 









 Control CBD PSP P values 
M:F 
16:11 9:5 10:12 nsa 
Age 69.0 (7.34) 70.0 (7.91) 70.9 (8.69) ns 
Education in years 14.9 (3.65) 12.4 (3.03) 12.1 (4.33) 0.005 
ACE-R total (max. 100) 95.9 (3.81) 78.2 (18.9) 80.4 (12.7) <0.001 
PSPRS (max. 100) 0.148 (0.534) 26.9 (7.88) 33.3 (9.86) <0.001 
NODDI MRI - [11C]UCB-J PET scan 
interval (days) 
255.5 (168.9) 119.1 (109.8) 167.0 (134.7) 0.04 















































Figure 4-1 (cortical) and Figure 4-2 (subcortical). Permutation-based statistical comparisons 
across all imaging measurements are reported for PSP and CBD relative to controls, 
adjusted for age and FDR corrected, in Figure 4-3 and Figure 4-4. 
4.3.2.1 Progressive supranuclear palsy  
 
Statistical results and corresponding effect sizes from the comparisons between PSP and 
controls are illustrated in Figure 4-3A-C.  Non-parametric permutation-based tests showed 
that, relative to controls, the PSP group exhibited significant cortical thinning particularly 
in the motor cortex and frontal cortices; subcortical atrophy was found in the thalamus, 




putamen and pallidum and midbrain. In PSP, significant reductions in cortical ODI were 
more widespread than areas affected by atrophy, including multiple areas within the cortical 
mantle and also subcortically including the basal ganglia.  Post-hoc paired t-tests of the 
regional Fisher’s transformed Cohen’s D indicated that the regional effect sizes were 
significantly larger for ODI compared to grey matter atrophy (Figure 4-3C). As expected, 
the PSP group showed extensive and severe reductions of [11C]UCB-J BPND across the 
cortex and subcortical regions compared to controls, replicating findings in Chapter 3, here 
in a larger sample size. Across the whole brain, reductions in [11C]UCB-J BPND yielded the 
largest effect size relative to both ODI and grey matter atrophy.  
4.3.2.2 Corticobasal Degeneration 
 
Statistical results and corresponding effect sizes from the comparisons between CBD and 
controls are illustrated in Figure 4-4A-C. Relative to controls, the CBD group showed focal 
cortical thinning in motor cortex, superior frontal cortex and the occipital lobe, as well as 
atrophy in the left putamen and bilateral pallidum. In contrast, widespread ODI reductions 
were found extending beyond the atrophy-affected motor cortices to other regions that were 
relatively preserved from atrophy, notably the temporo-parietal and cingulate cortices. In 
addition, there was bilateral significant ODI reductions in the caudate and putamen, both 
of which showed no significant grey matter atrophy. Accordingly, regional Cohen’s D of 
ODI was significantly larger than that of grey matter atrophy (Figure 4-4C). Finally, 
[11C]UCB-J BPND comparisons revealed a generalised and widespread extent of 
significantly reduced [11C]UCB-J BPND  across the cortex and subcortical regions compared 
to controls, replicating results in Chapter 3; similar to the PSP cohort, reductions in 
[11C]UCB-J BPND yielded the largest effect size relative to both ODI and grey matter 
atrophy (Figure 4-4C). 
 
  
























































Figure 4-1. Regional distributions of mean (sd) cortical thickness, cortical ODI and cortical [11C]-UCB-J 
BPND across controls, CBD, and PSP.  
Abbreviations: ODI = Orientation Dispersion Index, CBD = amyloid negative Corticobasal Syndrome; PSP 

















































Figure 4-2. Subcortical (basal ganglia and brainstem) distributions of mean (sd) grey matter volumes, ODI and [11C]-UCB-J 
BPND across controls, CBD, and PSP.  
Abbreviations: ODI = Orientation Dispersion Index, CBD = amyloid negative Corticobasal Syndrome; PSP = Progressive 
Supranuclear Palsy-Richardson’s Syndrome; sd = standard deviation; GM = grey matter.  







Figure 4-3. GM atrophy, reduced ODI and [11C]UCB-J BPND in PSP vs Controls.  
A: p-values of regions surviving FDR correction are visualised on cortical and subcortical brain templates 
showing reduced ODI and [11C]UCB-J binding beyond atrophic areas. B: The regional effect sizes (Cohen’s 
D) for the regional reductions in GM, ODI, [11C]UCB-J BPND compared to controls. C: Density plots of 
distributions of effect sizes and boxplots of effect sizes of grey matter atrophy, ODI and [11C]UCB-J BPND 
from the group comparisons showing significantly larger effect sizes for presynaptic loss compared to ODI 
and atrophy. Abbreviations: ODI = Orientation Dispersion Index; PSP = Progressive Supranuclear Palsy-
Richardson’s Syndrome; FDR = False Discovery Rate; GM  = grey matter. 






Figure 4-4. GM atrophy, reduced ODI and [11C]UCB-J BPND in CBD vs Controls.  
A: P-values of regions surviving FDR correction are visualised on cortical and subcortical brain 
templates B: The effect sizes (Cohen’s D) for the regional reductions in GM, ODI, [11C]UCB-J 
BPND compared to controls. C: Density plots of distributions of effect sizes and boxplots of effect 
sizes of grey matter atrophy, ODI and [11C]UCB-J BPND from the group comparisons showing 
significantly larger effect sizes for presynaptic loss compared to ODI and atrophy. Abbreviations: 
ODI = Orientation Dispersion Index; FDR = False Discovery Rate; GM = grey matter; CBD = 
amyloid negative Corticobasal Syndrome. 




4.3.3 REGIONAL ASSOCIATION OF ODI WITH [11C]UCB-J BPND 
Non-parametric permutation models were used to assess the inter-regional associations 
between ODI and [11C]UCB-J BPND across the full patient sample, while sensitivity 
analyses were conducted for PSP and CBD groups separately. To visualise the spatial 
patterns of these regional correlations, accounting for age, regional grey matter atrophy and 
NODDI/UCB-J PET scan interval, the p values are projected on brain templates ( 
Figure 4-5). Within the total sample of CBD and PSP patients, multiple cortical and 
subcortical regions demonstrated local positive associations where [11C]UCB-J BPND 
locally predicted ODI, i.e. across subjects, both presynaptic density and dendritic 
complexity showed reciprocal associations within the same region ( 
Figure 4-5A). Scatter plots for each significant local association are shown in supplementary 
Figure B1. The regions showing the strongest correlations between ODI and [11C]UCB-J 
BPND were primarily in bilateral pre- and postcentral gyri  and the prefrontal cortex, but 
also extended to subcortical areas including the basal ganglia, thalamus and the midbrain.  
When the analyses were restricted to the CBD sample, the spatial extent of local 
associations was markedly attenuated, although significant associations were still present 
within the bilateral pre- and postcentral gyri, and isolated regions in the frontal and occipital 
lobe  
Figure 4-5B. Within the PSP group, [11C]UCB-J BPND  was significantly correlated with 
ODI in a widespread spatial pattern similar to that of the total sample. Peak correlations 
were identified within the motor cortex and cingulate regions ( 
Figure 4-5C), but also included the thalami, midbrain and parts of the basal ganglia. These 
analyses did not include the control group and are thus not indicative of a group effect. 
Nevertheless, to determine the specificity of the coupling between ODI and [11C]UCB-J 
BPND, the same non-parametric permutation model was performed on the controls. This 
analysis did not yield any significant local associations that retained statistical significance 
after FDR correction. 
  





Figure 4-5. Local associations between ODI and [11C]UCB-J BPND.  
(A) total sample of patients, (B) CBD and (C) PSP, separately. I: Statistical p values for the regional 
association of [11C]UCB-J BPND and ODI,  for regions surviving FDR correction, are overlaid on cortical and 
subcortical brain templates. II: Scatter plots showing the relationships between ODI and [11C]UCB-J BPND 
for all regions surviving FDR correction, coloured by lobes and subcortex. Abbreviations: ODI = Orientation 
Dispersion Index. PSP = Progressive Supranuclear Palsy-Richardson’s Syndrome; CBD = amyloid negative 
Corticobasal Syndrome.  
  





In this chapter I tested the hypothesis that changes in presynaptic density are closely linked 
to MRI measures of cortical microstructure, in the neurodegenerative tauopathies of CBD 
and PSP. The main insights are that (i) in the neurodegenerative tauopathies of CBD and 
PSP, widespread changes in grey matter dendritic complexity are observed even in areas 
without significant atrophy; and (ii) NODDI ODI, an MRI-based measure of postsynaptic 
dendritic structure and complexity, correlates with the loss of presynaptic density estimated 
by the PET radioligand [11C]UCB-J; this effect is not a result of changes in grey matter 
atrophy. The findings extend previous investigations of ODI microstructural changes in 
PSP and CBS/CBD (Mitchell et al., 2019), demonstrating the in vivo coupling of dendritic 
complexity to presynaptic density, in line with preclinical models of tauopathies (Hoffmann 
et al., 2014; Rocher et al., 2010).   
Grey matter atrophy within the motor cortex, as well as the basal ganglia and brainstem are 
common MRI findings in PSP and CBD; the pattern of atrophy shown in Figure 4-1 and 
Figure 4-2 concords with previous studies (Jabbari et al., 2019). In this chapter however, I 
show that both within areas of the brain where there is atrophy, and in areas with absent 
atrophy, there is significant and more severe loss of dendritic complexity and, as previously 
shown in Chapter 3 and replicated here, presynaptic density in the patient cohort. The 
widespread pattern of cortical ODI and presynaptic deficits in PSP and CBD matches the 
expected pattern of tau pathology, both in the subcortical and cortical areas (Dickson et al., 
2011; Kovacs et al., 2020), and concords with preclinical models of tauopathy. For 
example, in a P301S mouse model of tauopathy, using confocal microscopy of   
hippocampal and medial frontal cortical dendrites, Walker et al. have shown age-related 
vulnerability to dendritic spine remodelling and reductions in the hippocampus and medial 
prefrontal cortex, respectively, in response to tau pathology (C. K. Walker et al., 2021).  
Loss of dendritic complexity and presynaptic loss, in non-atrophied areas of the brain, for 
example the occipital lobes, potentially reflects early changes in synaptic function, in 
response to tau pathology or toxic oligomers of tau, that later in the disease process progress 
to atrophy. Indeed, in preclinical models, pathological tau oligomers (Kaniyappan et al., 
2017; Polydoro et al., 2014; Usenovic et al., 2015; Yasumasa Yoshiyama et al., 2007) 




induce synaptic degeneration rather than neurofibrillary tangles (Kuchibhotla et al., 2014), 
and interfere with synaptic function and density, in the absence of neuronal loss.  
The effect size for the comparison between ODI and [11C]UCB-J BPND in patients relative 
to controls, was stronger than for atrophy. Together, the larger extent of ODI reductions 
relative to grey matter atrophy indicate that NODDI can reveal new aspects of cellular 
pathology in tauopathies, in keeping with the recent demonstration that changes in ODI 
parameters closely reflect complex histological changes (Grussu et al., 2017). 
Notwithstanding the cross-sectional design of this experiment, this observation highlights 
the early structural changes in disease pathogenesis that may underlie the emergence of 
cognitive and motor symptoms not attributable to atrophy. Indeed, human studies of 
cortical physiology in PSP, and animal models of tauopathy have illustrated abnormal 
electrophysiology in the absence of atrophy (Hughes et al., 2013; Sami et al., 2018) or 
neuronal loss (Menkes-Caspi et al., 2015). The findings of reduced ODI beyond atrophy 
are in agreement with the literature in the related tauopathy of Alzheimer’s disease (Parker 
et al., 2018) where there is a stronger relationship between cognitive function and synaptic 
density than with atrophy (Masliah et al., 1992; Scheff et al., 2006; Terry et al., 1991).  
The observation of a tight coupling between dendritic complexity, as measured with ODI, 
and presynaptic density, as measured with [11C]UCB-J, in the patient cohort, echoes 
preclinical findings in animal models of tauopathy (Dorostkar et al., 2015; Harris & Kater, 
1994; Herms & Dorostkar, 2016; Kweon et al., 2017), and post mortem studies (Bigio et 
al., 2001; Lipton et al., 2001). There are two potential explanations for this tight coupling: 
first, tau protein is enriched in axons and associated with axonal growth and transport; the 
synaptic toxicity associated with pathological tau is observed both in pre- and postsynaptic 
structures (Kweon et al., 2017; Y. Wang & Mandelkow, 2012), leading to both a reduction 
in dendritic complexity and presynaptic density. Second, while a cross-sectional design 
precludes inferences of causality, alterations in presynaptic function in CBD and PSP are 
expected to induce dendritic morphological alterations with early loss of dendritic spines 
and reduced dendritic branching. This has been illustrated in animal studies, where 
postsynaptic dendritic morphology correlates with the numbers of presynaptic vesicles and 
synaptic strength (Schikorski & Stevens, 1999). It is possible that primary dendritic 
degeneration in CBD and PSP causes a reduction in the density of the presynaptic contacts 
on the distal dendrites. These alternative accounts are not mutually exclusive and could act 




in parallel to impair effective transneuronal connectivity, and subsequently motor and 
cognitive function.    
The downstream effect of the above is a loss of functional connectivity. Indeed in PSP there 
is reduced resting state connectivity between cortical and subcortical areas (reviewed in 
Filippi et al. (2019)). In CBD, the evidence is more heterogenous given the mixed 
underlying pathology, and the lack of categorising amyloid status in previous functional 
studies (also reviewed in Filippi et al. (2019)).  
Synaptic pathology is a common feature in many neurodegenerative diseases (Clare et al., 
2010; Herms & Dorostkar, 2016; Kweon et al., 2017). In the related tauopathy of 
Alzheimer’s disease, widespread reduction in synapses have been shown using [11C]UCB-
J PET in patients (M. K. Chen et al., 2018; Mecca et al., 2020), as well as changes to 
dendritic complexity seen both in vivo as reduced ODI (Parker et al., 2018) and in animal 
models of Alzheimer’s disease (Dorostkar et al., 2015). Similar pre- and postsynaptic losses 
are seen in the substantia nigra of patients with Parkinson’s disease (Bellucci et al., 2016; 
Reeve et al., 2018), and within the hippocampi of patients with Lewy Body Dementia 
(Revuelta et al., 2008). The tight coupling of the presynaptic and postsynaptic 
compartments shown in here, may therefore extend to pathologies other than primary 4-
repeat tauopathies, where synaptic dysfunction is one of the earliest stages of disease, 
regardless of the culprit protein aggregate in question. If so, the opportunity to utilise both 
MRI and PET to understand disease pathogenesis would greatly facilitate cohort studies of 
individual phenotypic differences or repeat testing in clinical trials monitoring. 
Furthermore, the in vivo observation of the tight coupling between the pre- and postsynaptic 
compartments, offers a new angle of interpretation for future studies utilising either of these 
methods in isolation. For example if cost, scalability and resources are limited for larger 
cohort studies, MRI measures of dendritic complexity can offer a close surrogate of 
presynaptic density, although I appreciate it is not a substitute given the significantly larger 
effect sizes seen with [11C]UCB-J (Figure 4-3C and Figure 4-4C) . This latter observation 
may indicate a more severe toxic effect at the pre-synapse compared to dendritic pathology, 
although longitudinal studies are required to confirm this. However, it is important to note 
that ODI should not be taken as a direct representation of the postsynaptic density seen in 
histological studies. Rather, it provides complementary information to the PET data, with 




support from histological studies that have shown ODI to be a close surrogate (Grussu et 
al., 2017). 
There are several strengths to the experimental procedures in this chapter. First, the NODDI 
resolution of 1.75mm was specifically optimised for the investigation of cortical 
microstructure, and is higher than previous NODDI studies in early onset AD (2.5 mm) 
(Parker et al., 2018) , Parkinson’s disease (5 mm) (Kamagata et al., 2016) and PSP (2.0 
mm) (Mitchell et al., 2019) . Second, I use amyloid imaging to exclude patients with CBS 
likely due to Alzheimer’s disease. This helps in reducing the potential underlying 
pathologies at play in the CBS cohort to predominantly 4-repeat tauopathies, although I 
acknowledge other pathologies are possible but less likely (Alexander et al., 2014) – in this 
regard it is reassuring that the spatial patterns of reductions in ODI and [11C]UCB-J binding 
are not substantially different between the PSP and CBD cohorts. Thirdly, the use of non-
parametric permutation analyses also confers additional robustness to the statistical results, 
since this approach is not reliant on data distributions (Winkler et al., 2014). 
I acknowledge the limitations of this experimental chapter including the relatively small 
sample size in the CBD cohort. However, given the large effect sizes seen of ODI and 
[11C]UCB-J  binding reduction  in both patient groups, the study was sufficiently powered 
to examine the relationships between both imaging markers. Secondly, I acknowledge that 
the MRI measure of ODI is not a direct measure of postsynaptic density but rather dendritic 
complexity; PET radioligands targeting the postsynaptic density may therefore provide 
further useful insights into postsynaptic pathology. Furthermore, although a tight 
correlation between our two measures of synaptic health is illustrated, I do not show 
causality in this cross-sectional study design.  
Understanding the pathological processes that precede atrophy in neurodegeneration is key 
not only in expanding our knowledge of the pathophysiology of disease but also in 
informing the design of clinical trials both in terms of the imaging options for measuring 
disease-related changes, and the optimal timing of intervention in the disease process. The 
data presented in this chapter implicate correlated changes in dendritic microstructure and 
synaptic density in patients with primary degenerative tauopathies including PSP and CBD. 
Further cross-validation of ODI with [11C]UCB-J BPND may help further our understanding 




of the pathophysiology of neurodegeneration, applicable to future studies of early 
neurodegeneration with a safe and widely available MRI platform.  
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5 THE RELATIONSHIP BETWEEN IN VIVO 
MOLECULAR PATHOLOGY AND SYNAPTIC 
LOSS IN PRIMARY TAUOPATHIES: A 
COMBINED [18F]AV-1451 AND [11C]UCB-
J PET STUDY.  
  
A manuscript related to this chapter is currently under revision as:  
Holland N, Malpetti M, Rittman T, Mak E, et al. The relationship between molecular 
pahtology and synaptic loss in the primary tauopathies: a combined [18F]AV-1451 
and [11C]UCB-J PET study. 
The original data, on which the analyses in this chapter are based, were collected by 
myself, Dr George Savulich and Mrs Julie Wiggins.  Patients were scanned and 
assessed as part of the Synaptic and Tau Evaluation in NeuroDegeneration Research 
(SENDeR and TENDeR) studies which were conceived by Professor James Rowe 
and Professor John O’Brien. The PET data were pre-processed by Dr Tim Fryer and 
Dr Young Hong. I designed the analysis strategy, performed the analyses, constructed 
the figures, and wrote the manuscript. 
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The relationship between in vivo synaptic density and tau burden in primary tauopathies is 
key to understanding the impact of tauopathy on functional decline and in informing new 
early therapeutic strategies. In this chapter, I determine the in vivo relationship between 
synaptic density and molecular pathology, in the primary tauopathies of Progressive 
Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD), as a function of disease 
severity. 
Twenty-three patients with PSP, and twelve patients with amyloid-negative Corticobasal 
Syndrome (CBS) were recruited from a tertiary referral centre. Nineteen education, sex-
and gender-matched control participants were recruited from the National Institute for 
Health Research ‘Join Dementia Research’ platform. Cerebral synaptic density and 
molecular pathology, in all participants, were estimated using PET imaging with the 
radioligands [11C]UCB-J and [18F]AV-1451, respectively. Patients with CBS also 
underwent amyloid PET imaging with [11C]PiB to exclude those with likely Alzheimer’s 
pathology – I refer to the amyloid negative cohort as having CBD. Disease severity was 
assessed with the PSP rating scale; regional non-displaceable binding potentials (BPND) of 
[11C]UCB-J and [18F]AV-1451 were estimated in regions of interest from the 
Hammersmith Atlas, excluding those with known off-target binding for  [18F]AV-1451. As 
an exploratory analysis, I also investigated the relationship between molecular pathology 
in cortical brain regions, and synaptic density in subcortical areas.  The patient data were 
normalised against the controls, in all regions of interests.  
Across brain regions, there was a positive correlation between [11C]UCB-J and [18F]AV-
1451 BPND (=0.3, t=4.7, p<0.0001). However, the direction of this correlation became less 
positive as a function of disease severity in patients ( = -0.01, T = -2.2, p = 0.03). Between 
brain regions, cortical [18F]AV-1451 binding was negatively correlated with synaptic 
density in subcortical areas (nucleus accumbens, caudate nucleus, and putamen). 
Brain regions with higher synaptic density are associated with a higher [18F]AV-1451 
binding in PSP/CBD, but this association diminishes with disease severity. Moreover, 
higher cortical [18F]AV-1451 binding correlates with lower subcortical synaptic density. 
Longitudinal imaging is required to confirm the mediation of synaptic loss by molecular 
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pathology. However, the effect of disease severity suggests a biphasic relationship between 
synaptic density and tauopathy, with synapse rich regions vulnerable to accrual of 
pathology, followed by a loss of synapses in response to pathology. Given the importance 
of synaptic function for cognition, the findings here elucidate the pathophysiology of 
primary tauopathies and may inform the design of future clinical trials.    
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Synaptic loss is a feature of many neurodegenerative disorders. In chapters 3 and 4, I 
reviewed the critical role of synaptic dysfunction in the pathogenesis and cognitive 
impairment in PSP and CBD, which can begin long before, and is more extensive than 
neuronal loss (DeKosky & Scheff, 1990; Jacobsen et al., 2006; Terry et al., 1991). 
However, the in vivo relationship between synaptic loss and the underlying proteinopathy 
in primary tauopathies, tau, remains to be determined.   
5.2 TAU-INDUCED TOXICITY IN TAUOPATHIES 
The neurofibrillary tangles associated with PSP are postulated to begin within the 
pallidonigrolusyian system, spreading to the basal ganglia, pontine nuclei, and cerebellar 
dentate nucleus early in the disease process, before spreading into other cortical areas 
(Figure 5-1) (Kovacs et al., 2020). However as shown in chapter 3, significant synaptic loss 
is seen even in areas of the brain that are affected later in the disease stage, for example the 
occipital lobes. Whilst loss of cortico-cortical connections can account for this, an 
alternative explanation is that tau oligomeric spread to these areas precede tau tangles and 
lead to synaptic toxicity (DeVos et al., 2018). This is in accordance with preclinical models 
where synaptotoxicity of oligomeric tau leads to reduced synaptic plasticity and density 
(DeVos et al., 2018; Niewiadomska et al., 2021; Pickett et al., 2017; Ward et al., 2012). In 
tauopathies, mutant tau is present not only in the axons, but also the cell body and dendrites. 
As such, the mechanisms by which synaptic loss occurs following tau pathology are both 
direct and indirect (reviewed in Jadhav et al. (2015) and (Spires-Jones & Hyman, 2014)), 
but can also occur in response to the underlying genetic risk factors. For example, in 
patients with mutations of microtubule-associated protein tau (MAPT), there are 
deficiencies in many synaptic pathways including GABA-mediated signalling and synaptic 
plasticity (Jiang et al., 2018).   
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Figure 5-1. The neuropathological distribution of neurofibrillary tangles in different stages of PSP. 
Sequences of PSP related tau pathology based on the distribution of neuronal, astroglial, and 
oligodendroglial tau pathology. In Stage one disease, although the predominant findings are that of 
subcortical neuronal tau accumulation, pathological astroglial tau is present within the frontal lobes and 
can therefore alter synaptic physiology indirectly. Figure reproduced from Kovacs et al. 2020. with 
permission from Springer. 
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5.2.1 DIRECT TAU SYNAPTO-TOXICITY 
Under normal physiological conditions, neuronal tau is involved in maintaining synaptic 
integrity and maintaining dendritic spine and axonal structure (as reviewed in 1.1.5.1). 
Under pathological conditions, it directly interferes with the function of many synaptic 
vesicle proteins including synaptophysin, synaptotagmin and synaptogyrin-3, leading to 
reduced synaptic vesicle mobility and therefore neurotransmitter release (Hanger et al., 
2019). At the postsynaptic membrane, overexpression of tau in the P301L transgenic mouse 
model of tauopathy significantly interferes with the functioning of the postsynaptic density 
proteins, and thus the structure and integrity of dendritic spines (Regan & Cho, 2019).  
5.2.2 INDIRECT TAU SYNAPTO-TOXICITY 
Given the key role of tau as a microtubule-associated protein, under pathological 
conditions, hyperphosphorylated tau interferes with axonal cytoskeletal structure and thus 
the transport of key cargoes (for example synaptic vesicle proteins, mitochondria, and ion 
channels) to the cell body and axon terminal. This disruption to the normal transport 
machinery leads to a lack of vital molecules for the normal functioning of synapses 
(Kneynsberg et al., 2017).  Pathological tau also interferes with normal functioning of 
mitochondria (particularly of complex I), in doing so it has a deleterious effect on calcium 
homeostasis (and therefore neurotransmitter release), and postsynaptic dendritic integrity 
(Eckert et al., 2014; Kopeikina et al., 2011; Lasagna-Reeves et al., 2011a; Yu et al., 2017).  
Despite the physiological function of tau as an intracellular microtubule-associated protein, 
various species of tau have been observed in the extracellular environment, the so-called 
extracellular tau, albeit in smaller concentrations. Under normal physiological conditions, 
extracellular tau is found in the interstitial fluid and the cerebrospinal fluid (CSF) of mice 
(Yamada et al., 2011), and in human brains (Magnoni et al., 2012). Extracellular tau is also 
found in the hyperphosphorylated form in the CSF of patients with PSP and CBD, where 
reductions in the CSF are directly correlated with the severity and rate of disease 
progression in PSP (Rojas et al., 2018). In its hyperphosphorylated form, extracellular tau 
can cause synaptic toxicity in three ways: first, by directly interfering with calcium 
homeostasis, and therefore synaptic function (Gómez-Ramos et al., 2006; Gómez-Ramos 
et al., 2008), leading to impaired memory (Lasagna-Reeves et al., 2011b). Indeed clearance 
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of extracellular tau oligomers can reverse the deleterious effect on memory and locomotor 
deficits in mouse models of 4-repeat tauopathy with the P301L-MAPT mutation (Castillo-
Carranza et al., 2014). Secondly, extracellular tau pathology can indirectly affect synaptic 
function through inflammation-induced synaptic toxicity (Reid et al., 2020). Mouse models 
of tauopathies support the idea that both extracellular tau pathology as well as astrocytic 
tau pathology contribute to glial degeneration, as a consequence leading to synaptic 
degeneration and loss (Amro et al., 2021; Blutstein & Haydon, 2014; Haydon, 2001; 
Kovacs, 2020; Vogels et al., 2019). Thirdly, ongoing synaptic toxicity can result from the 
intercellular propagation of pathology, which I review next. 
5.3 TRANS-SYNAPTIC SPREAD OF TAU 
Increasing evidence suggests that tau pathology can be transmitted from one cell to another 
through intercellular transmission in both in vitro and in vivo animal models (Clavaguera 
et al., 2009), following a prion-like hypothesis of spread (Goedert et al., 2017b; B. B. 
Holmes & Diamond, 2014) . This process is dependent on intracellular tau released from 
the presynaptic membrane, the uptake of extracellular tau, and ongoing aggregate formation 
within the recipient cell through recruitment of endogenous tau (‘seeding’). It has been 
suggested that under normal physiological conditions, tau is actively secreted 
predominantly by ectosomes, and a shift towards exosomal secretion occurs upon 
increasing cellular tau accumulation (Dujardin et al., 2014). However, 
hyperphosphorylated tau can also directly translocate through the plasma membrane into 
the extracellular space (Katsinelos et al., 2018). This process is accelerated in response to 
lysosomal dysfunction, nutrient deprivations, and changes in Golgi dynamics and 
membrane trafficking properties (Mohamed et al., 2017; Mohamed et al., 2014). Once in 
the extracellular space, tau is taken up by recipient cells either via bulk endocytosis (Evans 
et al., 2018; B. B. Holmes et al., 2013), receptor-mediated endocytosis (Gómez-Ramos et 
al., 2009; Lasagna-Reeves et al., 2012), through tunnelling nanotubes (Tardivel et al., 2016) 
or extracellular vesicle shuttles (Guix et al., 2018). Once in the recipient cell, pathologic 
tau has the ability to induce seeding (Guo & Lee, 2011; Mirbaha et al., 2015).  
Although tau is toxic to synapses, the spread of tau pathology is dependent on synaptic 
connections. This concept has been confirmed both in animal models of Alzheimer’s 
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disease (DeVos et al., 2018; Seemiller et al., 2021) and in the P301L mouse model of 
primary tauopathy (Ahmed et al., 2014; Polanco et al., 2018). In this respect seemingly 
distant neurons can affect each other’s synaptic transmission if they are synaptically 
connected (for example cortical-subcortical connections, or cortico-cortical connections).  
In clinical disorders, tau burden can be characterised by PET imaging, using a variety of 
radiotracers (Y. T. Wang & Edison, 2019). In patients with amyloid positive mild cognitive 
impairment for example, increased temporal lobe binding of the tau radioligand [18F]MK-
6240 is associated with decreased synaptic density measured by the radioligand [11C]UCB-
J (Vanhaute et al., 2020). Similarly, in patients with Alzheimer’s disease, Coomans et al, 
report reduced [11C]UCB-J uptake, with increased uptake in the tau tracer [18F]AV-1451, 
but within subjects this relationship is modulated by the individual’s neocortical tau load 
(Coomans et al., 2021).  However, the pathology of Alzheimer’s disease is multifaceted 
with amyloid and tau aggregation, vascular changes and neuroinflammation (Malpetti et 
al., 2020a; Spires-Jones & Hyman, 2014). In this chapter, I assess the in vivo relationship 
between tau burden and synaptic density in the primary tauopathies of PSP and amyloid 
negative CBS cohorts. As reviewed in previous chapters and above, animal models of 
tauopathy have illustrated the colocalisation of misfolded tau protein and synaptic loss at 
the synaptic bouton (Hanger et al., 2019; Pooler et al., 2014) but the tau-synapse association 
is yet to be determined in vivo.  
Figure 5-2 illustrates my hypotheses. Previous studies suggest that the strength of 
connectivity within a region and between brain regions can promote the spread of tau 
pathology, in humans (Cope et al., 2018) as in preclinical models (Ahmed et al., 2014). 
Therefore, I hypothesise that brain areas with higher synaptic density would develop more 
tau pathology. I predict that the spatial distribution of pathology, as measured with the PET 
radioligand [18F]AV-1451, would be correlated with synaptic density, as measured with the 
PET radioligand [11C]UCB-J. Since tauopathy in a region may impair efferent projections, 
a corollary hypothesis is that tau accumulation in one region (source region) leads to 
diaschisis characterised by reduced synaptic density in the areas to which it connects (target 
regions). I acknowledge the relatively low affinity of [18F]AV-1451 for 4-repeat tauopathy 
compared to Alzheimer’s disease, and the off-target binding of this ligand within the basal 
ganglia. I therefore refer to its binding target as ‘molecular pathology’, covering tau and 
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non-tau targets. A second part of the model describes the consequence of pathology, which 
is to reduce synaptic density. The predicted result is a positive relationship between 
[18F]AV-1451  binding and synaptic loss, negatively moderated by disease progression.  
  
Figure 5-2. Schematic diagram illustrating the predicted toxic effect of tau on synaptic density.  
At a regional level (A) synaptic density promotes the spread of tau from one region to another (for example 
from Region 1 to Region 2). Tau is however toxic to synapses, such that at a regional level it leads to a loss 
of synapses as the disease progresses. (B) Tau burden within a given region therefore, depends on a region’s 
baseline synaptic density: for example, Region 3 with a high baseline synaptic density, would accumulate 
more tau in the mild stages of disease. But as the disease progresses over time, to moderate and advanced 
stages (yellow and red in B, respectively), with increasing tau accumulation, tau induced synapto-toxicity 
occurs with a decline in the number of synapses within any given region. The prediction would therefore be 
that, whilst in mild disease the degree of tau accumulation is dependent on baseline synaptic density, as the 
disease progresses this relationship breaks down, moving towards a negative direction between tau 
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5.4.1 PARTICIPANTS AND STUDY DESIGN  
The current experiment and the experiments reported in Chapters 3 and 4 are part of the 
same study protocol. Thus, the participants, inclusion and exclusion criteria, and study 
procedure are as described in Chapter 2. In this chapter however, there are a few additional 
participants compared to Chapters 3-4; thus, the full sample available for assessment of the 
relationship between synaptic density and molecular pathology consisted of 19 controls, 12 
patients with CBD, and 23 with PSP-Richardson’s syndrome. Demographic details for this 
extended cohort are provided in Table 4-1. All participants underwent 3T MRI, [18F]AV-
1451 PET, and [11C]UCB-J PET.  
5.4.2 NEUROIMAGING PRE-PROCESSING 
The procedure for [11C]UCB-J synthesis, PET data acquisition, image reconstruction and 
kinetic analysis is as described in Chapter 2, and published in Holland et al. (2020). 
[18F]AV-1451 synthesis and data acquisition followed the protocol described in Chapter 2.  
5.4.3 STATISTICAL ANALYSES 
Differences in demographic and clinical variables between the diagnostic groups were 
tested using ANCOVA, and chi-square tests where appropriate. A linear mixed effects 
model was used to assess the overall relationship between [18F]AV-1451 and [11C]UCB-J 
BPND, and the effect of group (patients vs controls) and brain region on this relationship. 
Subsequently, the patient data were normalised against controls by subtracting the mean 
regional control values (for both PET ligands) from each individual patient to remove any 
off-target binding beyond that seen in the basal ganglia. For this analysis, regions of interest 
with previously reported off-target binding of [18F]AV-1451 (basal ganglia, and substantia 
nigra (Leuzy et al., 2019)) were excluded. To investigate the effect of individual variability 
on the relationship between [11C]UCB-J and [18F]AV-1451 BPND, a linear mixed effects 
model was used, allowing for an uncorrelated random slope and intercept per individual, 
with the interval between the two PET scans (in days) as a covariate of no interest. I 
subsequently extracted the slope of [11C]UCB-J on [18F]AV-1451 for each individual and 
used this in a linear model with the PSP rating scale (a measure of disease severity) as the 
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independent variable, and age as a covariate of no interest. To explore the correlation 
between [11C]UCB-J and [18F]AV-1451 BPND between regions, I calculated a correlation 
matrix between cortical [18F]AV-1451 binding, and synaptic density in cortical and 
subcortical regions.  Analyses were performed with and without partial volume correction, 
yielding similar results. I focus on partial volume corrected BPND to limit the potential 
effect of atrophy on our ligand cross-correlation but present data without partial volume 
correction in the supplementary material (Appendix C). Statistical analyses were 
implemented in R (version 3.6.2).  
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The patients (PSP and CBD) and control groups were similar in age, sex, education and 
injected activity of [11C]UCB-J and [18F]AV-1451 (Table 5-1).  A typical cognitive profile 
for people with PSP and CBD was observed with impairment in verbal fluency, memory, 
and visuospatial domains of the ACE-R and MMSE. 
 
 
Table 5-1. Demographics and neuropsychological profile for each participant cohort. 
Results are given as mean (and standard deviation) unless otherwise stated. PSP refers to patients with PSP-
Richardson’s syndrome. CBD refers to amyloid negative corticobasal syndrome. The F-statistic and p-values 
are derived from ANOVA. ACE-R: revised Addenbrooke’s Cognitive Examination, MMSE: Mini-mental 
State Examination, PSPRS: Progressive Supranuclear Palsy Rating Scale. a chi-squared test. ns = non-
significant at p<0.05.   
 
Control PSP CBD F (p) 
 Gender (M:F)  11:8 10:13 7:5 ns
a 
 Age at [11C]UCB-J PET in years  68.9 (7.1) 71.3 (8.6) 70.9 (7.9) ns 
 Symptom duration (years)  - 3.9 (2.2) 3.9 (2.1) ns 
 Education (years)  13.6 (2.8) 12 (4.4) 12.5 (3) ns 
 ACE-R total (max. 100) 96.7 (2.7) 81.5 (12.7) 81.2 (10.3) 8.8 (<0.001) 
       Attention_Orientation (max .18) 17.9 (0.3) 15.8 (4) 15.4 (5.2) ns 
       Memory (max .26) 24.6 (1.7) 21 (6) 18.5 (8) 4.4 (0.02) 
       Fluency (max .14) 12.8 (1.0) 6.5 (3.3) 7.3 (3.6) 25.6 (<0.001) 
       Language (max .26) 25.6 (0.8) 22.2 (6.6) 20.5 (8.3) 3.3 (0.04) 
       Visuospatial (max .16)  15.7 (0.6) 12.3 (4.3) 12.2 (4.6) 5.7 (0.01) 
 MMSE (max. 30) 
 
29.4 (1.2) 27.1 (2.6) 26.6 (3.0) 5.2 (0.01) 
 PSPRS (max. 100) 
 
- 34 (9.4) 25.9 (12.4) 4.6 (0.04) 
Injected activity (MBq)     
       [11C]UCB-J 370.7 (114.3) 322.2 (86.0) 320.4 (113.8) ns 
       [18F]AV-1451 
 
182.3 (10.8) 182.1 (11.4) 186.1 (11.1) ns 
[11C]UCB-J and [18F]AV-1451   PET 
scan interval (in days) 
157.2 (125.6) 155.9 (129.2) 45.5 (65.7) 4.6 (0.02) 
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5.5.2 RELATIONSHIP BETWEEN [11C]UCB-J BPND AND [18F]AV-1451 BPND  
In patients, there was a positive relationship between regional [18F]AV-1451 BPND and 
[11C]UCB-J BPND (=0.3, t=4, p<0.0003). There was a significant region-by-[
18F]AV-1451 
interaction (p<0.0001) driven by subregions of the frontal, parietal, temporal and occipital 
lobes, as well as the thalamus. There was no effect of PET scan interval on the overall 
significance of the model (p=0.7). There was individual variability in the slope of the 
relationship between [18F]AV-1451 BPND and [
11C]UCB-J BPND (individual grey lines in 
Figure 5-3A). The direction of this relationship in each individual (i.e. the slope of each 
grey line in Figure 5-3A) negatively correlated with disease severity (= -0.01, t= -2.2, R= 
-0.34, p=0.03), independent of age (p=0.4) (Figure 5-3B). In other words, those patients 
with more severe disease displayed a less positive relationship between [18F]AV-1451 
BPND and [
11C]UCB-J BPND. Similar findings were observed using BPND derived from data 
without partial volume correction (Figure C1).  
Figure 5-3. The association between synaptic density ([11C]UCB-J) and molecular pathology ([18F]AV-1451) is a function of 
disease severity. 
A) Scatter plot of [11C]UCB-J BPND and [18F]AV-1451 BPND in 35 patients with PSP-Richardson’s syndrome and amyloid-
negative CBD (each grey line represents a patient) normalised against controls, across 73 regions of interest (excluding those 
with previously reported off-target binding, i.e. basal ganglia and substantia nigra); the dark black line in A depicts the overall 
fit of the linear mixed model, whilst grey lines represent individual patient participants. B) The slope for each individual (i.e. 
each grey line in A) is negatively correlated with disease severity (as measured with the PSP rating scale); R= -0.34, p<0.03. 
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5.5.3 CROSS-REGIONAL CORRELATION BETWEEN [18F]AV-1451 BPND AND 
[11C]UCB-J BPND  
Synaptic density in a region is proposed to be affected by both local tau pathology and tau 
burden in connected regions from which it receives afferent projections. As a result, despite 
a positive correlation at a regional level, the synaptic density in any given region may be 
negatively affected by remote insult, with diaschisis between anatomically connected 
regions (illustrated schematically in Figure 5-2).  As an exploratory analysis, the 
asymmetric Pearson’s correlation matrix shown in Figure 5-4 was computed, between 
cortical [18F]AV-1451 BPND (horizontal axis of matrix) and [
11C]UCB-J BPND  (vertical axis 
of matrix) in cortical and subcortical regions in patients. Here I show that overall, there are 
significant negative correlations between cortical (frontal, temporal, parietal, and occipital) 
[18F]AV-1451 BPND and subcortical [
11C]UCB-J BPND within the basal ganglia (nucleus 
accumbens, caudate nucleus and putamen). There were strong positive correlations 
between [18F]AV-1451 BPND and [
11C]UCB-J BPND within the thalamus where strong local 
connections exist (Figure 5-4). Subcortical [18F]AV-1451 BPND  in the matrix in Figure 5-4 
were not included, given the off-target binding in these regions which undermines the 
interpretability of the signal. However, I include these regions as well as other subregions 
in the larger correlation matrix in Supplementary Figure D3 for completeness.  Similar 
findings are seen using BPND from data without partial volume correction (Supplementary 
Figure C2).      
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 in a target region (vertical axis) both cortically and subcortically in patients. Only 
significant correlations (at p<0.05 uncorrected for multiple comparisons) are shown in this 
figure. The colour and width/shade of the ellipse depict the direction (i.e. blue = negative, red 
= positive correlations), and strength (i.e. narrow darker ellipses show stronger correlations), 
respectively.  
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In this chapter I have identified a complex relationship between molecular pathology 
(estimated with [18F]AV-1451 PET) and synaptic density (estimated with [11C]UCB-J 
PET), in patients with the primary tauopathies of Progressive Supranuclear Palsy and 
Corticobasal Degeneration (inferred in vivo from amyloid-negative corticobasal 
syndrome). There are three principal results: (i) regions with higher synaptic density have 
higher pathology, (ii) within regions, synaptic density becomes less dependent on [18F]AV-
1451 binding as disease severity increases, and (iii) between regions, increased cortical 
[18F]AV-1451 binding is associated with reduced subcortical synaptic density. I interpret 
these three findings in the context of connectivity-based susceptibility to tauopathy, 
synaptotoxic effects of tauopathy, and cortico-subcortical diaschisis, respectively.  
The effect of 4-repeat hyperphosphorylated tau pathology such as PSP and CBD, on 
synaptic function and density is complex. It involves both direct and indirect pathways of 
injury with changes in cellular physiology preceding the loss of neurons. Through direct 
pathways, pathological tau interferes with dendritic morphology, synaptic protein 
expression, the number of NMDA (N-methyl-D-Aspartate) and AMPA (α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid) receptors on the presynaptic membrane, 
mitochondrial function, synaptic vesicle numbers, and ultimately synaptic loss (reviewed 
in Chapter 1 and in Jadhav et al. (2015)). Tau also directly affects the axon cytoskeleton 
and trafficking, as well as the soma (Kneynsberg et al., 2017). Indirectly, 
hyperphosphorylated tau adversely affects the functioning of the neuronal support network, 
including glia cells and astrocytes (Kovacs, 2020; Reid et al., 2020). These events are 
affected by the stage and severity of the disease process, and in relation to regional 
differences in connectivity which I discuss next (concepts schematically illustrated in 
Figure 5-2).  
There was a positive relationship between the binding of [11C]UCB-J and [18F]AV-1451 
such that areas of the brain with higher synaptic density develop higher pathology. This 
accords with preclinical and clinical models of tauopathy in which the strength of local 
network connectivity facilitates the transneuronal spread of tau pathology (Ahmed et al., 
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2014; Clavaguera et al., 2013; Clavaguera et al., 2009; Cope et al., 2018; Polanco et al., 
2018).  
However, the relationship between tau accumulation and synaptic density changes with 
disease progression, at least as inferred from the cross-sectional moderation by disease 
severity. With increasing scores on the PSP rating scale, synaptic density becomes less 
dependent on local tau accumulation. In other words, in areas with relatively low tau 
accumulation synaptic density is minimally affected, whereas in areas with higher tau 
accumulation there is reduction of synaptic density as the disease progresses and this 
preferentially occurs in synapse rich areas. As the disease progresses, other pathological 
processes may contribute to synaptic loss, such as inflammation, another predictor of 
prognosis and mediator of synaptic loss (Malpetti et al., 2021). There is therefore not a 
simple linear relationship between tau accumulation and synaptic density in moderate and 
advanced disease. This observation accords with human post mortem and animal studies. 
In post mortem studies of the related tauopathy of Alzheimer’s disease, there is a biphasic 
synaptic protein response during disease progression, with increases in 
synaptophysin/syntaxin/SNAP-25 in early Braak stages and synaptic loss observed only 
when the disease has progressed to the neocortex (Mukaetova-Ladinska et al., 2000). In the 
P301L transgenic mouse model of PSP-like tauopathy, there is a differential loss of 
synapses, as well as synaptic proteins, depending on disease stage (Kopeikina et al., 2013).   
To understand the biphasic relationship between tau accumulation and synaptic density, 
one must consider other key players in synaptotoxicity in tauopathies, such as 
neuroinflammation (Palleis et al., 2020). Recent in vivo studies have confirmed the regional 
co-localisation of inflammation and [18F]AV-1451 binding in PSP (Malpetti et al., 2020b), 
in line with previous in vivo (Gerhard et al., 2006; Gerhard et al., 2004), and post mortem 
reports  of the tight interplay between neuroinflammation and tau accumulation in 
tauopathies (Kovacs, 2020). There is growing evidence that these two pathological 
processes affect synaptic function both independently and synergistically (Vogels et al., 
2019).  
The relationship between tauopathy and synaptic density is even more intriguing when 
considering the change in synaptic density in one region as a function of pathology in 
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another. There are strong correlations between [11C]UCB-J binding within the basal ganglia 
and [18F]AV-1451 binding in most cortical areas. The reverse association, between 
subcortical [18F]AV-1451 and cortical [11C]UCB-J binding is also observed 
(Supplementary Figure C3) but is dismissed here as uninterpretable in view of subcortical 
off-target binding of [18F]AV-1451. The significant negative correlation between cortical 
[18F]AV-1451 binding and synaptic density in the basal ganglia could be a reflection of 
severe disease in the basal ganglia and accumulating pathology in the neocortex. In other 
words, synapses are severely affected in the basal ganglia as one of the earliest sites of 
pathology, with pathology spreading and accumulating in synapse-rich areas of the brain, 
for example the neocortex. A second explanation is that loss of descending cortico-striatal 
axons due to cortical pathology, may cause diaschisis, affecting subcortical synaptic density 
even further. Previous reports of diffusion tensor imaging in patients with PSP/CBD have 
revealed extensive white matter abnormalities (within the main association fibres) beyond 
the degree of cortical atrophy (Borroni et al., 2008; Padovani et al., 2006)  resulting in loss 
of cortical afferents onto subcortical structures. A third, though not mutually exclusive, 
explanation is the weakening of cortical-subcortical functional connectivity resulting from 
dysfunctional synapses rather than synaptic loss as suggested from previous functional 
connectivity studies in PSP (Cope et al., 2018; Gardner et al., 2013).  
Although at a regional level there is a positive correlation between [11C]UCB-J and 
[18F]AV-1451 BPND, synaptic function or synaptotoxic tau oligomers are not being directly 
measured here. This caveat must be borne in mind when interpreting PET data. It is the 
preclinical models that have shown that oligomers of tau are toxic to synaptic function, 
even in the absence of tau polymers/fibrils (Acquarone et al., 2019; Fá et al., 2016; 
Kaniyappan et al., 2017; Menkes-Caspi et al., 2015; Niewiadomska et al., 2021). By the 
time tau aggregates are established, oligomers of tau are expected cortically, and perhaps 
interfering with cortical function and the integrity of descending axons.  
There are a few limitations of this experimental chapter. First, the low affinity of [18F]AV-
1451 for PSP and CBD 4-repeat tau. Even where this radioligand recapitulates the 
distribution of post mortem neuropathology in PSP and CBD, and binds PSP 4-repeat tau, 
the affinity is very much lower than for 3-repeat tau in Alzheimer’s disease (Soleimani-
Meigooni et al., 2020; Y. T. Wang & Edison, 2019). Second, there is well-established off-
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target binding of [18F]AV-1451, particularly within subcortical structures where 
monoamine oxidase is present. Off-target binding is most prominent in the basal ganglia 
which I excluded before running the statistical analysis in this chapter, in addition to 
normalising the patient data against controls. I included these regions in the detailed 
descriptive correlation matrices in Supplementary Figure C2 and 3 for completeness sake, 
noting the strong negative correlations between cortical [18F]AV-1451 BPND and 
subcortical [11C]UCB-J BPND. Third, I note that in PET studies of neurodegeneration with 
atrophy, grey matter volume loss can affect the interpretation of PET signals. However, 
synaptic loss in PSP and CBD occurs even in areas of the brain without discernible atrophy 
on MRI as shown in Figure 3-4 and Figure 4-3. Nevertheless, a stringent partial volume 
correction method (GTM) has been used, to minimise the effect of atrophy on the ligand 
cross-correlations. Of note, the data without partial volume correction yield similar results 
in all the main analyses (Supplementary Figure C1 and 2). Lastly, the cross-sectional design 
of this study limits the interpretation of the dynamic relationship between tau accumulation 
and synaptic loss. Although I include patients at various stages of their illness, a 
longitudinal design is necessary to test the proposed dynamic relationship, and the 
mediation of synaptic loss by progressive tauopathy.  
In conclusion, I have demonstrate a widespread positive association between [18F]AV-1451 
and [11C]UCB-J binding in patients with symptomatic PSP and amyloid-negative 
corticobasal syndromes. Individual variability in this association correlates with disease 
severity. The complex relationship between tau accumulation and synaptic density in vivo 
may explain changes in cognitive and motor physiology. I hope that these insights will 
inform the design of new clinical trials to arrest PSP and CBD.  
  
|   ti  l  i  ri r  
18F]AV-1451 and [11C]UCB-J PET study. 




6 GENERAL DISCUSSION 
Summary 
The final chapter of this thesis brings together the hypotheses and evidence presented in 
Chapters 3 to 5, summarising the key findings, and emphasising how they advance our 
understanding of synaptic pathology in neurodegeneration. I then integrate this work with 
the prior literature, discuss significant limitations, and provide directions for future 
research. Specifically, I discuss (i) the key role of synaptic pathology as an early 
pathological mechanism in primary tauopathies and other neurodegenerative disorders, and 
(ii) therapeutic options for the maintenance and recovery of synapses in neurodegeneration.  
  




6.1 REVIEW OF THE PRINCIPAL FINDINGS  
In the introduction to this thesis, I proposed that synaptic loss is critical to the pathogenesis 
of primary tauopathies. In chapter 3, I tested the specific hypothesis that synaptic density 
is reduced by the primary tauopathies of Progressive Supranuclear Palsy (including 
Richardson’s syndrome, PSP-RS) and amyloid-negative corticobasal syndrome 
(interpreted as due to CBD), and that this reduction correlates with disease severity. A new 
cohort of patients with PSP and CBD, as well as healthy controls underwent synaptic PET 
imaging with [11C]UCB-J, structural MRI imaging, as well as neuropsychological 
assessment. A general linear model assessed group differences in synaptic density (patients 
versus controls), and relationship between synaptic density and disease severity. I 
confirmed a significant loss of synapses in the patient cohort, even in areas of the brain 
without significant volume loss. I illustrated that synaptic loss was highly correlated with 
functionally relevant measures of cognition, and with disease severity. The results are the 
first to demonstrate in vivo synaptic loss in primary tauopathies; they enable better 
understanding of the early pathophysiology of these neurodegenerative diseases, with 
outcomes directly relevant to the design of clinical trials aiming to restore or maintain 
synapses.  
Having observed presynaptic synaptic loss, in chapter 4, I tested whether loss of the 
presynaptic compartment relates to changes to the postsynaptic compartment, in terms of 
loss of dendritic complexity as measured with the Orientation Dispersion Imaging (ODI) 
with MRI. I confirmed that in both PSP and CBD, there is widespread reduction in ODI, 
which is tightly linked to the loss of presynaptic SV2A (in presynaptic vesicles). The ODI 
results offer the possibility of utilising less invasive methods as complementary and a 
surrogate marker of synaptic density in future clinical studies.   
A third question addressed in this thesis, was how changes in synaptic density relate to 
pathology in PSP and CBD. In chapter 5, I show a complex correlation between synaptic 
loss and pathology, mediated by disease severity. Furthermore, I report a negative 
correlation between molecular pathology in one region and synaptic densities in areas of 
the brain that are structurally and functionally connected with it. 




The findings here are in accord with other neurodegenerative disorders, and suggest 
synaptic toxicity is a common pathogenic feature, offering a potential target for new 
therapeutic strategies.  
6.2 SYNAPTIC LOSS IN PRIMARY TAUOPATHIES 
The in vivo loss of synapses in corticobasal degeneration (CBD) and Progressive 
Supranuclear Palsy-Richardson’s syndrome (PSP) is significant and widespread (chapter 
3). It is seen in the brain areas identified as those affected early in the disease (for example 
basal ganglia (Kovacs et al., 2020)), and areas associated with minimal volume loss (for 
example frontal cortical regions). This latter finding suggests synaptic pathology in some 
areas begins before the large scale cell death, and may be as result of toxic oligomeric tau, 
as evident from animal models of tauopathy (Fá et al., 2016; Kaniyappan et al., 2017; 
Niewiadomska et al., 2021). The synaptic loss is potentially identifiable in both the pre- 
and postsynaptic compartments (chapter 4). This is suggested in vivo in PSP and CBD, 
through the tight coupling between [11C]UCB-J binding (presynaptic density), and the 
Orientation Dispersion Index (ODI; measuring postsynaptic dendritic complexity). 
However, the presynaptic change in both patient groups had a higher effect size than 
changes in ODI (Cohen’s d, Figure 4-3C and Figure 4-4C). This observation may in part, 
be due to [11C]UCB-J being a more specific and accurate surrogate for presynaptic density 
as it directly binds a presynaptic vesicle protein (Finnema et al., 2016), than ODI is for 
postsynaptic complexity, where it measures structural integrity and complexity rather than 
specific postsynaptic proteins (H. Zhang et al., 2012). Nevertheless, the significant 
reduction in presynaptic density, and dendritic complexity is in accordance with animal 
models of tauopathy (Clare et al., 2010; Herms & Dorostkar, 2016; Tyebji & Hannan, 2017) 
and in vivo studies of other neurodegenerative disorders where synaptic and dendritic 
pathologies are interlinked and key pathogenic mechanisms (M. K. Chen et al., 2018; 
Matuskey et al., 2020; Mecca et al., 2020; Nicastro et al., 2020). 
Synapses play a central role in memory formation and cognition (Stewart et al., 2014; 
Südhof, 2004). I recapitulate this in PSP and CBD (chapter 3), where a strong correlation 
between in vivo global synaptic density, and global cognition and disease severity is 
observed (Figure 3-5). This close correlation between in vivo synaptic density and cognition 
has been replicated in the closely related tauopathy of Alzheimer’s disease, where reduced 




hippocampal binding of the synaptic PET ligand [11C]UCB-J is associated with lower 
episodic memory and higher scores on the clinical dementia rating scale (Mecca et al., 
2020).  
Tau-induced synaptic toxicity is well documented in animal models, acting through direct 
and indirect pathogenic mechanisms (chapter 5).  In chapter 5, I illustrate that the binding 
of [11C]UCB-J colocalises, and is strongly positively correlated, with that of [18F]AV-1451, 
suggesting that areas of the brain with a higher synaptic density, harbour more pathology. 
Although the interpretation of the signal from [18F]AV-1451 PET in 4-repeat tauopathies 
is currently under debate (chapter 5), the in vivo colocalisation of the two measures is in 
line with animal and post mortem studies (Spires-Jones & Hyman, 2014; Vogels et al., 
2019). This positive correlation between synaptic density and the underlying pathology has 
also been observed in Alzheimer’s disease where, amyloid PET ligand binding is positively 
associated with in vivo hippocampal synaptic density (O'Dell et al., 2021). In PSP and CBD, 
the positive correlation between synaptic density and molecular pathology is moderated by 
disease severity (Figure 5-3B), similar to findings in a recent [11C]UCB-J PET study in 
Alzheimer’s disease; Coomans et al. report that the in vivo relationship between cortical 
tau PET binding and synaptic density is moderated by each individual’s cortical tau burden, 
such that with higher tau load, the relationship becomes negative (Coomans et al., 2021).  
Although connectivity is not directly measured in Chapter 5, it is central to the 
interpretation of the results. For example, despite synaptic loss in PSP and CBD, it is 
possible that the functional connectivity of the remaining synapses is strengthened as a 
compensatory mechanism, therefore promoting accrual of pathology locally (at least in the 
early stages of disease). Indeed, increased cortical-cortical functional connectivity, as 
measured with resting-state function MRI, in PSP and CBD has been previously reported 
(Cope et al., 2018; Filippi et al., 2019). Long-distance functional connections (for example 
cortical-subcortical connections) are however weakened in primary tauopathies (Filippi et 
al., 2019; Gardner et al., 2013) providing a potential explanation for the negative 
correlations observed between cortical pathology and subcortical synaptic density Figure 
5-4. 
Synaptic pathology is not unique to the primary tauopathies of PSP and CBD. Indeed, it is 
a central pathogenic mechanism underlying the cognitive deficits, and clinical phenotypes 




of many neurodegenerative diseases, as well as a feature of the neuropsychiatric disorders 
depression and schizophrenia. Together these disorders place a considerable social, 
emotional, and financial burden on sufferers, care providers, and health services. There is 
therefore an urgent need to develop therapeutic strategies to delay or halt progression of 
this group of conditions. Given the critical role synapses play in the pathogenesis, they 
provide the perfect platform for the development of synapse-specific therapeutics with a 
much broader application alongside disease-specific treatment advances. In the following 
section, I will review the central aspects of synaptic dysfunction in prevalent 
neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease and Lewy 
body dementia, frontotemporal lobe dementia, and prion disease. 
6.3 SYNAPTIC LOSS IN OTHER NEURODEGENERATIVE DISORDERS 
Synapses are susceptible to a range of neurodegenerative stimuli, from trauma to infectious 
agents to underlying genetic risk factors. Given their key role in learning and memory 
(reviewed in Kandel et al. (2014)), any persistent perturbations in their normal physiology, 
as seen in neurodegeneration or chronic psychiatric disorders, result in malfunction and 
degeneration contributing to clinical symptoms. The increasingly used term ‘synaptopathy’ 
refers to the group of disorders where the above process occurs early and is a central 
pathogenic mechanism – I review these below:   
6.3.1 ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is the commonest cause of neurodegenerative dementia 
(accounting for 60% of cases (Ferri et al., 2005)) and a leading cause of global disease 
burden.  It is characterised pathologically by abnormal tau accumulation in neurofibrillary 
tangles (mixed 3 and 4 repeat) and the presence of extracellular amyloid-beta deposition 
(Selkoe & Hardy, 2016); clinically it presents with progressive memory loss and 
behavioural changes (Montine et al., 2012). The pathological hallmarks of AD however, 
do not correlate well with the severity of dementia or neuronal loss (Kril et al., 2002), unlike 
synaptic loss which occurs early in the pathogenesis  (Scheff et al., 2007), is closely 
associated with cognitive impairment (Scheff et al., 2006; Terry et al., 1991), and directly 
related to the duration of dementia (Blennow et al., 1996; Ingelsson et al., 2004)  




There is a wealth of evidence for synaptic loss in AD from animal models, post mortem 
data (reviewed in Honer (2003) and De Wilde et al. (2016)), and recent in vivo studies using 
the presynaptic ligand [11C]UCB-J or closely related analogues of this (M. K. Chen et al., 
2018; Coomans et al., 2021; Mecca et al., 2020; O'Dell et al., 2021). Significant reductions 
in synaptic density are seen in the hippocampus, fronto-temporal cortices, the cingulum 
and the entorhinal cortex, with the earliest and the most significant alterations in 
presynaptic proteins, seen within the hippocampus. The ubiquitous presynaptic protein 
synaptophysin is widely studied in neurodegeneration, but the extent of synaptic damage is 
more widespread and involves many other key proteins, albeit to varying degrees.  Some 
key affected proteins in AD are those involved in the SNARE (soluble NSF attachment 
protein receptor) machinery including:  SNAP-25, VAMP and syntaxin, key to the fusion 
of synaptic vesicles with the presynaptic membrane and neurotransmitter release. Other 
affected presynaptic proteins include the Rab family, calcium sensory proteins, and those 
key to the neuronal cytoskeleton. Likewise at the postsynaptic membrane, reductions in 
synaptic proteins responsible for the postsynaptic scaffolding and dendritic structure, as 
well as glutamate receptors and mitochondrial proteins, are seen. Additionally, amyloid 
beta oligomers engage synaptic receptors (Fyn, CDK5, and GSKβ) that trigger neurotoxic 
signalling pathways, leading to neuronal autophagy (reviewed in  Honer (2003) and De 
Wilde et al. (2016)).      
Whilst both tau tangles and amyloid plaques are known to cause neuronal loss, the degree 
to which the latter occurs exceeds that of tau tangles suggesting that tangles are not 
necessary for neuronal death in AD (Gómez-Isla et al., 1997). The toxic pathways leading 
to synaptic dysfunction and loss are in part due to the direct and indirect deleterious effects 
posed by both pathological tau and beta amyloid at the synapse (Spires-Jones & Hyman, 
2014). However, whilst the loss of some synaptic proteins is directly linked to 
neurofibrillary tangles, for example synaptophysin (Callahan & Coleman, 1995), the loss 
of others such as Rab3A is not (Blennow et al., 1996). Indeed, it is tau oligomers that are 
responsible for the majority of the toxic damage caused at the synapse both directly 
(Menkes-Caspi et al., 2015), and also indirectly by interfering with microtubule assembly, 
neuronal cytoskeleton, axonal transport and the integrity of the nucleus membrane, thereby 
jeopardising the DNA transcription and translation machinery (reviewed in (Niewiadomska 
et al., 2021)). Similarly, synaptophysin immunoreactivity in mouse models of AD, show 




an intact signal in response to amyloid beta fibrils and monomers (Ishibashi et al., 2006), 
but with a significant reduction in response to amyloid beta oligomers, where the latter is 
found to be a predictor of synaptic change in the entorhinal cortex and super frontal gyrus 
(Lue et al., 1999). These studies suggest that, as well as in their fibrillar and monomeric 
forms, amyloid beta and pathogenic tau in their soluble and oligomeric forms are especially 
toxic to synapses similar to observations seen in the P301L mouse model of primary 
tauopathy (Menkes-Caspi et al., 2015). Recent in vivo PET studies in AD, confirm AD 
region specific synaptic loss colocalising with PET radioligands targeting amyloid plaques 
(O'Dell et al., 2021) and neurofibrillary tangles (Coomans et al., 2021); these observations 
are in line with preclinical data, however we are as yet unable to image oligomers in vivo 
where the association with synaptic loss may be greater, echoing in vitro findings.  
6.3.2 FRONTOTEMPORAL DEMENTIA  
Frontotemporal dementia (FTD) is a clinical syndrome characterised by changes in 
personality, behaviour, and language (Gorno-Tempini et al., 2011; Rascovsky et al., 2007). 
It was formerly known clinically as Pick’s disease, although this term is now generally 
reserved for the particular pathological entity with 3-repeat tau aggregation linked to 
mutations in the microtubule-assisted tau protein (MAPT) gene (Irwin et al., 2016). Other 
causes of frontotemporal dementia include TDP-43 inclusions or fused-in-sarcoma (FUS) 
pathology starting in but not limited to the frontal and temporal lobes and extending to 
include the rest of the brain with disease progression (Rohrer et al., 2011). FTD falls within 
the spectrum of frontotemporal lobar degeneration syndromes (Figure 1-2), sharing 
phenotypic and pathological features with PSP and CBD (Chapter 1).  
Genetically, hexanucleotide repeat expansions of the chromosome 9 open reading frame 72 
(C9orf72), and mutations in the granulin, TAR DNA-binding protein (TDP43), fused-in 
sarcoma (FUS), and MAPT gene may cause either a behavioural variant FTD syndrome, 
motor neuron disease (MND), mixture of FTD-MND, or FTD and parkinsonism linked to 
chromosome 17 (Mackenzie et al., 2011; Rohrer et al., 2015). Reductions in synaptophysin 
immunochemistry in FTD was first reported in 1995, in a regionally specific manner 
including the superficial layers of the prefrontal cortex but not in parietal, inferior temporal 
or posterior regions (Brun et al., 1995; Liu & Brun, 1996). Since then, reductions in other 
synaptic vesicle proteins Rab3A, synaptotagmin, synapsin-1, and presynaptic plasma 




membrane proteins SNAP-25 and syntaxin-1, within the upper but not deeper layers of the 
frontal cortex have been reported, as well as reduced CSF synaptic marker neuronal 
pentraxin-2 (van der Ende et al., 2020). The postsynaptic compartment in FTD is also 
affected where marked reductions in dendritic spine numbers in the apical dendrites of 
pyramidal neurons are seen (I. Ferrer, 1999). Using a more sensitive protein staining and 
quantification method such as ELISA (enzyme-linked immunosorbent assay), Lipton et al. 
have reported a more widespread loss of synaptic proteins extending beyond the frontal 
lobes, into the tempro-parietal lobes, albeit in a small sample of post mortem brains of 
patients with FTD (Lipton et al., 2001).  
Animal models of primary tauopathies, such as the P301S (Hoffmann et al., 2014) or 
rTG4510 models (Rocher et al., 2010), harbour human MAPT gene mutations responsible 
for some phenotypes of frontotemporal lobe dementia and PSP-like disorders. Both these 
models, feature mutated tau oligomers and tangles, present with synaptic dysfunction and 
dendritic pathology in the prefrontal cortex and the hippocampus, and show difficulties in 
learning and memory (Kaniyappan et al., 2017; Liu & Brun, 1996; Menkes-Caspi et al., 
2015; Schindowski et al., 2006).   
Other protein aggregates associated with FTD, TDP-43, FUS, ubiquitin and p62 positive 
inclusions, have all been observed within dendritic spines (Brettschneider et al., 2012). In 
the transgenic mouse model harbouring the ubiquilin-2 mutation seen in some patients with 
FTD (UBQLN2P497H), ubiquitin and p62 positive inclusions within dendrites are associated 
with dendritic spine pathology, synaptic dysfunction, and cognitive deficits (Gorrie et al., 
2014).   
6.3.3 PARKINSON’S DISEASE AND LEWY BODY DEMENTIA 
Parkinson’s disease (PD) is the second most common neurodegenerative disease, 
characterised pathologically by the presence of intraneuronal alpha-synuclein containing 
Lewy bodies (Spillantini et al., 1997). Clinically it presents with a characteristic movement 
disorder typically manifesting as bradykinesia, rigidity, tremor and postural instability 
(Postuma  et  al.,  2015), and later in the disease course cognitive decline (Williams-Gray 
et al., 2009). Lewy body pathology, the hallmark of PD, occurs predominantly in the 
substantia nigra pars compacta but it is also found in the locus coeruleus and is associated 
with cell loss (Halliday et al., 1990). As with other neurodegenerative disorders, synaptic 




protein reductions in PD are observed in post mortem brains of patients, in particular 
reductions in the synaptosomal-associated protein 25 (SNAP25) which provides the driving 
force for synaptic vesicle fusion, and docking (Bereczki et al., 2016).  Synaptic protein 
dysfunction and reductions in PD are as a result of direct pathological aggregates of alpha-
synuclein but also the downstream effect of dysfunctional proteins from PD-linked genetic 
mutations. 
Synaptic dysfunction is a key pathogenic mechanism in PD in two respects (reviewed in 
Picconi et al. (2012), Pienaar et al. (2012), Nguyen et al. (2019), and Koziorowski et al. 
(2021)). First, alpha-synuclein (encoded by the SNCA gene) normally resides in the 
presynaptic compartment, promoting SNARE-complex assembly (Burré et al., 2010), and 
thus central to the regulation of synaptic activity, plasticity, synaptic vesicle pool 
maintenance and trafficking. Mutations in the synuclein protein and the subsequent 
aggregation in the presynaptic compartment, redistributes proteins of the presynaptic 
SNAR complex, and therefore interferes with synaptic vesicle fusion, and exo- and 
endocytosis (Bridi & Hirth, 2018; Garcia-Reitböck et al., 2010; Yavich et al., 2004), 
manifesting as cognitive dysfunction (Howlett et al., 2015).  
Second, PD-related genetic mutations in LRRK2, DJ1, PINK1, and PRKN genes, are 
deleterious to the harmonious interaction between synaptic vesicle proteins (including 
SV2A) involved in synaptic vesicle transport (Abeliovich & Gitler, 2016; Belluzzi et al., 
2012; Plowey & Chu, 2011). Mutations in the above genes therefore reduce synaptic vesicle 
trafficking and neurotransmitter release (Esposito et al., 2012). Other recently identified 
PD-linked genes involved in synaptic endocytosis are also thought to contribute to PD 
pathogenesis. Such genes include DNAJC6 (encoding auxilin (Olgiati et al., 2016)), SYNJ1 
(encoding synaptojanin-1 (Quadri et al., 2013)), and SH3GL2 (encoding endophilin A1 
(Chang et al., 2017)). Similar to PSP pathogenesis, LRRK2 mutations play a particular role 
in PD pathogenesis by interfering with the functioning of other PD-linked gene products. 
For example, in a drosophila model of PD, LRRK2 mutations lead to abnormal 
phosphorylation of endophilin A1, and therefore interferes with its interaction with 
synaptotagmin-1 (Islam et al., 2016), and in mouse models lead to reductions in synaptic 
vesicle density (Xiong et al., 2018).  




Observations from animal models and post mortem studies have recently been confirmed 
in vivo with UCB-J PET, where reduced binding are reported in subcortical areas 
(substantia nigra, caudate, locus coeruleus), as well as in the cingulate and the prefrontal 
cortex  (Andersen et al., 2021; Matuskey et al., 2020). Of note, no differences in volumetric 
measures were observed between patients and controls despite the significant loss of 
synapses; this is in line with preclinical data where synaptic dysfunction is seen before 
overt neuronal loss (Janezic et al., 2013).  Although Matuskey et al. did not observe a 
correlation with clinical measures (possibly due to a small sample size and absence of 
participants with a clinical diagnosis of PD dementia), Andersen et al report a positive 
correlation between synaptic density and executive cognitive domains in patients with 
Parkinson’s dementia (Andersen et al., 2021).  
Similar to Parkinson’s disease, Lewy Body Dementia (LBD) is a neurodegenerative 
disorder associated with an underlying alpha-synucleinopathy. Clinically it is characterised 
by parkinsonism, early cognitive dysfunction, recurrent visual hallucinations, and rapid eye 
movement sleep behaviour disorder (McKeith et al., 2017). Despite a more aggressive form 
of cognitive dysfunction (Oesterhus et al., 2014; Williams et al., 2006), brain atrophy is 
less pronounced in LBD compared to AD (Mak et al., 2015). Synaptic pathology has 
therefore been proposed as a central pathogenic mechanism. Indeed, animal models of LBD 
(Kramer & Schulz-Schaeffer, 2007), and post mortem data (Bereczki et al., 2016) confirm 
presynaptic protein and dendritic spine loss, contributing to cognitive dysfunction. 
Bereczki et al. report a significant reduction in the concentration of neurogranin (a 
postsynaptic protein involved in the regulation of synaptic transmission through binding to 
calmodulin), the presynaptic vesicle protein Rab3A (reflective of the recycling pool of 
synaptic vesicles), and SNAP-25, with the latter two correlating with cognitive decline 
(Bereczki et al., 2016). Recent in vivo [11C]UCB-J PET studies have reported reduced 
synaptic density within the substantia nigra and cortical regions (Andersen et al., 2021; 
Nicastro et al., 2020), correlating with clinical measures (Andersen et al., 2021) in the 
absence of overt atrophy.  
6.3.4 HUNTINGTON’S DISEASE 
Huntington’s disease (HD) is a neurodegenerative disorder caused by a mutation in the 
huntingtin gene causing a trinucleotide repeat expansion, presenting with a movement 




disorder and cognitive dysfunction (F. O. Walker, 2007). HD provides an opportunity to 
study the early preclinical phase of neurodegeneration in presymptomatic individuals 
carrying the culprit mutation, and also in mouse models where copy numbers of the 
trinucleotide expansion can be controlled giving rise to a spectrum of clinical severity. The 
key pathological hallmark of HD is the degeneration of the striatum with selective 
vulnerability of medium-spiny neurons which receive significant cortical projections (de la 
Monte et al., 1988); under normal physiology these cortico-striatal projections are rich in 
the protein huntingtin (Fusco et al., 1999). Abnormal functioning of these projections are 
evident even in the preclinical phase where neuronal loss is absent (reviewed in Cepeda et 
al. (2007) and in Levine et al. (2004)), suggesting that synaptic pathology plays a key role 
in the early pathogenesis of HD. In transgenic HD mouse models (e.g. R6/2), and in patients 
with HD, the concentration of complexin II (a protein that regulates fusion between 
synaptic vesicles and the presynaptic membrane) is reduced in neurons expressing mutant 
huntingtin (Morton & Edwardson, 2001). Similarly, the phosphorylation of synapsin 1 (a 
presynaptic protein that attaches to the cytoskeleton and involved in vesicle exocytosis), is 
also significantly reduced in neurons expressing mutant huntingtin (Xu et al., 2013). 
Postsynaptically, mutant huntingtin expressed in the R6/1 transgenic mouse model, results 
in reductions in PSD-95 (a membrane associated kinase, acting as the major scaffolding 
protein involved in dendritic spine changes and synaptic plasticity) (Nithianantharajah & 
Hannan, 2013).  
At the synapse, under normal physiology, huntingtin interacts with vesicular structures 
such as clathrin-coated vesicles, endosomal compartments, and microtubules (Velier et al., 
1998), and in its mutant form therefore, disrupts neurotransmitter synthesis, transport and 
release (reviewed in Tyebji and Hannan (2017)). At the postsynaptic membrane, clathrin, 
via its adaptor protein 2 (AP2), mediates neurotransmitter receptor surface expression. AP-
2, along with huntingtin and huntingtin-interacting protein-1, bind to AMPA and NMDA 
receptor for internalisation (Metzler et al., 2007); mutant huntingtin disturbs this 
physiological interaction and thus interferes with signal transduction between the pre- and 
postsynaptic compartments (Milnerwood et al., 2010).  
Transgenic mouse models of HD harbouring mutant huntingtin, exhibit changes in 
membrane potential leading to changes in synaptic input (Stern, 2011). The latter leads to 
an imbalance in inhibitory and excitatory inputs (Spampanato et al., 2008) thus causing 




alterations in long-term depression and long-term potentiation and short-term plasticity in 
the frontotemporal cortices (Cummings et al., 2007; Dallérac et al., 2011), reflective of the 
cognitive impairment seen clinically.  
An additional deleterious effect of mutant huntingtin is in inducing alterations in the 
activity of the brain derived neurotrophic factor (BDNF), and its transport along the axon. 
BDNF has a central role in synaptic plasticity and synaptic health (reviewed in Tyebji and 
Hannan (2017)) by interacting with other key proteins and regulating intracellular calcium 
stores, but also through inducing change in neurite morphology and spine density (Herms 
& Dorostkar, 2016). This pathogenic mechanism has been of interest therapeutically. For 
example, in mouse models, treatment with long-term BDNF increases spine density in the 
hippocampal CA1 region (Tyler & Pozzo-Miller, 2001), and enlarges dendritic spines at 
glutamatergic synapses (Tanaka et al., 2008), offering a potential therapeutic avenue for 
synaptic restoration. 
6.3.5 PRION DISEASE 
Prion disease is caused by the misfolding of the prion protein, clinically manifesting as a 
rapidly progressive and fatal dementia with motor and psychiatric symptoms (Aguzzi et al., 
2007). Post mortem brains of patients with prion disease, and mice transfected with the 
mutant prion protein show reduced synaptic density (reviewed in Senatore et al. (2013)); 
specifically, reduced synaptophysin, synapsin-1, syntaxin-1, SNAP-25, and PSD-95 (I. 
Ferrer, 1999, 2002). Mice transfected with the mutated prion protein show abnormal 
endoplasmic-reticulum dependent phosphorylation of key synaptic proteins, leading to 
degeneration of the presynaptic compartment and loss of dendritic spines in the 
postsynaptic compartment, preceding cell death (Jeffrey et al., 2000). This toxic effect of 
misfolded prion protein is thought to occur in response to large aggregates but also in 
response to monomers and soluble oligomers similar to observations in primary tauopathies 
(Simoneau et al., 2007; Zhou et al., 2012).    
6.3.6 NEUROPSYCHIATRIC DISORDERS 
Synaptic dysfunction forms a key part of neuropsychiatric disorders including autism 
spectrum disorders, schizophrenia and depression. Given the heterogeneity of 
neuropsychiatric disorders, it is suggested that mapping transdiagnostic symptoms to their 
underlying neurobiology and brain circuitry may have a greater translational impact than 




identifying targets for categorical disorders (Cuthbert, 2014). One such common 
neurobiological pathway is synaptic pathology. For example, persistent high levels of stress 
is thought to result in synaptic loss in circuits underlying affective and cognitive disorders 
(Duman et al., 2016), potentially contributing to the symptoms of depression. Post mortem 
studies in patients with major depressive disorders show reduced synaptic density in the 
dorsolateral prefrontal cortex (Kang et al., 2012), consistent with in vivo evidence of 
network disruption in the prefrontal cortex and connected limbic regions (Kaiser et al., 
2015; Murrough et al., 2016). Using [11C]UCB-J PET imaging, Holmes et al. have recently 
shown reduced synaptic density in the anterior cingulate, hippocampus, and dorsolateral 
prefrontal cortex, in patients with severe depression in accordance with post mortem data. 
They further show a negative correlation between prefrontal synaptic density and 
performance on working memory in line with previous reports in this condition (S. E. 
Holmes et al., 2019; Johnsen & Asbjørnsen, 2008). Chronic neuroinflammation has been 
identified as a major pathological mechanism underlying depression. Given the key role 
astrocytes play in synaptic maintenance, it is perhaps not surprising to see synaptic loss in 
response to a chronic state of neuroinflammation, and synaptotoxic chemical release 
(reviewed in Troubat et al. (2021)), similar to the synapto-toxic effects of 
neuroinflammation in PSP/CBD (Kovacs, 2020; Malpetti et al., 2020b).  
Synaptic dysfunction and loss has been identified as a central pathogenic mechanism in  
schizophrenia – a neurodevelopmental psychiatric illness (much like autism spectrum and 
bipolar disorders). Schizophrenia presents with positive (delusions, hallucinations, and 
personality change) and negative symptoms (apathy, and withdrawal) (McCutcheon et al., 
2020), and is associated with abnormal synaptic pruning and connections (Germann et al., 
2021). Post mortem data illustrates reduced synaptic proteins (synaptic vesicle proteins, 
synaptophysin , synaptobrevin, PSD-95) and dendritic spine density (Osimo et al., 2019) 
in the frontal cortex and the anterior cingulate, in line with reduced in vivo [11C]UCB-J 
PET signal in patients (Onwordi et al., 2020), and in vivo altered functional connectivity 
(Mwansisya et al., 2017).  
In summary, the pathways leading to synaptic toxicity as a result of toxic species of disease-
specific protein aggregates, can affect the synapse either by interfering with the surrounding 
environment (e.g. mitochondrial dysfunction, and neuroinflammation) or by disturbing 
synaptic protein homeostasis (as discussed above). The two pathways are not mutually 




exclusive and occur in parallel with the end result of overwhelming neuronal stress, 
abnormal signal transmission, and weakening of functional connectivity. Common to the 
pathogenesis of the neurodegenerative disorders explored above, is the disturbance in 
synaptic function, stability and integrity, before structural breakdown. Therefore, subtle 
changes in functional processes within the synaptic compartments (for example, 
imbalances in synaptic proteostasis) have wide ranging and profound implications on 
synaptic plasticity, and connectivity. Synaptic manipulation, restoration and maintenance 
therefore provides a therapeutic platform early in neurodegeneration, before the onset of 
overt function impairment, as depicted schematically in Figure 1-3. 
6.4 TARGETING THE SYNAPSE THERAPEUTICALLY  
The maintenance, compensation and recovery of synapses in neurodegenerative processes 
may provide potential therapeutic avenues early in neurodegeneration (reviewed in J. 
Jackson et al. (2019)). 
Early therapeutic approaches towards synaptic function have focused on synaptic 
maintenance by attempting to improve the efficiency of remaining synapses and boosting 
the levels of deficient neurotransmitters; for example by using the following 
pharmacological agents: anti-cholinesterase inhibitors (donepezil, rivastigmine) (Anand & 
Singh, 2013) and NMDA receptor antagonist memantine in mild to moderate Alzheimer’s 
disease (Prentice et al., 2015); dopaminergic therapy for Parkinson’s disease and Lewy 
Body dementia (Mao et al., 2020), PSP and CBD (albeit with a milder benefit compared to 
PD) (Stamelou & Höglinger, 2016); and selective reuptake inhibitors of serotonin 
(citalopram), and noradrenaline (atomoxetine) for the treatment of behavioural symptoms 
in frontotemporal lobar degeneration syndrome, Parkinson’s disease and Huntington’s 
disease (reviewed in Rittman et al. (2016), Holland et al. (2021), and Shannon and Fraint 
(2015). The efficacy of the above agents are however limited by the number of intact 
synapses, and therefore their utility is restricted to use in mild to moderate disease.  
Another approach is to promote synaptic compensation by encouraging the brain’s natural 
ability to compensate for synapse loss in response to neurological diseases or insult. This 
may include increasing the size of remaining synapses (Scheff, 2003), upregulating 
synaptic proteins in mild disease (Mukaetova-Ladinska et al., 2000), changes in synapse 




dynamics (J. S. Jackson et al., 2017), or changes in synaptic connectivity (Abuhassan et al., 
2014). Key to these processes are the growth factors BDNF (brain derived growth factor), 
NGF (nerve growth factor), and VGF (non-acronymic; nerve growth factor regulated 
molecule), which are decreased or dysregulated in patients with AD (Cocco et al., 2010; I. 
Ferrer et al., 1999; Mufson et al., 1995), and HD (reviewed in Tyebji and Hannan (2017)). 
Intracerebroventricular infusion of NGF, in a phase 1 clinical trial of three AD patients, 
resulted in some cognitive improvement, albeit outweighed by the side effects relating to 
the method of delivery (Mandel, 2010). Further evidence on the efficacy of targeting the 
above neurotrophic factors therapeutically comes from animal studies.  For example, in an 
amyloid precursor protein mouse model of AD, BDNF administration resulted in 
significant recovery of synaptic loss (Nagahara et al., 2009). Similar evidence is present in 
mouse models of HD (reviewed in Alberch et al. (2004)), however a recent randomised 
phase 2 clinical trial of cysteamine (which upregulates BDNF, and also acts through 
antioxidant mechanisms) failed to show a statistically significant improvement in motor 
scores in HD patients (Verny et al., 2017)– albeit synaptic density was not measured as an 
end-point in this trial.  
Additional to modulating neurotrophic mechanisms, pathways promoting synaptic 
recovery have also proven promising. One such pathway includes the wnt pathway – a key 
modulator of synaptic integrity. Targeting this pathway for example, by blocking the effects 
of ROCK (Rho-associated kinase – a major cytoskeleton regulator)  (Sellers et al., 2018) 
or DKK-1 (Dickkopt wnt signalling pathway inhibitor 1 – a negative regulator of the wnt 
signalling pathway) (Marzo et al., 2016) has illustrated positive results in restoring 
synapses in animal models.   
There are currently two clinical trials with synaptic density (or surrogates thereof) as a trial 
endpoint. The LUCIDITY trial (NCT03446001) is a phase III trial in patients with mild to 
moderate Alzheimer’s disease, employing FDG-PET and cognitive endpoints to assess the 
effects of a methylene blue derivative (known to disrupt tau-tau binding and therefore stop 
tau aggregation) on synaptic function, with results expected in mid-2022. UCB-J PET is 
being used in a second trial to measure the effects of the sigma2 receptor antagonist CT1812 
on synaptic density in mild to moderate AD patients (NCT03493282) – results are expected 
later this year.  




A third trial (NCT02167256) also used FDG-PET and cognitive endpoints, to assess the 
effects of the Src/Abl tyrosine kinase inhibitor saracatinib on synaptic function. Saracatinib 
(AZ0530) blocks the toxic effects of the fyn kinase pathway which affects tau 
hyperphosphorylation, as well as promotes beta amyloid toxicity (Kaufman et al., 2015; 
Nygaard et al., 2014). This drug had offered therapeutic promise in mouse models of AD 
(APP/PS1), where it led to increased synaptic density in the hippocampus (as measured 
with UCB-J PET (Toyonaga et al., 2019)) and rescued spatial memory deficits (Kaufman 
et al., 2015). The trial was however ended in 2019 due to lack of clinical benefit in human 
participants with AD (van Dyck et al., 2019). In the same year however, a phase 1 study of 
saracatinib in patients with Parkinson’s disease commenced using functional MRI, as well 
as FDG-PET and electrophysiological measures of brain activity through EEG monitoring 
– the trial is still ongoing with results expected soon. Clinical trials targeting the  
neuroinflammatory system in neurodegeneration (for example by using non-steroidal anti-
inflammatory drugs, minocycline, or CHF5074 - a microglial modulator, in AD) have 
illustrated mixed clinical benefit, albeit none directly measure synaptic density as an 
endpoint (reviewed in Kwon and Koh (2020)). Anti-inflammatory drugs used for the 
treatment of multiple sclerosis are currently being trialled in patients with motor neuron 
disease (NCT02469896), with results expected soon.  
Therapeutic approaches targeting synapses in human, have been limited thus far, due to the 
limitations posed by translating animal research into human clinical trials. For example, we 
have yet to discover a sensitive enough biomarker to measure changes in synapses either 
over time or in response to therapy. However, advances in the development of UCB-J PET 
are promising, as well as the developments in detecting fluid biomarkers of synaptic 
function (for example, CSF neurogranin (Kester et al., 2015), and SNAP25 levels 
(Brinkmalm et al., 2014)). Moreover, the discovery, and in-human validation of PET 
ligands measuring mitochondrial complex I ([18F]BCPP-EF PET), and sigma-1R ([11C]SA-
4503), as markers of neuronal stress are also promising (Mansur et al., 2020). A second 
limitation is the difficulty in mimicking human disease in animal models. A possible way 
of overcoming this limitation is the use of inducible pluripotent stem cells (iPSCs) from 
patients with neurodegenerative disorders, enabling the study of human disease but also 
neurodevelopment and neurophysiology in early disease (Taoufik et al., 2018). 




Although clinical trials in primary tauopathies have not directly targeted synapses thus far, 
the lessons learnt from those in other neurodegenerative disorders will be directly 
applicable given common pathogenic pathways of synaptic toxicity. Current trials in PSP 
are mainly focused on the removal of, or reductions in, the toxic tau species, in turn 
reducing tau-induced-synaptotoxity. Potential therapeutic approaches to achieve this aim 
include: (1) reducing MAPT gene expression through the use of anti-sense oligonucleotide 
(similar to approaches used in spinal muscular atrophy (Finkel et al., 2017) and 
Huntington’s disease (Pharmaceuticals, 2018)); (2) targeting the post-translational 
modification pathways - for example,  reducing tau hyperphosphorylation, and acetylation 
which may allow increased clearance through the ubiquitin pathway; (3) preventing tau 
aggregation; (4) immune neutralisation or clearance of different tau species via either active 
or passive strategies, thereby preventing cell-to-cell transmission and synaptotoxicity; (5) 
microtubule stabilisation. Thus far there are 24 tau-targeting therapeutics agents that have 
gone through, at least, a phase I clinical trial in tauopathies, with a further 15 in 
development.  
Cell-to-cell transmission of pathological tau has been proposed as a key pathogenic method 
of spread in tauopathies. One therapeutic approach is therefore to prevent this process and 
the ensuing tau seeding and synapto-toxicity, by using immune-mediated mechanisms 
(reviewed in VandeVrede et al. (2020) and Giunta et al. (2021)). Monoclonal antibodies 
against certain pathogenic epitopes of extracellular tau have been trialled in AD, and a few 
in PSP/CBS with the most recent, using the agent BIIB092 (PASSPORT (NCT03068468), 
TauBasket study (NCT03658135)), and C2N (NCT02985879), terminating early due to a 
lack of efficacy on primary or secondary endpoints.  
Lastly, given dendritic and synaptic function also occur as a result of loss of cytoskeletal 
integrity, stabilising the microtubule has been proposed as a potential therapeutic 
mechanism. However, microtubule stabilising agents davunetide (trialled in PSP) (Boxer 
et al., 2014) and abeotaxane (a taxane derivative; trialled in PSP and CBS) (Tsai et al., 
2020), ended early due to lack of clinical efficacy, and worsening of cognitive symptoms, 
respectively.   
The success of any of the clinical trials summarised above are dependent on a few factors: 
first the ability of the proposed agents crossing the blood-brain barrier; second, is the 




pathological diversity of tauopathies imposing a challenge in finding a common treatment 
that can be applied to all diseases in which tau plays a toxic role; and third is the limited 
knowledge about the exact pathogenic region of extracellular tau to target with immune-
mediated therapies. An added limitation is the lack of a sensitive enough trial endpoint able 
to detect clinical efficacy. The PSP rating scale has been used in almost all PSP/CBS trials 
as the gold standard endpoint and in all has failed to show any change in response to 
treatment. Whether the latter observation is as a result of lack of clinical efficacy of the 
agents under investigation, or whether the PSP-rating scale is not a sensitive endpoint is 
not clear as yet, and warrants further attention (M. K. Chen et al., 2021; Grötsch et al., 
2021).  
The pathogenic mechanisms leading to cognitive decline in PSP and CBD are complex 
with synaptic density point of convergence of multiple processes. However, although 
targeting pathways that lead to synaptic maintenance is promising, we must consider the 
role environmental, genetic, and epigenetic factors play in the pathogenesis of tauopathies 
(Litvan et al., 2021). Likewise, we must consider the consequences of clinical benefit in 
any of the trials above – the success of any agent able to slow down or reverse the pathology 
in PSP/CBD must be complementary to effective symptomatic management of what will 
become a chronic condition.  
6.5 OVERALL STUDY LIMITATIONS AND FUTURE DIRECTIONS 
There are limitations to my work. In each of the experimental chapters I discuss key 
limitations, however, here I reprise the discussion of principal limitations. 
Firstly, I used the clinical diagnostic criteria for PSP-Richardson’s syndrome and amyloid 
negative CBS (here called CBD) to select a clinical cohort with likely a 4-repeat tauopathy 
as the underlying pathological diagnosis. Whilst both PSP-Richardson’s syndrome and 
amyloid negative corticobosal syndrome are highly correlated with a 4-repeat tauopathy at 
post mortem both from our local data and internationally (Alexander et al., 2014; Gazzina 
et al., 2019; Respondek et al., 2017), other pathologies are possible, and indeed so are 
coexistent pathologies that may synergistically contribute to neurodegeneration (Robinson 
et al., 2018). The results in all experimental chapters would be strengthened by 
neuropathological correlates, to test the correlations between phenotype and pathology, and 




between in vivo to post mortem measures of synaptic density, as well as tau-to-synapse 
correlations. Post mortem validation will be available in the next 3-4 years for many pf my 
participants through the ongoing SENDeR research study. However, given the demanding 
nature of the protocol, the initial cohort was biased towards patients in earlier stages of 
disease with a longer interval expected to pathology.  
Second, there are limitations posed by potential non-specific binding of particular PET 
ligands, and by the interpretability of PET signals in relation to their molecular target. For 
example, in the case of [11C]UCB-J PET the signal has been attributed to presynaptic 
density. The ligand specifically binds the presynaptic protein SV2A; in this regard the PET 
signal is a marker of SV2A or synaptic vesicle density which may not necessarily reflect 
synaptic density at large. However, the number of vesicles per nerve terminal is a stable 
feature of neurons, as well as the number of SV2A molecules per vesicle – the synaptic 
pool size is rapidly replenished during neuronal activity to sustain capacity for ongoing 
neurotransmitter release (Bajjalieh et al., 1993a; Südhof, 2004). Therefore, radioligand 
binding to SV2A provides an estimate of the density of nerve terminals and serves as a 
proxy for the quantification of synaptic density (Finnema et al., 2016). No direct measure 
of postsynaptic density exists currently but specific postsynaptic receptor ligands (for 
example glutamate or AMPA receptors) are in development.  
There are however, increasing debates about the interpretability of the signal from [18F]AV-
1451 PET. This ligand was originally developed to bind paired helical filaments (3-
repeat/4-repeat tau) of Alzheimer’s disease, with very strong in vivo and post mortem 
correlation. Although this radioligand has also been successfully used in non-Alzheimer’s 
pathology, it has a lower affinity for the 4-repeat tauopathy of PSP and CBD, with reports 
of off-target binding to other non-tau targets (for example monoamine oxidase in the 
striatum, and neuromelanin in the brainstem) therefore bringing the interpretability of its 
signal under question (Marquié et al., 2017; Soleimani-Meigooni et al., 2020). Despite the 
caveats to using this ligand in PSP and CBD, [18F]AV-1451 binding is highest in disease-
related subcortical regions of PSP compared to healthy controls (Passamonti et al., 2017; 
Jennifer L Whitwell et al., 2017b) suggesting that, despite off-target binding, it is able to 
capture pathological changes compared to controls. In chapter 5, I illustrated that in brain 
regions beyond those identified as potential sites of off-target binding, there is a strong 
correlation with synaptic density moderated by disease severity. The [18F]AV-1451 signal 




from cortical areas is unlikely to be affected by currently identified off-target binding sites, 
but further research in this field is required as to the driving pathological factor underlying 
the PET signal if not tau. The field of in vivo tau imaging is still relying on [18F]AV-1451 
but next generation radioligands are soon to be utilised as research tools with a higher 
affinity for 4-repeat tauopathy (on post mortem tissue) and less off-target binding (for 
example [18F]PI-2620) (Brendel et al., 2020; Kroth et al., 2019; Mormino et al., 2020; A. 
Mueller et al., 2020). It would therefore be important to replicate the findings in chapter 5 
using a next generation tau ligands (e.g. [18F]PI-2620) to further assess the tau/synapse 
interaction in vivo.   
The cross-sectional design of my experiments is another limitation. One is unable to draw 
any conclusion about the progressive change in synaptic density over time, or causation of 
synaptic loss secondary to tauopathy. There are plans in the SNEDeR study to follow-up 
patients longitudinally, but this this has been stalled by the Covid-19 pandemic. It is 
however, reassuring to know that [11C]UCB-J is sensitive to changes in synaptic density 
over time in another disease context (Glorie et al., 2020), allowing the study of causality, 
and mediation.  
Lastly, I use a relatively small sample size; despite the large effect sizes depicted in chapters 
3-5, my cohort may not be representative of the entire PSP population, in that it only 
included patients with PSP-Richardson’s syndrome; and my study was not inclusive of a 
broad ethnic background. Caution must therefore be taken in generalising the interpretation 
of the results. Related to this, the study aims to extend PSP recruitment to non-Richardson’s 
syndrome subtypes, and also to early stage disease through the recruitment of asymptomatic 
MAPT carriers.  
6.6 CONCLUSION 
In this thesis, I illustrate the importance of synaptic density, and the consequences of 
synaptic dysfunction in progressive supranuclear palsy and amyloid negative corticobasal 
degeneration, as disease models for neurodegeneration. I provide the first in vivo evidence 
for pre- and postsynaptic synaptic change in patients with PSP and CBD and their 
correlations with disease severity, using a novel PET radioligand [11C]UCB-J. I show that 
synaptic loss colocalises with other markers of pathology in PSP and CBD. Together, my 




results inform the understanding of primary tauopathies, based on in vivo assessment in 
human patients, with direct implications for design of future trials targeting synaptic 
maintenance and recovery in neurodegeneration.   
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Figure A1. Progressive Supranuclear Palsy Diagnostic Criteria. 
A selection of the 8 subtypes of PSP are outlined in this figure; please refer to Hoglinger 2017 for full 
details of all subtypes. It is not unusual for patients to meet criteria for several PSP subtypes, in which 
case the Multiple Allocations eXtintion (MAX) rules criteria (Grimm et al. 2019) suggest that a 
diagnosis of PSP-Richardson’s Syndrome and/or higher levels of diagnostic certainty are prioritised.   




  Figure A2. Corticobsal Syndrome Diagnostic Criteria (Armstrong et al. 2013a). 




B. Supplementary materials for Chapter 4  
Figure B1. Regional association between cortical ODI and [11C]UCB-J BPND in PSP-RS and CBD.  
Significant regional associations are observed within the patient group (FDR p < 0.05, after adjusting for age and local GM atrophy). 
Abbreviation: ODI = Orientation Dispersion Index; FDR = False Discovery Rate; GM = Grey Matter. 
 
Figure B2. Regional association between cortical ODI and [11C]UCB-J BPND in PSP-RS and CBD.  
Significant regional associations are observed within the patient group (FDR p < 0.05, after adjusting for age and local GM atrophy). 
Abbreviation: ODI = Orientation Dispersion Index; FDR = False Discovery Rate; GM = Grey Matter. 












Figure C1. The association between synaptic density ([11C]UCB-J) and molecular pathology ([18F]AV-1451) is a function 
of disease severity.  
A) Scatter plot [11C]UCB-J and [18F]AV-145 partial volume uncorrected BPND from 23 patients with PSP and 12 patients 
with amyloid-negative corticobasal syndrome . Each grey line in A represents a patient’s data across 73 regions of interest 
(excluding those with previously reported off-target binding, i.e. basal ganglia and substantia nigra); the black line illustrates 
the overall model fit from equation 2. B) The slope for each individual (i.e. each grey line in A) is negatively correlated with 
disease severity (as measured with the PSP rating scale); R= -0.38, p = 0.03. 






Figure C2. Cortical molecular pathology is negatively correlated with subcortical synaptic density (Partial Volume Uncorrected).  
Correlation between [18F]AV-1451 BPND in a source region (horizontal axis) and [11C]UCB-J BPND in a target region (vertical axis), 
across 79 regions of interest in patients, using partial volume uncorrected binding potentials. The black box in the lower left quadrant 
focuses on cortical [18F]AV-1451 BPND and subcortical  [11C]UCB-J BPND. Abbreviation: l: left, r:right, FL: Frontal Lobe, OFC: 
Orbitofrontal Cortex, AOG: Anterior Orbital Gyrus, MOG: Middle Orbital Gyrus, LOG: Lateral Orbital Gyrus, POG: Posterior 
Orbital Gyrus, mid_fr_G: Middle Frontal Gyrus, strai_G: Straight Gyrus, precen_G: Precentral Gyrus, inf_fr_G: Inferior Frontal 
Gyrus, sup_fr_G: Superior Frontal Gyrus; PL: Parietal Lobe, postce_G: Postcentral Gyrus, sup_pa_G: Superior Parietal Gyrus: TL: 
Temporal Lobe, Ant_med: Anterior Medial, Ant_inf_lat: Anterior Inferiolateral,  "G_sup_temp_cent: Superior Temporal Gyrus – 
superior part, G_sup_temp_ant: Superior Temporal Gyrus- Anterior part,  G_tem_midin_r: Middle and Inferior Temporal Gyrus, 
G_paraH_amb: Parahippocampal and ambient gyri, G_occtem_la: Occipitotemporal Gyrus – Lateral Part (Fusiform Gyrus), 
OL_ling_G_l: Lingual Gyrus, Subcall_area: Subcallosal Area, OL_rest_lat: Latera Remainder of Occipital Lobe, G_cing_ant_sup: 
Cingulate Gyrus Anterior Part,  Subgen_antCing: Subgenual Frontal Lobe, Presubgen_antCing: Presubgenual Frontal Lobe, 
G_cing_post: Cingulate Gyrus – posterior part; Fl: Frontal Lobe; TL: Temporal Lobe; PL: Parietal Lobe; OL: Occipital Lobe; BG: 
Basal Ganglia; BS: Brainstem. Uncorrected for multiple comparison.  


















Figure C3. Cortical molecular pathology is negatively correlated with subcortical synaptic density (Partial Volume 
corrected).  
Correlation between [18F]AV-1451 BPND in a source region (horizontal axis) and [11C]UCB-J BPND in a target region 
(vertical axis), across 79 regions of interest in patients, using GTM partial volume corrected binding potentials. The black 
box in the lower left quadrant focuses on cortical [18F]AV-1451 BPND and subcortical  [11C]UCB-J BPND.. Abbreviation: 
l: left, r:right, FL: Frontal Lobe, OFC: Orbitofrontal Cortex, AOG: Anterior Orbital Gyrus, MOG: Middle Orbital Gyrus, 
LOG: Lateral Orbital Gyrus, POG: Posterior Orbital Gyrus, mid_fr_G: Middle Frontal Gyrus, strai_G: Straight Gyrus, 
precen_G: Precentral Gyrus, inf_fr_G: Inferior Frontal Gyrus, sup_fr_G: Superior Frontal Gyrus; PL: Parietal Lobe, 
postce_G: Postcentral Gyrus, sup_pa_G: Superior Parietal Gyrus: TL: Temporal Lobe, Ant_med: Anterior Medial, 
Ant_inf_lat: Anterior Inferiolateral,  "G_sup_temp_cent: Superior Temporal Gyrus – superior part, G_sup_temp_ant: 
Superior Temporal Gyrus- Anterior part,  G_tem_midin_r: Middle and Inferior Temporal Gyrus, G_paraH_amb: 
Parahippocampal and ambient gyri, G_occtem_la: Occipitotemporal Gyrus – Lateral Part (Fusiform Gyrus), OL_ling_G_l: 
Lingual Gyrus, Subcall_area: Subcallosal Area, OL_rest_lat: Latera Remainder of Occipital Lobe, G_cing_ant_sup: 
Cingulate Gyrus Anterior Part,  Subgen_antCing: Subgenual Frontal Lobe, Presubgen_antCing: Presubgenual Frontal 
Lobe, G_cing_post: Cingulate Gyrus – posterior part; Fl: Frontal Lobe; TL: Temporal Lobe; PL: Parietal Lobe; OL: 
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